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Aflatoxin, produced by the fungi Aspergillus flavus and A. parasiticus, is the most potent 
naturally occurring human hepatocarcinogen.  Food crops colonized by these fungi, especially 
maize and groundnut, are the major sources of dietary aflatoxin exposure. Aflatoxin and chronic 
hepatitis B virus (HBV) infection, two liver cancer risk factors that synergize with each other, 
are prominent in sub-Saharan Africa and certain parts of Asia. Furthermore, increasing evidence 
from epidemiological studies suggests that aflatoxin may cause child growth impairment, which 
can increase risks of premature deaths. A broad range of aflatoxin control strategies, developed 
to reduce aflatoxin exposure or its toxicity, include preharvest, postharvest, and dietary 
interventions; as well as the HBV vaccine, which does not reduce aflatoxin exposure but reduces 
the risk of aflatoxin-induced liver cancer. 
We compared the efficacy and the cost-effectiveness of four aflatoxin risk-reduction 
strategies: HBV vaccine, biocontrol (preharvest), a postharvest intervention package, and 
NovaSil clay (dietary) in preventing liver cancer and stunting in Nigeria. Aflatoxin and chronic 
HBV infection are attributable for 8-27%, and 59-62%, respectively, of total liver cancers in 
Nigeria. We found that the HBV vaccine provides the greatest health-based efficacy and the 
lowest cost to avert one disability-adjusted life year (DALY) in Nigeria, compared with the 
selected aflatoxin control interventions. The prospective burden of aflatoxin-related stunting in 
Nigeria varies depending on aflatoxin exposure levels, which can vary substantially by year and 
location.  At higher levels of aflatoxin exposure, the burden of aflatoxin-associated stunting is 
significant.  Preventing stunting by any of these interventions would greatly reduce the cost per 
DALY and turn these interventions from non-cost-effective to very cost-effective. Our technical 
feasibility assessments of these four interventions suggest some advantages and disadvantages of 
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each intervention over the others.  These data are crucial components in a decision making 
process to effectively allocate public health resources, and to position interventions for further 
development of public health interventions to prevent some aflatoxin-related public health 
problems, especially in high risk populations.  
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1.0  AFLATOXINS 
1.1 DISCOVERY OF AFLATOXIN 
Aflatoxins are toxic metabolites produced by certain fungi. In 1960, over 100,000 turkeys in 
England died within a few months.  This disease was first described as turkey X syndrome. Later 
it spread to ducklings and pheasants. Finally, after an intensive investigation, it was found that 
the reason of this epidemic in the poultry was caused by Brazilian peanut meal used to feed these 
poultry. Because of the course of the disease, fungi were suggested as the origin of these 
toxins(1).  
The toxin is named aflatoxin since it is produced by a fungus; Aspergillus flavus. At 
present, it has been found that other fungi, including some strains of A. parasiticus , plus related 
species, A. nomius and A. niger, can produce aflatoxins.  There are at least 6 types of aflatoxins 
identified according to their structure: B1, B2, G1,G2, B2A and G2A (1, 2). In addition, two 
metabolites, aflatoxin M1 and M2 have been found in the milk of the animals fed with aflatoxin 
contaminated food. B1 and B2 got B as their designation from their properties in producing blue 
fluorescence with UV light; whereas, G1 and G2 give yellow-green fluorescence under UV light. 
These toxins have closely similar structures. B2, and G2 are considered as dihydroxy derivatives 
of B1, and G1; M1, and M2 are 4-hydrogenated derivatives of  B1, and B2,  respectively(1).  
Aflatoxin B2A and G2A have been produced in a small amount by A. flavus and A. parasiticus. 
Moreover, A. flavus also produces other closely related compounds; aflatoxin GM1, parasiticol 
and aflatoxicol (3).   
Aflatoxins are highly contaminated in maize, peanuts, and oil seeds, such as cottonseed, 
but they are also detected in milk, cheese,  tree nuts, almonds, figs, spices, and a variety of other 
foods and feeds (1).  Poor storage conditions, especially during rainy seasons, can increase 
concentration of aflatoxins (4).  Moreover, aflatoxins have been identified not only in raw 
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agricultural products, but also in processed foods because they are stable in most food processes 
(1). Humans are affected by consuming food contaminated with aflatoxins. (5).  
Acute exposure to aflatoxins could lead to a condition called “aflatoxicosis”.  Early 
symptoms of aflatoxicosis are anorexia, malaise, and mild fever. If individuals are acutely 
exposed to high levels of aflatoxins, the symptoms can progress to lethal hepatitis with vomiting, 
abdominal pain, jaundice, fulminant hepatic failure, and death. The fatality rate from 
aflatoxicosis is about 25% (6). Several factors, including environment, exposure level, and 
duration of exposure, age, and health status can influence the aflatoxin toxicity. One major 
epidemic of aflatoxicosis occurred in more than 150 villages in India in 1974. This outbreak 
caused 397 ill-persons and 108 deaths. The contaminated maize with aflatoxin levels of 0.25 to 
15 mg/kg was identified.  The minimum estimated daily intake of aflatoxins was about 55 
ug/kgBW. Eight years later, another outbreak took place in Kenya. Twelve out of twenty people 
admitted to the hospital died in this event with a minimum aflatoxin dose of 38 ug/kgBW per day (5).  
During another outbreak of aflatoxicosis in eastern Kenya in 2004-2005, 125 deaths were 
reported.  This outbreak was caused by poorly harvested and low quality storage conditioned 
maize. The average AFB1 level in maize samples was 4,400 ppb− 220 times of Kenyan limit of 
aflatoxin in food.  From January to June 2004, 317 patients sought hospitals with the symptoms 
of liver failure (7). The numbers of aflatoxicosis cases might be underestimated, since people 
who had mild forms of aflatoxicosis might not have gone to hospitals. 
In 1988 AFB1 was classified as a potent carcinogen in humans by the International 
Agency for Research on Cancer (IARC) (1). Hepatocellular carcinoma (HCC) has been related to 
aflatoxins, especially in the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) (3, 
4). The other health effects from chronic exposure to aflatoxins might include immunologic 
suppression, impaired growth, and nutritional interference (1). Aflatoxins have been found to 
affect growth in children who are exposed to aflatoxins in their early life (3). Chronic toxicities 
of aflatoxin are often resulted from ingestions of low or moderate levels of aflatoxins (5). 
Though susceptibility to acute and chronic toxicities of aflatoxin varies along the species, 
for most species, LD50−the dose that kills 50% of tested animals− of aflatoxin ranges from 0.5 
to10 mg/kgBW (1). Because of aflatoxin toxicities, the US Food and Drug Administration 
(USFDA) does regulate the levels of aflatoxins in food and feed. No more than 20 ppb of 
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aflatoxins is allowed in food or commodities in the US trade.  Allowable limit of AFM1 in milk 
is less than 0.5 ppb (8).  
1.2 AFLATOXIN AND LIVER CANCER 
Being exposed to low levels of aflatoxins increases risk of liver cancer (7). However, some 
studies showed that a single, high doses of aflatoxin  also induce liver cancer (9). Co-presence of 
aflatoxin and HBV increases the risk of liver cancer several times higher than either exposure 
alone. The proposed mechanisms of aflatoxin on liver cancer are (i) aflatoxins may suppress 
DNA repair mechanisms , which help to limit the progression of HBV infection to liver cancer, 
and (ii) HBV might interrupt the detoxification process of aflatoxins (10).  
1.2.1 Mode of toxicity 
It has been believed that the metabolic pathway of AFB1 plays an important role in its 
toxicity, since metabolic activation is needed to exert its carcinogenicity (4). The main organ 
responsible for metabolism of aflatoxin is the liver; however, the metabolism of aflatoxin might 
occur at extrahepatic organs (11, 12).  Metabolism of aflatoxins can be divided to 3 phases: 
bioactivation, conjugation, and deconjugation.  
1.2.1.1 Bioactivation 
The CYP450 enzyme system, mainly 1A2 and 3A4, metabolizes AFB1 to the reactive 
metabolite; AFB1-8,9 -epoxide (AFBO) (4). Other predominant metabolites of AFB1 by CYP 
450 system are , aflatoxin Q1 (AFQ1), aflatoxin P1 (AFP1), which are considered less toxic than 
the parent form (AFB1) (9). AFM1 is one of the major AFB1 metabolites. Though less mutagenic, 
AFM1 is considered equally toxic as AFB1 (13). 
AFBO is highly unstable. It readily reacts with other cellular molecules. In the human 
liver, even both exo and endo isoforms of AFBO have been found, but the exo isoform is 
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predominant, much more mutagenic, and much more efficient to form DNA-adduct than the 
endo epoxide. At low substrate level, CYP1A2 is 3-6 times more efficient than CYP3A4 in 
metabolizing AFB1 to AFBO, with the ratio between exo and endo isoform of 1:1. Even both 
AFM1 and AFBO are produced by CYP1A2 activity, but the ratio between AFBO and AFM1  
produced is about 2.5:1(9).   
CYP 3A4 can either metabolize AFB1  to AFQ1−non genotoxic metabolite−or to AFBO 
at the ratio of 10:1, but because of the high expression levels of CYP3A4, it is the major 
contributor to AFBO production (9). CYP3A5 is not found enormously in adult liver compared 
with CYP3A4, but a small percentage of population carries the functional variant termed 
CYP3A5*1 and can express higher or equivalent levels of CYP3A5 when compared to CYP3A4. 
Furthermore, since AFBO is preferentially produced by CYP3A5 under low substrate conditions, 
CYP3A5 acts as an bioactivation pathway, while CYP3A4 acts as a  detoxification pathway (9). 
 All metabolites of AFB1 are hydroxylated, but only AFM1 is considered toxic via oral 
ingestion. However, this metabolite is detoxified by conjugation with taurocholic or glucuronic 
acid before excretion to the bile or urine (14). 
Other non-CYP activating pathways of aflatoxins include  epoxidation of AFB1 from 
prostaglandin H synthase and DNA-bound derivative of  AFB1 by enzyme  lipoxygenase (9). 
1.2.1.2 Conjugation 
Several enzymes involve in this phase including glutathione S-transferase (GST), ß-
glucuronidase, and sulfate transferase which produce conjugates of AFB1-glutathione, AFB1-
glucuronide, and AFB1-sulfate, respectively. Conjugation makes the toxin more hydrophilic and 
readily to excrete in the bile. This is essential to reduce toxicity of aflatoxins (15). However, 
human cytosolic fractions poorly conjugate AFBO with glutathione (9), which results in the low 
ability of the body to excrete aflatoxin.  
1.2.1.3 Deconjugation 
This phase happens in intestinal tract by intestinal bacteria.  This results in re-absorption of 
aflatoxin metabolites (16) or fecal excreted in an unbound form of aflatoxin(17). However, this 
phase has not been well characterized (16). 
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1.2.2 Pathways of pathogenesis of aflatoxin-induced liver cancer 
Carcinogenic effects of AFB1 are generally caused by the formation of AFB1-DNA adduct, 
AFB1-
7N-guanine, (AFB1-N7-Gua) leading to the base transversion from guanine to thymine. 
AFB1-N7-Gua  is formed by covalently bonding C-8 of AFB1-8,9-exo-epoxide and 
7N-guanine 
base in DNA(15).  AFB1-N7-Gua are naturally converted to two secondary lesions, an apurinic 
site and a stable form–AFB1-formamidopyrimidine (AFB1-FAPY) adduct (4). The stable adduct 
is believed to be the most mutagenic lesion (4, 9).   
There was a wealth of  evidence that  the carcinogenicity of aflatoxin is correlated well 
with the number of  DNA-adducts (9). There has been evidence from the Kenyan aflatoxin 
outbreak in 2004-2005 showing that the levels of DNA adducts in aflatoxicosis survivors are 10 
times higher than that of controls. People who died from this outbreak had more DNA adducts 
than the survivors (7). 
A mutation of p53 at codon 249 is believed to be associated with aflatoxin exposure. P53 
acts as a cancer suppressor gene by inducing apoptosis in damaged cells. In a normal situation, 
p53 binds to the protein upstream p21 and activates p21 transcription. P21 protein binds to cyclin 
dependent kinase 2 (cdk2) and impedes the roles of cdk2 in cell division. This process is an 
important checkpoint in DNA replication leading to repair before the next stage of cell divisions. 
Thus the cell division and proliferation are inhibited by the binding of p53 and p21. Therefore, a 
mutation in p53 l eads to uncontrolled cell division and proliferation, which can later result in 
tumor formation. A mutation in p53 is believed to be the underlying mechanism of HCC 
development (18).  
How aflatoxins induce liver cancer is complicated. Whereas the affinity of aflatoxins to 
other codons, such as codon 245 and 273, is similar or greater than its affinity to codon 249, only 
the codon 249 (AGGCC) represents a site of intermediate affinity for the AFB1-induced lesion. 
Therefore, not only the affinity of aflatoxins to codons but also some factors not yet indentified 
influence the selectivity in the sites of mutations (4). 
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1.3 AFLATOXIN AND OTHER AFLATOXIN TOXICITIES  
1.3.1 Immunosuppression 
Most mycotoxins affect the immune system. Suppression of the immune system makes animals 
or humans more vulnerable to infectious agents. Several animals infectious outbreaks in the past 
were associated with the presences of mycotoxins. Salmonellosis and candidiasis outbreaks in 
domestic animals in 1960 were associated with Turkey X syndrome caused by aflatoxins. In 
1977, following the presence of high concentration of aflatoxins in corn crops, a salmonellosis 
outbreak in swine took place in the Southeastern United States (19).  
1.3.1.1 Animal studies 
The effects of aflatoxins on t he immune system have been reported in several animal studies. 
These effects include, but are not limited to, cell-mediated immune response suppression,  
lymphoblastogenesis suppression, impairment of delayed cutaneous hypersensitivity, impairment 
of the graft-versus-host reaction, the decreases in splenic CD4 (helper T) cell numbers and 
interleukin 2 ( IL-2) production, and absence of the heat-stable serum factors involved in 
phagocytosis. Surprisingly, aflatoxin also affected parasite. Morbidity from malaria was 
decreased in mice treated with aflatoxins by the direct effect of aflatoxins to plasmodium parasite 
(10).  
Aflatoxins impair macrophage function in the host defense system (10) and suppressed 
murine macrophages’ productions of nitric oxide, superoxide anion, hydrogen peroxide, TNF-α, 
IL-1, and IL-6 (20). AFB1 at ≥ 100 pg/ml is cytotoxic to monocytes. Even at the much lower 
doses as 0.5-1 pg/ml, aflatoxin could inhibit phagocytosis ability of monocytes to Candida 
albicans (10). Marin and colleagues found a decrease in the immune response induced by 
Mycoplasma agalactiae in weanling piglets exposed to 280 ppb aflatoxins. The mRNA 
expressions of proinflammatory  IL-1β and TNF-α in aflatoxins treated weanling piglets (140 
and 280 ppb aflatoxins) were decreased (21).  
Several studies revealed that aflatoxins have more profound effect on cell mediated 
immune responses than humoral immunity (19); however, aflatoxin may reduce the efficiency of 
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vaccinations by decreasing humoral antibody responses to vaccines. This effect has been 
observed in poultry, rabbits, and dairy cattle. In a poultry study, aflatoxin reduced antibody titers 
to Newcastle disease, infectious bronchitis, and infectious bursal disease vaccines in the poultry 
treated with 200 ppb of  aflatoxin for less than 40 weeks (10). Furthermore, immunosuppressive 
activities induced by aflatoxin can be transferred across the porcine placentas. The offspring of 
pigs and rats treated with aflatoxin contaminated diet exhibited the reductions in humoral 
immune functions (10).  
1.3.1.2 Human studies 
Recently, a study found that aflatoxins reduced phagocytosis in normal human peripheral 
monocyte in vitro (10). A survey conducted in Gambia, where the population has the highest 
record of chronic exposure to aflatoxin, showed the reverse relationship between the saliva 
immunoglobulin (sIgA) and AFB1-albumin (AF-alb) adducts levels (22).  
Jiang et al. (2005) determined the relationship between cellular immune response and 
AF-alb adducts levels in 64 Ghanaians. They found that the individuals with high AFB1-albumin 
AF-alb adducts levels had higher levels of CD69+ activation biomarker (CD3+69+ and 
CD19+69+) than participants who had low levels of AF-alb adducts (23). CD69+ is the molecule 
which seems to be the earliest inducible cell surface glycoprotein acquired during lymphoid 
activation (24). These activated T cells and B cells, (CD3+69+ and CD19+69+), are important 
for the body to respond against infectious diseases and for the productions of antibody to 
vaccines. Also, the CD8+T cells which contained perforin or both perforin and granzyme A, 
used in a cell killing process, were found in a lower percentage in the Ghanaians who had high 
levels of AF-alb adducts (20).  However, the percentages of monocytes in peripheral blood are 
not affected by aflatoxins. Whereas, Jiang and colleagues found a non s ignificant reduction in 
human macrophage phagocytosis in individuals having high AF-alb adducts, this effect is more 
prominent in several animal studies (20). The difference in the amplitude of responses might 
suggest the existence of the species differences in the immunomodulating effect induced by 
aflatoxins.   
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1.3.1.3 Interaction between aflatoxin and human immunodeficiency virus (HIV) infection 
Recently, Jiang and colleagues reported an interaction between aflatoxin and acquired immune 
deficiency in Ghanaian population. One of the major findings from this study was that 
individuals with high AF-alb adducts (≥ 0.91 pmol/mg albumin) had lower percentages of CD4+ 
T regulatory cells and naïve CD4+ T cells and lower percentages of B-cells, compared with the 
HIV patients, who had low levels of AF-alb adducts (<0.91 pmol/mg albumin) (25). The 
interactions between aflatoxin and HIV infection, therefore, could exacerbate HIV status, 
accelerate progression to AIDS, and worsen quality of life. Williams et al. (2004) suggested that 
oxidative stress induced by aflatoxins could be an underlying interaction effect of aflatoxin and 
HIV, since oxidative stress increases HIV replication by direct effect or through the induction of 
infected leucocyte apoptosis(10).  
1.3.1.4 Mechanism  
The mechanism of immunosuppression-induced by mycotoxins is believed to be due to the 
inhibition of DNA, RNA, and protein syntheses. Aflatoxin may regulate the immune system 
through the modulation of cytokine production by a selective inhibition of certain mRNAs. 
Aflatoxins may inactivate some kinases, which inactivate genes coding for cytokines.  
AFB1 strikingly raised mRNA levels of major cytokines from macrophages, but 
suppressed the productions of their proteins. However, the same dose of AFB1 slightly reduced 
mRNA and protein syntheses of cytokines from lymphocyte (26). These findings suggested that 
aflatoxins have predominant effect on m acrophages and affect protein transcription and 
translation in macrophage (20).  
1.3.2 Growth impairments 
Children could be exposed to aflatoxins during their early lives. Initially after birth, if mothers 
consume diets contaminated with aflatoxin, the infants are exposed to the hydroxylated 
metabolite of aflatoxin, aflatoxin M1 (AFM1), through breast milk. Later, they gradually make 
the transition from breast milk to other sources of nutrients. This is a dynamic process, in which 
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the transition involving first the combination of breast milk and weaning food, then family food, 
will completely replace breast milk (27).  
According to Ghana survey in 1987, 58% of children had body weights below 80% of the 
National Center for Health Statistics (NCHS) weight-for-age, 8% were severely malnourished, 
and 52% were stunted. In Ondo State, Nigeria, a survey in 1986 revealed that 32% of children 
aged 6-36 months were stunted, 7% were wasted, and 28% were severely malnourished. A later 
national survey in 1990 showed that 43% and 22% of children were stunted and wasted, 
respectively (28).   
There has been a wealth of evidence from either laboratory or epidemiological studies 
suggesting an association between aflatoxin and growth performances, of aflatoxin exposure in 
children (see chapter 5). Moreover, in utero aflatoxin exposure is associated with infant’s low 
birth weights (29, 30), lower height at birth (31) and lower increases of the heights and weights 
of children within first year of life (32)  
1.3.2.1 Mechanism 
The mechanisms by which  of aflatoxin leads to stunted growth in children have yet to be 
understood. Several possible mechanisms have been proposed, including immune suppression 
and intestinal toxicity. In animal studies, aflatoxins cause immunosuppressive effects either in 
the cell mediated immune system or the humoral immune system. Nontheless, the reduction in 
sIgA, an important component in mucosal immunity, was found in aflatoxin exposed children 
(22). The impairment in mucosal immune response makes the intestinal epithelium vulnerable to 
bacteria or toxins and could  i ncrease local inflammation (27) thus impairing nutrient 
reabsorption. 
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2.0  COSTS AND EFFICACY OF PUBLIC HEALTH INTERVENTIONS TO 
REDUCE AFLATOXIN–INDUCED HUMAN DISEASE 
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2.1 ABSTRACT 
This study reviews available information on the economics and efficacy of aflatoxin risk-
reduction interventions, and provides an approach for analysis of the cost-effectiveness of public 
health interventions to reduce aflatoxin-induced human disease.  Many strategies have been 
developed to reduce aflatoxin or its adverse effects in the body.  However, a question that has 
been under-addressed is how likely these strategies will be adopted in the countries that need 
them most to improve public health.  This study evaluates two aspects crucial to adoption of new 
technologies and methods: the costs and the efficacy of different strategies.  First, we describe 
and categorize different aflatoxin risk-reduction strategies into preharvest, postharvest, dietary, 
and clinical settings.  Then we compile and discuss relevant data on the costs and efficacy of 
each strategy, in reducing either aflatoxin in food or its metabolites in the body.  In addition, we 
describe which crops are affected by each intervention, who is likely to pay for the control 
strategy, and who is likely to benefit.  A framework is described for how to evaluate cost-
effectiveness of strategies according to World Health Organization standards.  Finally, we 
discuss which strategies are likely to be cost-effective and helpful under different conditions 
worldwide of regulations, local produce and soil ecology, and potential health emergencies. 
2.2 INTRODUCTION 
Aflatoxins are secondary metabolites of the fungi Aspergillus flavus and A. parasiticus.  These 
species are prevalent in food crops – particularly maize, groundnuts, oilseeds, and tree nuts - in 
tropical and subtropical regions worldwide.  Factors that influence whether these fungi produce 
aflatoxin include drought stress and rainfall, adaptation of crop genotype for its climate, insect 
damage, and agricultural practices.    These fungi can also produce aflatoxin in postharvest 
conditions: storage, transportation, and food processing.  Maize and groundnuts are the major 
sources of human exposure (the number of exposed persons exceeding several billion) because 
of these foods’ high consumption rates worldwide and their susceptibility to aflatoxin 
contamination (6).   
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Aflatoxin B1 (AFB1), the most toxic aflatoxin, is the most potent naturally occurring 
chemical liver carcinogen known.  For people who are chronically infected with hepatitis B  
virus (HBV; common in China and Africa), aflatoxin consumption raises by up to thirty-fold the 
risk of hepatocellular carcinoma (HCC; liver cancer) compared with either exposure alone (33).  
Acute aflatoxicosis, characterized by hemorrhage, acute liver damage, edema, and death, can 
result from extremely high doses of aflatoxin.  In recent years, hundreds of aflatoxicosis cases in 
Africa have been associated with consumption of contaminated home-grown maize (34).  
Aflatoxin exposure is also associated with immunotoxicity in humans (10, 22, 23, 25) , and with 
stunted growth in children (32, 35, 36).  
To limit aflatoxin exposure, over 100 na tions worldwide have set maximum tolerated 
levels (MTLs) of aflatoxin in food (19).  These standards offer public health protection in 
industrialized nations, but arguably have little effect in less developed countries (LDCs), for 
several reasons.  First, the food consumed from subsistence farms, which are widespread in 
LDCs, rarely enters any sort of regulatory inspection for aflatoxin (6, 10).  Second, even if this 
food did meet the MTLs for aflatoxin, many people in LDCs consume such high levels of maize 
and groundnut products that their daily aflatoxin exposure would still render them vulnerable to 
disease (37).  Third, LDCs that attempt to export maize and nuts abroad may find their export 
markets severely jeopardized by strict aflatoxin standards, resulting in potential countervailing 
risks of exporting the best foods and keeping the worst domestically (38). 
Hence, it is estimated that about 5 bi llion people worldwide suffer from uncontrolled 
exposure to aflatoxin (6).  Aflatoxin-associated health effects pervade sub-Saharan Africa and 
East Asia. These effects could be mitigated through effective use of current agricultural 
knowledge and public health practice. The discussion of this problem and its remedies must 
include the underlying question of food insufficiency and more general economic challenges in 
developing countries (6). 
Several interventions to reduce and prevent aflatoxin toxicity have been developed.  
These range from aflatoxin control methods in agricultural practice through chemopreventive 
dietary constituents to vaccination against HBV. Agricultural interventions to reduce aflatoxin 
could be done either in preharvest (field) or postharvest (drying, storage, transportation, etc.) 
conditions.  Meanwhile, there is growing research interest in using certain substances available 
in foods and natural products to reduce aflatoxin’s adverse impacts in the body.  By binding 
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aflatoxin in the gastrointestinal tract, or inducing enzymes involved in aflatoxin metabolism 
pathways, several substances can reduce aflatoxin bioavailability in humans.  The HBV vaccine 
neither reduces aflatoxin levels in food nor reduces aflatoxin’s bioavailability in the body; 
however, it reduces aflatoxin-induced liver cancer by greatly reducing the risk of chronic HBV 
infection, thereby preventing the synergistic impact of HBV and aflatoxin in HCC pathogenesis. 
Understanding the costs and efficacy of different aflatoxin control interventions can help 
decision makers–be they government policymakers or farmers or consumers–to optimally 
allocate resources, particularly in conditions of scarcity. Wu et al. (2008) presented three case 
studies for cost-effectiveness of aflatoxin control in the United States: two biocontrol agents 
(Afla–GuardTM in groundnuts and AF36 in cottonseed) and a transgenic crop (Bt maize) (39).  
However, this assessment was limited to the US, and may not have equal applicability 
worldwide.  This study reviews the available data on costs and effectiveness for interventions 
that could be used to control aflatoxin from a global perspective.   
Table 2-1 shows the factors that we include in our analysis.  First, we are interested in 
whether the intervention is agricultural (methods that take place in the field or postharvest 
settings), dietary (supplements or processing or natural constituents in food), or clinical (HBV 
vaccination).  This gives us information about who needs to implement the intervention, and how 
often and in what context it needs to be done.  Second, we are interested in whether the 
intervention in question reduces aflatoxin concentrations in food, or whether it reduces 
bioavailability of aflatoxin or its metabolites in the body.  This provides useful information on 
the nature of the intervention and whether the intervention can potentially reduce health impacts, 
trade losses, or both.  Third, we are interested in how much the intervention costs, and how 
effective it is.  These are obviously the main factors in a cost-effectiveness assessment.  Finally, 
we are interested in who pays for the intervention (e.g., growers, consumers, or local / national 
government) and who benefits from it.   
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Table 2-1. Factors included in cost-effectiveness analysis of public health interventions to reduce aflatoxin 
and its related illnesses. 
Factor Categories Rationale 
Stage at which 
intervention occurs 
• Agricultural 
• Dietary 
• Clinical 
To understand how many people, and 
what group of people, must 
implement the intervention; and 
under what conditions 
What the intervention 
reduces 
• Aflatoxin levels in food 
• Bioavailability of aflatoxin 
and its metabolites in body 
To determine whether the 
intervention reduces adverse health 
effects, adverse market effects, or 
both 
Cost–effectiveness of 
intervention 
• Cost 
• % reduction of aflatoxin or 
bioavailability of aflatoxin / 
metabolites 
To determine the economic factors 
underlying each intervention: costs 
vs. potential benefits 
Stakeholder involvement • Who pays for the 
intervention 
• Who benefits from the 
intervention 
To understand if the appropriate 
economic and health incentives exist 
for people to adopt the intervention 
2.2.1 Preharvest interventions  
Because most aflatoxin problems begin and develop in the field, strategies are needed to prevent 
infection of growing plants by toxigenic fungi.  Developing genetic resistance to Aspergilli in 
maize and groundnuts is a high priority (40, 41).  Worldwide, the advantages of using resistant 
plant genotypes include direct health and economic benefits, the lack of impact on crops or the 
environment, and the ability to use these genotypes in combination with other aflatoxin control 
strategies (42).  
A number of resistant inbred maize lines have been indentified, including MI82 (43), 
Mp420, Mp313E, and GT-MAS:gk (44).  Sources of resistance to each of these pathogens have 
been identified and have been incorporated into public and private breeding programs, and have 
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been extended to include germplasm lines from Africa (42, 45). Potential biochemical and 
genetic resistance markers have been identified in crops, particularly in maize, which are being 
utilized as selectable markers in breeding for resistance to aflatoxin contamination (40).  Several 
proteins associated with resistance (RAPs) include, but are not limited to, globulin-2 proteins, 
late embryogenesis abundant proteins (LEA3 and LEA14), a stress-related peroxiredoxin 
antioxidant (PER1), heat-shock proteins (HSP17.2), a cold-regulated protein (COR), and an 
antifungal trypsin-inhibitor protein (TI) (46).  Now that the sequencing of the A. flavus genome 
has been completed, and genes that potentially encode for enzymes involved in aflatoxin 
production have been identified, genomics as a tool for combating aflatoxin biosynthesis has 
gained much ground (47-49).   
The development of groundnut cultivars with resistance to preharvest aflatoxin 
contamination has also yielded promising results.  S creening techniques have been developed 
that can measure genetic differences in susceptibility to aflatoxin contamination, and these 
techniques have been used to identify multiple accessions that have shown significant aflatoxin 
reduction in multiple environments.  Groundnut genotypes with drought resistance have also 
shown aflatoxin reduction (50, 51).  Aflatoxin resistant genotypes have been developed in other 
parts of the world, and have shown success in aflatoxin reduction (52).  
Transgenic (genetically modified) crops may also play a role in reduction of preharvest 
aflatoxin accumulation. Insect damage is one factor that predisposes maize to mycotoxin 
contamination, because insect herbivory creates kernel wounds that encourage fungal 
colonization, and insects themselves serve as vectors of fungal spores (53, 54). Bt maize is one 
of the most commonly grown transgenic crops in the world today. It contains a gene from the 
soil bacterium Bacillus thuringiensis (hence the name Bt), which encodes for crystalline proteins 
that are toxic to certain members of the insect order Lepidoptera (reviewed by Wu 2007).  Earlier 
Bt events showed only mixed success in controlling aflatoxin (55), as they provide insect 
protection primarily against European corn borer and Southwestern corn borer, as opposed to the 
insects that have been associated with aflatoxin contamination: fall armyworm and maize 
earworm.  However, a new Bt event that has just become available commercially and provides 
enhanced protection against these insects has shown promise in significantly reducing aflatoxin 
in field trials (56). In addition to Bt maize, prototypes of genetically engineered crops have been 
developed that contain genes encoding fungal growth inhibitors for reducing fungal infection. 
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Gene clusters housing the genes governing formation of aflatoxin have been elucidated and are 
being targeted in strategies to interrupt its biosynthesis (40). 
Biocontrol of aflatoxin refers to the use of organisms to reduce the incidence of 
Aspergilli in susceptible crops, so as to reduce aflatoxin contamination.  The most widely used 
biocontrol method employs atoxigenic strains of Aspergilli that can competitively exclude 
toxigenic strains from colonizing crops. These biocontrol methods have been used in maize, 
groundnuts, and cottonseed worldwide (57-62).  Importantly, atoxigenic A. flavus strains have 
been found in sub-Saharan Africa, which show promise for controlling aflatoxin in African 
maize (59, 62).  Biocontrol methods, though applied in the field, can result in reduced aflatoxin 
in crops for as long as six months postharvest (Dr. Ranajit Bandyopadhyay, personal 
communication). 
Cultural practices, including crop rotation, tillage, planting date, and management of 
irrigation and fertilization, can also help to prevent Aspergillus infection and subsequent 
aflatoxin accumulation by reducing plant stress.  These practices can have important effects on 
infection and subsequent mycotoxin accumulation (41).  Ultimately, a combination of preharvest 
strategies, as described above, may be needed to adequately prevent mycotoxin contamination in 
the field (40).  
2.2.2 Postharvest interventions 
Current food storage and processing practices in industrial nations can prevent postharvest 
development of mycotoxins, but postharvest aflatoxin accumulation remains a threat in less 
developed countries (LDCs), especially in tropical areas.  Hence, knowledge of the key critical 
control points during harvesting, drying and storage stages in the cereal production chain are 
essential in developing effective prevention strategies post-harvest (63).  Possible intervention 
strategies include good agricultural and storage practices, such as early harvesting, proper 
drying, sanitation, proper storage, and insect management, among others (64).  This is true not 
just for maize and groundnuts (the major sources of aflatoxin exposure for humans), but also for 
tree nuts such as pistachios, where there have been dramatic improvements in aflatoxin reduction 
in Iran due to improved drying and storage conditions over the past decade (65). 
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Removing existing aflatoxin contamination is possible by sorting aflatoxin-contaminated 
kernels from relatively cleaner ones. This can be done by either simple physical (e.g., 
handsorting) or flotation and density segregation methods. Sorting by these types of methods has 
been shown to significantly decrease aflatoxin levels in postharvest maize (66).  
After sorting, there are several methods to prevent the growth of Aspergilli and hence 
reduce aflatoxin contamination postharvest. These include control of moisture levels in stored 
crops, temperature, and insect pests and rodents (66). 
Combinations of these methods to reduce postharvest aflatoxin have been tested for 
efficacy in actual rural village conditions.  Turner et al. (2005) describe a postharvest 
intervention package to reduce aflatoxin in groundnuts, tested in Guinea.  The package consisted 
of six components: education on  hand-sorting nuts, natural-fiber mats for drying the nuts, 
education on proper sun drying, natural-fiber bags for storage, wooden pallets on which to store 
bags, and insecticides applied on the floor of the storage facility under the wooden pallets (67). 
In industrial nations, drying with forced air and supplemental heat is common to control 
moisture levels in crops. At 70°C, A. flavus infection in maize is significantly reduced compared 
to that in the maize dried at 40°C. But this method can potentially reduce seed germination and 
increase stress cracks (68). 
Chemical methods can detoxify aflatoxins by reduction, destruction, or inactivation.  
These methods include ammoniation, acid treatment, oxidizing agents, and reducing agents; and 
are reviewed in-depth in Kabak et al. (2006).  There are several issues and risks associated with 
these methods: it is  difficult to detoxify the aflatoxin without reducing nutritive value and 
palatability; parameters such as reaction time, temperature, and moisture must be monitored; 
some necessary additional cleaning treatments can be expensive and time-consuming, and toxic 
byproducts may be produced.   
2.2.3 Dietary and food processing interventions 
A variety of dietary interventions can reduce aflatoxin-related health risks.  One simple dietary 
intervention, where feasible, is to consume less maize and groundnuts, in favor of other food 
crops that have significantly lower aflatoxin contamination, such as sorghum and pearl millet 
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(69).  Where it is not easy to make such a dietary shift, however (e.g., where maize and 
groundnuts have traditionally been staples), other dietary interventions may prove helpful. 
One class of dietary interventions involves adsorption of aflatoxin.  A dsorbent 
compounds can be included in food or feed or taken separately during mealtimes to bind 
aflatoxin in the gastrointestinal (GI) tract, resulting in reduced aflatoxin bioavailability.  Several 
materials have varying degrees of this ability to bind aflatoxin, including bentonites, zeolites, 
diatomaceous earth, activated charcoal, and fibers from plant sources. One material that has 
proven effective in animal feed and is showing promise in human trials is calcium 
montmorillonite, marketed as NovaSil clay (NS).  NS has been shown to prevent aflatoxicosis in 
many animal species when included in their diet, by binding aflatoxin with high affinity and high 
capacity in the GI tract (70). NS has been shown to reduce  aflatoxin toxicity on body and organ 
weights, feed intake, and hepatic vitamin A when tested in broiler chicks. No toxicity has been 
found in a dose as high as 0.5% w/w in the diet (71). Phase I (72) and Phase II (73) clinical trials 
confirm the safety of NS for use in human food, and provide assurance that NS does not bind 
with vitamin A and E, thereby does not result in elimination of these nutrients.   
Green tea polyphenols (GTPs) have been shown to inhibit chemically-induced cancers in 
animal and epidemiological studies (70, 74).  GTPs inhibit initiation of aflatoxin-induced HCC 
in rats by modulating aflatoxin metabolism (75); and in humans, there are inverse associations 
between green tea consumption and cancer risk (76).   
Chlorophyllin, a derivative of chlorophyll, is a natural constituent of green vegetables in 
the human diet that has shown anticarcinogenic effects in animals (77).  Chlorophyllin appears to 
protect against aflatoxin by sequestering aflatoxin during the digestive process and hence 
impeding aflatoxin’s absorption.  In addition, chlorophyllin may have enzyme-inducing 
properties that contribute to its mechanism of detoxification (74, 78). Aside from binding 
aflatoxin, chlorophyllin is capable of binding certain carcinogenic substances, such as polycyclic 
aromatic hydrocarbon (PAH), heterocyclic amines, and other hydrophobic molecules (79). 
Moreover, other modes of action of chlorophyllin, such as scavenging free radicals (80), 
inducing  apoptosis in cancer cells (81), inducing cell-cycle arrest, and  altering markers of cell 
differentiation (82), have been proposed for its protective effects against DNA damage and colon 
cancer. Side effects of chlorophyllin are rare, but may include diarrhea and discoloration in urine 
and feces (83). 
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A variety of substances have the potential to reduce aflatoxin-induced HCC by inducing 
enzymes, such as glutathione-S-transferases (GSTs), that mediate conjugation of the reactive 
intermediate aflatoxin-8,9-epoxide. Genetic differences exist in the extent to which aflatoxin in 
the diet is biotransformed into this harmful epoxide; therefore, agents that induce GSTs have 
varying effectiveness among individuals. Dithiolethiones (oltipraz) and sulforaphane have this 
ability, and may also inhibit HBV transcription through elevation of p53 tumor suppressor genes 
(84). Oltipraz is an antischistosomal drug; while the precursors to sulforaphane, glucosinolates, 
can be found in cruciferous vegetables such as broccoli (74, 85, 86).   
There is increasing evidence that some lactic acid bacteria have the ability to bind 
aflatoxin B1 (87-89). These bacteria are important in the fermentation of many foods, including 
vegetables, fruits, and dairy products. The main purpose of Lactobacillus inclusion in food has 
typically been fermentation, not the prevention of aflatoxin risk.  Hence, inclusion of culturally 
appropriate fermented foods in the diet may be a feasible method of partially reducing aflatoxin 
risk.   Other methods of food processing have moderate ability to reduce aflatoxin and other 
mycotoxins (90), such as extrusion processing at temperatures greater than 150°C.   
2.2.4 Hepatitis B vaccination 
A regular practice now in the US and other developed nations, HBV vaccination in children is 
still rare in many parts of the world.  Vaccinating children against HBV has been shown, over 
the last three decades, to significantly decrease HBV infection in several regions including 
Europe (91, 92), Taiwan (93), and Thailand (94).  This vaccine has already had, and will 
continue to have, significant impacts on liver cancer incidence, particularly in Africa and East 
Asia, considering that roughly 65 million out of 360  million individuals who are chronically 
infected live in Africa (95).  Though the vaccine itself has no impact on actual aflatoxin levels in 
diets, it  reduces aflatoxin-induced HCC by lowering HBV risk, thereby preventing the 
synergistic impact of HBV and aflatoxin in inducing liver cancer. However, other health effects 
of aflatoxin such as retardation of growth and immunomodulation are not altered by HBV 
vaccination.  Moreover, those who already have chronic HBV infection would not benefit from 
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the vaccine, which is why it is very important for this vulnerable subpopulation to avoid 
aflatoxin exposure as much as possible. 
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Table 2-2. Costs and efficacy of agricultural interventions to reduce aflatoxin and its adverse health effects. 
  Efficacy    
 Intervention Aflatoxin reductiona Aflatoxin 
adduct reduction 
Cost Who pays Who benefits 
Agricultural 
(preharvest 
and 
postharvest) 
Aflatoxin 
resistance 
breeding 
(conventional 
and transgenic) 
Conventional: >70%; 82–
93% [G] (50, 52) 
– Research & development costs; no 
expected additional cost to grower 
Institutes funding 
research 
Growers, 
Consumers 
Transgenic: 47% in Bt 
maize (56) 
– $21/acre [Bt maize] (39) Growers Growers, 
Consumers 
Biocontrol 
using 
competitive 
fungi 
60–87% [M] (58) – $10–$12/ha ($4–$5/acre; Dr. 
Ranajit Bandyopadhyay, personal 
communication) 
¢0.52 –¢0.63/kg (Nigeria) 
Growers Growers, 
Consumers 
70–91% [G] (96) – $17–$32/acre [Afla-GuardTM] (39) 
¢0.21–¢0.39/kg (USA) 
Growers Growers, 
Consumers 
 80% AF36 [C] (97) – $6–$16/acre [AF36] (39)  
¢1.50–¢4.00/kg USA) 
Growers Growers, 
Consumers 
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Table 2-2 (continued) 
  Efficacy    
 Intervention Aflatoxin reductiona Aflatoxin 
adduct reduction 
Cost Who pays Who benefits 
 Irrigation+ 
insecticide  
99% [M] (98) – $1,100–$1,300/acre to install 
irrigation (99)  
Drip-Micro Irrigation System 
$960–1,770 / acre  for the drip on 
orchard (surface) irrigation system 
(CI) 
$1,300–2,250/acre for the drip on 
orchard (buried)  irrigation system 
(CI) 
$640–1,600/acre (CI)  + $240–480 
(AC for hose replacement cost) for 
the above ground row crop drip 
system 
$ 1,440–4,010/acre for  permanent 
installation cost of subsurface row 
crop drip (100) 
Government, 
growers 
Growers, 
Consumers 
    Sprinkler Irrigation System 
$ 740–940/acre  (CI)+ $130 –170 
(AC) (101) 
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Table 2-2 (continued) 
  Efficacy    
 Intervention Aflatoxin reductiona Aflatoxin 
adduct reduction 
Cost Who pays Who benefits 
    Surface Irrigation System 
$400–810/acre (CI) + $220/acre 
(AC) for the siphon tube 
$210–420/acre (CI) + $170/acre 
(AC) for the gated pipe 
$600–1,200/acre (CI) + $250 (AC) 
for the surge flow 
$340–680/acre (CI ) + $190 (AC) 
for the cablegation pipe (102) 
  
 Postharvest 
intervention 
package 
(natural fiber 
bags, wooden 
drying pallets, 
insecticide) 
69% [G] (67) 57.2% lower aflatoxin 
albumin  adducts in 
humans 
$61 per household for several 
years [bags and wooden pallets 
can be reused] (67) 
Growers Growers, 
Consumers 
 Artificial 
drying 
  4.5 cents per bushel (M) (103) Growers Consumers 
Note: **All cost data are converted to USD 2009 values.    a C= cottonseed, M= Maize, G = Groundnut, NA = Not available, CI = Capital investment, AC = Annual cost 
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Table 2-3. Costs and efficacy of dietary and clinical interventions to reduce aflatoxin’s adverse health effects. 
Intervention Efficacy Cost Who pays Who benefits 
Aflatoxin 
adduct reduction 
HCC reduction 
Dietary/ 
Chemo–
prevention 
 
NovaSilTM  
clay  
58.7% lower AFM1; 
~25% lower Aflatoxin 
albumin adducts in 
humans (104) 
– $0.73 per  person per year  b ased on 3-g 
daily dose clay preparation  (Dr.  Timothy 
Phillips, personal communication 2009) 
Consumers, 
government 
Consumers 
Green tea 
polyphenols 
(500–1000 
mg) 
~ 43% lower AFM1 in 
humans; > 15% lower 
aflatoxin  a lbumin 
adducts at 500 mg 
dose (105); 
20–30%  lower AFB1–
DNA adduct in rats 
(75) 
Up to 70% lower 
hepatic preneoplastic 
lesions in rats (75) 
$0.20 − $1 per day 
(polyphenols levels range from 710.5 – 
900 mg) 
(106-108) 
Consumers 
 
Chlorophyllin 55% lower AFB1-N
7-
Guanine in humans 
(78) 
– $0.10/day  (Dr. Thomas  Kensler, personal  
communication) 
Consumers 
 
Oltipraz 51% lower AFM1 [500 
mg weekly], 2.6-fold 
increase in aflatoxin 
B1 mercapturic-acid 
excretion [125 mg 
daily] (109) 
42% lower HCC 
incidence in F344 rats 
(110)  
$ 59, $ 236 / per 5 and 25 mg (111) 
[Note: these are costs for analytical grade 
Oltipraz; no cost data for pharmaceutical 
grade] 
Consumers 
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Table 2-3 (continued) 
Intervention Efficacy Cost Who pays Who benefits 
Aflatoxin 
adduct reduction 
HCC reduction 
 Sulforaphane   
(400 µmol ~ 
70 mg) 
No significant 
reduction in AFB1-N
7-
Guanine, but inverse 
association for 
dithiocarbamate 
excretion and AFB1-
N7-Guanine  (85)  
– $24.80 for 30 capsules  
(0.21% of sulforaphane  in 250 mg) 
(amazon.com); 
If consuming broccoli sprouts or sprouts 
tea: 1 dose (385 g sprouts) = $0.31 
Consumers 
 
Vaccine 
 
Hepatitis B 
vaccine 
– 84–95% HBV reduction 
 45–50% HCC 
reduction  
(112-114) 
$910.41/death averted 
$23.09 per DALY averted (115) 
Government  HBV-
uninfected 
individuals 
   Note: ** All cost data are converted to USD 2009 values 
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2.2.5 Costs and efficacy of preharvest interventions 
Breeding aflatoxin resistance into crops requires upfront research and development funds in and 
between various nations, depending on w here the seed will be deployed.  H owever, once the 
resistant strains of crops are bred, the seed need not be significantly more expensive to farmers 
than existing genotypes.  Efficacy in reducing aflatoxin has been shown to be as high as 90–98% 
in resistant maize varieties developed and tested in the US (116). Groundnuts bred for aflatoxin 
resistance in the US achieved at least a 70% reduction in preharvest aflatoxin contamination in 
multiple environments (50). Similarly, naturally aflatoxin-resistant lines in India had 
significantly lower aflatoxin levels compared with susceptible lines and produced higher pod 
yield (52).  These efficacies do not necessarily apply to maize- and groundnut-producing regions 
outside the US and India, but demonstrate what the breeding technologies have the potential to 
achieve.  A  caution with interpreting these differences in aflatoxin levels is that one should 
distinguish between naturally resistant vs. specifically bred lines in terms of aflatoxin reduction. 
Importantly, drought stress is a critical factor for preharvest aflatoxin contamination in 
groundnuts and maize. In years when drought stress is not critical, even susceptible lines of 
groundnuts are less likely to be contaminated by aflatoxin. Now breeding efforts are focused in 
releasing lines with the specific aflatoxin-resistant attribute rather than improving on 
serendipitous levels found in natural lines. 
Transgenic maize varieties will likely incur a greater cost to growers; however, the cost 
of transgenic seed is lower in LDCs because biotechnology companies are providing free 
intellectual property there.  In the US, Bt maize seed costs about $21 per acre more than 
conventional maize seed (39); the cost would be significantly lower in LDCs.  Field trials of new 
Bt maize events in the US, which are effective against the insect pests that predispose maize to 
Aspergillus infection, show a 47% reduction in aflatoxin compared with non-Bt isolines (56).    
The costs of biocontrol vary depending on t he product and the locale.  In the United 
States, the per acre cost of applying AF36 to control aflatoxin in cottonseed ranges from $6–$16 
per acre, and achieves 70–90% aflatoxin reduction compared with cottonseed from untreated 
fields (39, 97).  Afla-GuardTM applied to groundnuts costs about $17–$32 per acre (39), with 70–
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91% aflatoxin reduction compared with untreated groundnuts (96). Because of the local strain-
specific response and to avoid introducing foreign Aspergilli, it is important to identify local 
atoxigenic strains that potentially competitively exclude toxigenic strains.  Biocontrol studies in 
Nigerian maize using local atoxigenic strains of A. flavus have shown efficacy levels at as high 
as 90%, with a cost of about $10–$12 per hectare: $4.04–$4.86 per acre (Dr. Ranajit 
Bandyopadhyay, personal communication). 
Though the cost per unit area provides useful information for policy makers and growers 
to determine total cost for applying biocontrol to a specific area, the cost of biocontrol per 
consumption unit helps policy makers and growers to roughly screen whether biocontrol is 
economic feasible. To convert the cost data to consumption unit, we obtained production yields 
per unit area (117) and divided by the per unit area cost. In the U.S., predicted groundnuts 
production in 2009 (based on 2003–2007 FAOSTAT database) is about 3,300 kg per hectare, or 
8,200 kg per acre, hence Afla-GuardTM costs 0.21–0.39 cents per kilogram of groundnuts. The 
cost of biocontrol per kilogram of maize in Nigeria ranges from 0.52 cents to 0.63 cents, based 
on the predicted maize yield in 2009 of 1,900 kg/ha. 
A combination of irrigation systems and insecticide applications can reduce aflatoxin 
levels by 99% in maize, compared with non-irrigated, non-treated maize in the US (98). 
However, this combined intervention might be costly in LDCs where irrigation systems have yet 
to be installed widely. The cost of insecticide varies widely, depending on t he locale and the 
chemical.  
Methods for irrigation vary greatly from a simple method using watering-cans or buckets 
to complicated methods that require complex equipment and maintenance. In the US, the initial 
cost of drip- and micro-irrigation systems ranges from US $ 640 t o $4,000 per acre, depending 
on the type; e.g. surface, buried or sub-surface drip systems (100). The capital cost per acre of 
sprinkler irrigation systems ranges from US $740–$940. The cost for ownership (depreciation, 
insurance, and interest) and operating per year is about US$ 130–$170 per acre (101). 
Compared to sprinkler methods, surface irrigation systems, in general, need lower energy 
and capital requirements, but this method has disadvantages: higher labor requirements, lower 
water efficiency and potential soil erosion. The costs of four types of surface irrigation systems, 
including the siphon tube, the gated pipe, the surge flow, and the cablegation pipe have been 
estimated for 20 acres at $220, $170, $250, and $190, respectively (102). The estimated cost for 
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irrigation system installation is about $1,100–1,300 per acre (99), but if traditional crop-watering 
methods are used, the cost is much lower (and efficacy is perhaps also lower).      
2.2.6 Costs and efficacy of postharvest interventions 
Aflatoxin control can also be achieved by sorting, proper drying of food, and suitable storage 
conditions. Mechanical blanching and sorting of groundnuts in the US has the ability to almost 
completely eliminate aflatoxin, and the blanching and sorting each cost about $150–$170 per ton 
(118). In LDCs, it is far less common to have blanching and sorting machines, so most sorting of 
groundnuts is done by hand. The cost in terms of lost product varies enormously, depending on 
aflatoxin levels in any given harvest. Even the efficacy of sorting may vary, depending on how 
well farmers can identify aflatoxin-contaminated nuts – hence, the importance of education and 
outreach to farmers on aflatoxin contamination and its identification.  However, time-related 
costs should also be taken into account. It is estimated that one farmer would require an entire 
day to hand-sort 40–50 kg groundnuts (Dr. Jonathan Williams, personal communication). 
Turner et al.’s (2005) postharvest intervention package reduced aflatoxin levels in 
groundnuts by 69% compared with control groundnuts.  Moreover, mean serum aflatoxin 
albumin adducts in villagers adopting this package was 57.2% lowered than that of the control 
villagers five months after harvest. While the initial cost of this package was about $50 per 
household in 2005 to improve the storage condition of 25 groundnut bags, many components of 
the package last for several years (e.g., the wooden drying pallets, storage bags, and insecticide) 
(67).  
The cost of artificial drying to reduce aflatoxin depends on t he costs of fuel and 
electricity, and the differences of moisture content (MC) in harvested crops and the required 
levels. Reducing one point of moisture from a bushel of maize (25.40 kg) costs about 4.5 cents 
(103). Whether they choose to dry their product using natural or artificial drying method, 
growers in developed countries, somehow, have to “pay” for excess moisture left in their grains. 
Increase in field loss due to stalk lodging, insect and spreading of ear molds often happens with 
field drying method. Grain storage operators charge growers about 11–12 cents per point (MC) 
per bushel (103) for drying grain delivered too wet. 
29 
One chemical treatment option, ozonation, costs only $5 per ton (119). Although ozonation can 
completely degrade AFB1 at high moisture and temperature for 2 hours, animals fed with the 
treated cottonseed and peanut meal had lower protein efficiency ratios than those fed the 
aflatoxin-contaminated meal, indicating that ozonation might degrade essential nutrients or 
produce new toxins (119). 
2.2.7 Cost-effectiveness of dietary aflatoxin risk reduction strategies 
Dietary interventions do not directly reduce aflatoxin in food, so aflatoxin biomarkers are the 
important intermediate endpoints to measure the efficacies of diet against aflatoxins’ toxicities. 
Several metabolites of AFB1 and aflatoxin macromolecular adducts are currently used as 
biomarkers of aflatoxin exposure. The most commonly used biomarkers for recent (short-term) 
aflatoxin exposure are urinary aflatoxin M1 (AFM1), and aflatoxin DNA adducts. AFM1, secreted 
in urine and breastmilk, is an oxidative metabolite of AFB1. Levels of AFM1 reflect aflatoxin 
exposure in the past 24 to 48 hours.  In humans, it is estimated that about 0.2% of AFB1 is 
excreted as AFB1-N
7-Guanine (120). Twenty-four hour excretions of aflatoxin B1-DNA adduct 
at N7 of guanine (AFB1-N
7-Gua) in urine following aflatoxin exposure in rats have shown to be 
linearly correlated with aflatoxin exposure. AFB1-N
7-Gua, aside from being a biomarker for 
aflatoxin exposure in more short-term time scales (over the last day), reflects DNA damage that 
can in the long term increase risk of developing HCC (121). It is noteworthy that high variations 
of the short-term aflatoxin biomarkers, which may reflect the heterogeneity of contamination, 
have been reported (104, 105). An increased excretion of urinary aflatoxin mercapturic acid 
(AFB1-NAC), a phase 2 AFB1 metabolite, is reported in a study of oltipraz, which is believed to 
induce phase 2 enzyme metabolism (109). 
Unlike urinary AFM1 and AFB1-N
7-Gua, albumin adducts of aflatoxin provide integrated 
levels of aflatoxin exposure over a period of months because of the relatively long turnover 
period of albumin (the half-life of albumin is approximately 20 da ys in healthy individuals). 
Though the longer period (e.g., years) of aflatoxin albumin adducts  in body is also proposed 
(104).   The level of aflatoxin albumin adducts  in maternal blood has been associated with 
decreased height and weight gain during the first year of life (32).  
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Aside from the aforementioned biomarkers, radiolabeled aflatoxin B1 has been used as 
markers in several in vitro and in vivo aflatoxin studies (122-124). The results from a ch icken 
study, in which carbon-14 (14C) radiolabeled aflatoxin was used as a marker, showed that with 
NovaSil doses of 0.5%, bioavailability of aflatoxin in the blood and liver were  5.3% and 14.6% , 
respectively, compared to those  in the control group (124). Aflatoxin-albumin adducts in both 
low-dose and high-dose NovaSil intervention arms – when administered in capsules three times 
daily – were significantly lower than those in the control arm after 3 months, with a roughly 25% 
reduction: 0.89–0.90 pmol mg-1 vs. 1.20. A 58.7% reduction in AFM1 was also observed in the 
high-dose arm three months into the study (104).  Adding 4.5 kg of calcium montmorillonite clay 
to a ton of animal feedstuffs costs $2–$6 (125).  Texas Enterosorbent, Inc. has developed a new 
related product intended for future human use: calcium aluminosilicate/uniform particle size 
NovaSil (CAS/UPSN). This new product would cost about 18 cents per 3-gram daily dose (Dr. 
Robert Carpenter, personal communication). If NovaSil were blended into food, such as maize 
meal, the cost could be decreased and the efficacy might be increased, depending on dose. As 
such, the cost could be as low as $0.73 per person per year (Dr. Timothy Phillips, personal 
communication). 
Green tea polyphenols (GTPs) appeared to inhibit aflatoxin-induced initiation of HCC in 
rats, with 20–25% lower AFB1-DNA adducts compared with rats in a control group (75). In a 
human study in China, subjects in an intervention group receiving 500 mg daily GTP had 13% 
lower aflatoxin-albumin adduct levels after 3 m onths, compared with the placebo group; but 
there was no s ignificant difference in albumin adduct levels between the placebo group and a 
group that received 1000 mg daily GTP.  There was, however, about a 43% lower AFM1 level in 
both GTP intervention groups compared with the control group (105). There were no significant 
differences between the groups after 1 month.  The cost of GTPs ranges enormously depending 
on how it is administered: in the form of green tea, or in capsules.  For tea that can be purchased 
in retail outlets, costs range from $0.20–$1.00 per day (106-108), providing a range of GTPs 
from 710–900 mg.   
In a randomized, double-blind, placebo-controlled trial in China, subjects who consumed 
chlorophyllin in each meal for 4 m onths showed 55% lower aflatoxin-N7-guanine adducts 
compared with subjects in the control arm (78). The cost of chlorophyllin is comparable to that 
of NovaSil: about $0.10 per daily dose (Dr. Thomas Kensler, personal communication). 
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Oltipraz administered in different schedules at different doses results in varied changes in 
aflatoxin biomarkers, indicating alterations in both Phase 1 and 2 metabolism of aflatoxin.  In a 
human intervention group in China, one month of 500 mg oltipraz administered weekly resulted 
in 51% lower AFM1 (phase 1 metabolite) levels compared with a placebo group, but no 
difference in aflatoxin-mercapturic acid (phase 2 metabolite) levels was found.  Lower doses of 
oltipraz (125 mg) administered daily resulted in a 2.6-fold increase in aflatoxin-mercapturic acid 
excretion, but no difference in AFM1 (109).  In a study involving rats administered high aflatoxin 
doses for 5 weeks, those given oltipraz during each week achieved a 42% reduction in HCC risk 
(110).  No cost information is available on pharmaceutical-grade oltipraz; the cost for analytical-
grade oltipraz is $59 per 5-mg sample and $236 per 25-mg sample (111).  Though oltipraz can 
reduce aflatoxin bioavailability via several mechanisms, its cost makes it a n economically 
impractical intervention. Second- and third-generation dithiolethiones are less expensive and 
more potent than oltipraz (126), but further studies on their potential side effects are needed.   
Sulforaphane administration did not result in significant reductions in aflatoxin-N7-
guanine in two human intervention groups in China (high dose and very low dose), but 
interindividual variation in bioavailability was high.  An inverse association was found between 
urinary levels of dithiocarbamates (sulforaphane metabolites) and aflatoxin-DNA adducts (85).  
Thirty sulforaphane capsules cost $25 ( 0.21% sulforaphane in 250 m g) (amazon.com).  If 
consuming broccoli sprouts or a tea from these sprouts, a dose of 385-gram sprouts containing 
over 400 µmol glucoraphanin (to be metabolized to sulforaphane) costs about $0.31. 
2.2.8 Costs and efficacy of hepatitis B vaccination 
Because of the massive production of hepatitis B vaccines through improved biotechnologies, 
second-generation HBV vaccines’ costs are much cheaper than the costs of the first generation 
vaccines. The vaccine’s efficacies against HBV infection and chronic HBsAg carriage were 84–
95% and 94–95%, respectively (112, 113).  It is estimated that 53% of global HCC cases are 
attributable to HBV (114); therefore, we assume in table 2-3 that the corresponding reduction of 
HCC risk due to HBV vaccination ranges from 45–50%.  Currently a dose of HBV vaccine costs 
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less than US $1 (127).  It is estimated that HBV vaccination costs $910 for every death averted 
and $23 for every disability-adjusted life year (DALY) averted (115). 
Currently available vaccines for HBV are multivalent vaccines. One of them is a 
pentavalent vaccine, in which HBV vaccine is combined with vaccines for diphtheria, tetanus, 
pertussis, and Haemophilus influenzae b (Hib). The five-in-one vaccine is believed to provide 
economic advantages over multiple immunizations of each monovalent preparation (128). The 
cost of the pentavalent vaccine is expected to drop to $2.94 per dose in 2010, 50 cents less than 
its cost in 2009 (129). Moreover, one of the major benefits of pentavalent vaccine; particularly in 
less developed countries where there is often a scarcity of health care personnel, is that the 
pentavalent vaccine reduces the total amount of time healthcare personnel spend to immunize 
children (128).    
2.3 HOW TO ANALYZE COST-EFFECTIVENESS OF INTERVENTIONS 
The World Health Organization (WHO) Commission for Macroeconomics and Health (130) 
provides the following guideline for thresholds of cost-effectiveness, as outlined in Wu and 
Khlangwiset (2010):  
(1) An intervention is considered very cost-effective, if the monetary amount spent on the 
intervention per DALY averted is less than the per capita gross domestic product (GDP) 
for the nation in which the intervention is applied.  In other words, the total cost of the 
intervention should be less than the product of the GDP and total DALYs averted.   
(2) An intervention is considered moderately cost-effective, if the monetary amount spent on 
the intervention per DALY averted is less than three times the per capita GDP.   
(3) An intervention is not cost-effective if, per DALY averted, its cost is greater than three 
times the per capita GDP. 
The disability-adjusted life year (DALY) is a measure of the burden of disease.  It 
includes both potential years of life lost due to premature death and years of “healthy” life lost in 
states of less than full health, broadly termed disability (131). The total number of DALYs 
associated with a disease is the sum of the years of life lost due to mortality from the disease 
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(YLL) and the number of years lived with a disability multiplied by a weighting factor between 0 
and 1, depending on the severity of the disability (YLD):  
 
𝐷𝐴𝐿𝑌 =  𝑌𝐿𝐿 + 𝑌𝐿𝐷 
Equation 1 Disability adjusted life year (DALY) 
 
Wu and Khlangwiset (2010) estimate the cost-effectiveness of two aflatoxin control 
methods – biocontrol and postharvest drying and storage methods – in sub-Saharan Africa.  By 
assuming a  decrease in aflatoxin-induced HCC that is proportional to decreases in aflatoxin 
levels in maize preharvest and postharvest (for biocontrol) and aflatoxin-albumin adducts (for the 
postharvest intervention package), cost-effectiveness ratios (effectiveness in saving lives from 
cancer divided by cost of intervention) of 5.10–24.8 for biocontrol and 0.21–2.08 for the 
postharvest intervention package were estimated.  Interventions whose cost-effectiveness ratios 
are greater than 1 can be deemed “very cost-effective” by WHO standards. These calculated 
ratios are actually underestimates of cost-effectiveness, because there are benefits to reducing 
aflatoxin other than decreasing liver cancer risk; there are benefits of improved immunity and 
reduced risk of stunting in children. 
The cost information is usually presented in varying formats depending on t he 
intervention in question; so cost-effectiveness analyses must be flexible, and care must be taken, 
to ensure that appropriate units are compared.  For example, Wu and Khlangwiset (2010) started 
with cost data on bi ocontrol and postharvest intervention packages in two different formats: 
Biocontrol cost was given as a monetary amount per hectare treated, while the postharvest 
intervention package cost was given as a monetary amount to store 500–1,250 kg of groundnuts.  
To convert this into usable cost-effectiveness information, it was necessary to convert the costs 
using other data (e.g., amount of maize produced per hectare, amount of maize consumed on 
average per individual per year, number of households in Republic of Guinea) to estimate how 
many individuals were affected by the intervention every year. 
It is important to choose appropriate health endpoints (i.e., effects) by which to evaluate 
DALYs.  Aflatoxin, as described in the Introduction, has multiple different adverse health 
effects.  The relationship between aflatoxin and HCC is the most well-established (132).  DALYs 
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have been estimated for HCC, so this makes HCC prevention a convenient endpoint by which to 
evaluate the cost-effectiveness of aflatoxin risk reduction strategies.  Stunted growth in children 
also has DALYs estimated for its societal impacts.   Acute aflatoxicosis is a relatively less 
common effect associated with aflatoxin exposure.  Immunosuppression is an extremely 
important effects associated with aflatoxin; however, the exact relationship is not as well 
characterized. 
Table 2-4 lists the average annual GDP per capita in select nations across the world 
(133). These figures shed light on how feasible some of the aforementioned public health 
interventions would be in different parts of the world.  In nations like Zimbabwe, where the 
average annual GDP per capita is $280 (USD), it is impossible for most individuals to afford an 
intervention that would cost more than a few cents per day; as the average daily income is less 
than $1.  Even if the one–time cost of an intervention could improve health for years, it cannot be 
assumed that most families have saved enough money to be able to afford such an intervention.  
There are many competing demands for scarce resources, and often availability of food is more 
important than quality of that food.  Moreover, a major challenge for any intervention in food-
insecure countries is that there is little price differential for quality; hence, producers may have 
no incentive to invest in quality enhancement. It is likely that governments would need to pay for 
aflatoxin reduction interventions, at least in the foreseeable future. 
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Table 2-4. Average annual gross domestic product (GDP) per head in select countries across the world, in 
USD 2008. 
Nation Annual GDP per capita, USD 2008 
Australia $48,253 
Canada $45,166 
China $3,292 
Cote d’Ivoire $1,137 
Kenya $788 
Nigeria $1,450 
Thailand $4,187 
United Kingdom $43,544 
United States $45,230 
Zimbabwe $314 
Note: Source: The Economist, 2007 (133), http://unstats.un.org/unsd/demographic/products/socind/inc-eco.htm 
Ironically, individuals in industrial nations such as the US, United Kingdom, Canada, and 
Australia rarely directly pay the price to reduce aflatoxin–induced illness, whether by 
agricultural or clinical means.     These costs are usually borne by growers (agricultural 
interventions to reduce aflatoxin) or by health insurance institutions or the national government 
(HBV vaccination). 
2.4 DISCUSSION 
The main purpose of this review is to bring together the scientific knowledge base (efficacies) 
and economic factors (costs, stakeholders) concerning aflatoxin risk-reduction strategies that 
could be deployed worldwide, and to highlight the importance of economic feasibility. Policy 
makers can use this information to decide: (1) whether the benefits (market and health) outweigh 
the costs of implementing the strategies, and (2) if so, then which stakeholders would pay the 
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costs and which would benefit in the long run, to resolve potential mismatches in economic 
incentives (39). 
This information can also be useful to researchers who are developing further aflatoxin 
control strategies, in that they can roughly position their interventions among various existing 
strategies in terms of economic feasibility.  It can also be useful to decision makers who want to 
weigh the relative importance of two categories of cost: the cost of preventing aflatoxin-related 
risks (to both markets and human health), and the cost of not preventing aflatoxin-related risks. 
In preharvest settings, conventional breeding of maize and groundnuts to resist aflatoxin 
has shown great promise in terms of achievable efficacies.    While initial research and 
development funding is of course necessary, once the resistant varieties are developed and 
disseminated, significant reduction of aflatoxin contamination can be achieved at very low, if 
any, additional cost to farmers.  Replacement of local maize cultivars with agriculturally-
improved varieties has been well-accepted by African farmers in recent history. It is estimated 
that a large part of 40% of present African maize yield is the result of planting improved 
cultivars (134).  Transgenic crops that demonstrate aflatoxin reduction, on the other hand, may 
encounter several problems regarding wide-scale adoption worldwide.  One problem is cost.  
Though the actual cost per acre for transgenic seeds may not be high, farmers may be required to 
buy new seeds each season if the seeds were developed in the private sector.  Such an expense 
for farmers who are used to saving seed from season to season might be considered 
unacceptable.  Another problem is governmental regulations against commercialization and trade 
of transgenic organisms in many parts of the world.   Hence, transgenic technologies in 
agriculture are at the moment best-suited to nations in which it is already customary to buy new 
seed each season, and where biosafety laws permit planting of transgenic seeds. 
Biocontrol through atoxigenic strains of Aspergilli has shown significant promise in 
controlling aflatoxin in a variety of crops in both preharvest and postharvest settings.  Depending 
on the product, costs vary widely; but low-cost options are available in LDCs that have naturally 
occurring atoxigenic strains in their native soils.  Biocontrol can be extremely cost-effective in 
reducing aflatoxin-induced disease (135) because of the protection against aflatoxin 
contamination that lasts for at least 6 months postharvest. As with transgenic crops, there may be 
regulatory issues to overcome in different nations, associated with the application of fungal 
strains to agricultural fields. 
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Good agricultural practices–those that can reduce various stresses on c rop plants and 
hence reduce fungal infection–can reduce aflatoxin contamination.  Irrigation systems combined 
with insecticides can achieve extremely high efficacy in aflatoxin reduction, but capital costs to 
install the systems can be very high, as can operation and maintenance costs.  These systems may 
not be affordable yet in many poorer LDCs. 
In postharvest settings, physical methods to reduce aflatoxin accumulation are generally 
both less expensive and less risky than chemical methods.  Physical sorting can remove the most 
contaminated food immediately postharvest.  The postharvest intervention package described in 
Turner et al. (2005), which includes sorting as well as wooden drying pallets, natural-fiber 
storage bags, and insecticides, was estimated to be extremely cost-effective in reducing 
aflatoxin-induced HCC (135), without significant health or environmental risks.   Chemical 
methods of destroying aflatoxin such as ammoniation and ozonation have extremely high 
efficacy levels at relatively low costs.  However, handling ammonia can be dangerous if done 
improperly, and the process can cause reduced palatability and produce a byproduct which, 
though much less risky than AFB1, may pose some health risks.  Ozonation, because it appears to 
reduce protein efficiency in animals, may carry nutritional risks. 
Dietary interventions to reduce aflatoxin risks can be considered forms of secondary 
prevention, as they do not actually reduce the amount of aflatoxin in the food, but can reduce its 
bioavailability in the body.  NovaSil clay and chlorophyllin can both be produced at extremely 
low cost, and have shown significant reduction in biomarkers of aflatoxin-induced damage.  
Because both NS and chlorophyllin must be consumed at the same time as contaminated food in 
order to adsorb or sequester the aflatoxin, one potentially feasible mechanism is to blend these 
agents into a food item that is frequently used in local diets (e.g., maize meal). Green tea 
polyphenols would be an extremely cost-effective way to potentially reduce aflatoxin-induced 
health risks in cultures where green tea is already common in the diet.  Otherwise, transportation 
costs and issues concerning the introduction of a relatively foreign drink (or pill) into the diet 
may render it impractical.   
Chemoprevention through oltipraz and sulforaphane has shown some promise in reducing 
aflatoxin-induced HCC.  Oltipraz is relatively expensive, however; and may not be practical as a 
long-term solution due to potential side-effects.  With regard to obtaining sulforaphane from 
natural foods, at least two constraints exist: 1) the foods should ideally be locally produced, and 
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2) there is much variation in the concentration of the active compound in food.  Therefore, it 
might be more reasonable to consider dietary chemoprevention as an additional intervention to 
other agricultural or clinical methods to reduce aflatoxin risks. 
Hepatitis B vaccination has been employed in some degrees in Africa, initially with 
support from non–profit organizations such as the Global Alliance for Vaccines and 
Immunization (GAVI) and the Vaccine Fund (136). However, if support is withdrawn, each 
country has to determine the feasibility and costs of continuing this program within its own 
budget.  As much of the infrastructure and basic materials needed for vaccination have been 
established during the initial phase, and inexpensive and effective vaccines are available, HBV 
vaccine programs are overall a useful, cost-effective, and feasible strategy to reduce aflatoxin-
induced HCC (and indeed, HCC in general).  However, the vaccine has no effect in those already 
infected with HBV.  Hence, other aflatoxin-reduction methods are desirable, particularly in 
nations where HBV prevalence is high and HBV vaccination is still scarce. 
Overall, efficacy tends to be higher for agricultural interventions (preharvest and 
postharvest) and for HBV vaccination than for dietary interventions, to reduce aflatoxin-related 
health risks.  However, there are times in which only dietary interventions would be helpful, such 
as in the case of an emergency.  For example, if an acute aflatoxicosis outbreak is occurring, it is 
too late to adopt agricultural interventions or to administer HBV vaccines to reduce aflatoxin’s 
health effects – at least, to counteract the current crisis.  Adsorbent compounds in the diet would 
make the most sense in such an emergency, if it is suspected that available food sources still 
contain dangerously high aflatoxin levels, and if the food cannot be simply discarded (e.g., for 
reasons of scarcity). 
A limitation with the cost estimates of several of these interventions is that many of the 
costs reflect estimates from pilot studies (field or clinical trials) or anecdotal data. Actual costs 
done on a  large scale for some interventions cannot be estimated, because some of the 
interventions have never been implemented on a large scale. Because of economies of scale, this 
is more likely to result in cost overestimates in this study, rather than underestimates. This 
highlights the need for further research to more accurately establish costs and efficacy of 
aflatoxin-risk reduction interventions worldwide. 
A critical component to implementing any or all of these methods is community 
education (70). Not only should educational efforts include how to use the intervention properly 
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to achieve maximum benefit regarding aflatoxin risk reduction, it should also include why the 
interventions are important from health and market perspectives, so that users have incentive to 
continue with the interventions. 
In summary, to reduce aflatoxin related problems in less developed countries, multiple 
types of interventions are potentially cost-effective; as they focus on di fferent targets, offer 
different outcomes, and achieve those outcomes under different time constraints.  Understanding 
the costs, efficacy, and affected stakeholders of different aflatoxin control interventions can help 
decision makers–be they government policymakers or farmers or consumers–to optimally 
allocate resources, with the ultimate aim of improving public health. 
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3.1 ABSTRACT 
Background: Chronic infection with hepatitis B virus (HBV) and high aflatoxin exposure in 
food synergistically predispose individuals to liver cancer (hepatocellular carcinoma, HCC) risk, 
especially in less developed countries where both risk factors are common. We wished to assess 
the relative efficacy of the HBV vaccine and two interventions intended specifically to control 
aflatoxin exposure in reducing aflatoxin-induced HCC.  
Methods: We calculated annual and lifetime HCC burden caused by aflatoxin and chronic HBV 
infection by quantitative risk assessment of aflatoxin-induced liver cancer and age-standardized 
liver cancer rates in the 2010 Nigerian birth cohort. We used epidemiological and agricultural 
data to estimate the efficacy of the HBV vaccine compared with two aflatoxin-specific 
interventions, biocontrol and NovaSil clay, on reducing the burden of HCC associated with 
aflatoxin in Nigeria. 
Results: 66-221 cases and 475-500 cases per 100,000 of the 2010 birth cohort are estimated to 
be attributable to aflatoxin and HBV, respectively. If 100% of the 2010 N igerian birth cohort 
were vaccinated against HBV, the lifetime prevalence of aflatoxin-induced liver cancer in this 
population would be reduced by 77%. Biocontrol and NovaSil, if adopted continuously in the 
entire Nigerian population, would reduce HCC incidence by 5–19% and 3–11%, respectively. To 
prevent one aflatoxin-induced liver cancer case, about 587-1,970 infants must be vaccinated, 
659–2,704 individuals must regularly consume biocontrol-treated maize, and 1,133–3,803 
individuals must regularly consume NovaSil.  Keywords: hepatitis B virus (HBV), aflatoxin, 
HBV vaccine, risk reduction, Nigeria, liver cancer       
3.2 BACKGROUND  
Liver cancer is the fifth most common cancer and the third most deadly cancer worldwide (137). 
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. The number of new 
HCC cases is estimated at over 500,000 annually (138). In general, once diagnosed, patients will 
die in under a year without any treatment (139).  
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Globally, the geographic distribution of liver cancer is not uniform. The age-adjusted 
death rates of liver cancer are highest in sub-Saharan Africa (8.9–14.0 per 100,000) and East and 
Southeast Asia (14.9–24.0 per 100,000) (137).  Three key risk factors for HCC in high-risk 
regions are chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) and 
foodborne aflatoxins (112, 140, 141). Globally, about 52% and 25% of HCCs are attributable to 
HBV and HCV, respectively (138). It has been estimated that aflatoxins may be responsible for 
5%–28% of total liver cancer worldwide (142).   
The role of HBV in causing HCC is supported by strong evidence from animal studies 
and epidemiological data, showing similar distributions of HCC and chronic HBV infection; 
higher detection rates of HBV surface antigen (HBsAg), a biomarker of chronic HBV infection, 
in HCC patients, compared with that in non-HCC populations; and evidence of chronic HBV 
infection  pr ior to the development of HCC (143). However, the mechanism by which HBV 
induces liver cancer is still unclear and may involve both direct and indirect effects (144).   
Aflatoxins, produced primarily by the fungi Aspergillus flavus and A. parasiticus, are 
found in multiple food commodities, most importantly maize and peanuts. One of the most 
potent naturally occurring human hepatocarcinogens, aflatoxin’s highly reactive AFB1 
metabolite, AFB1-8,9-exo-epoxide, intercalates in DNA and forms adducts with guanine, leading 
to base transversions in the p53 tumor suppressor gene.  
Aflatoxin and chronic HBV infection synergistically increase the risk of HCC 
development (74, 145, 146). In less developed countries, the coexistence of foodborne aflatoxin 
and HBV makes liver cancer risk much higher than is experienced in industrial nations, where 
aflatoxin exposure and HBV prevalence are relatively lower. The mechanism of this synergy has 
not yet been elucidated. Researchers have discussed plausible mechanisms in several articles 
(147, 148). One concerns inflammatory effects of chronic hepatitis that may inhibit DNA repair 
mechanisms against aflatoxin-induced DNA damage. Another concerns the ability of HBV to 
induce enzymes in P450 systems involving the activation pathways of aflatoxin. Additionally, 
metabolic products generated by hepatitis viruses, such as reactive oxygen species or reactive 
nitrogen species, may favor aflatoxin-induced p53 mutations at codon 249ser (147, 149).  
Multiple interventions to reduce aflatoxin risk have been developed. The costs and 
efficacy of various types of aflatoxin control interventions have been reviewed (150). One of 
these interventions is biocontrol, in which atoxigenic Aspergillus strains are strategically applied 
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to crops to outcompete toxigenic strains, so that the crops may be infected with fungus, but there 
is little or no toxin.  These biocontrol methods have been tested in maize, groundnut, and cotton 
fields in various parts of the world. Biocontrol can decrease aflatoxin levels in harvested crops 
by 70%–90% compared with untreated crops (58, 62, 96, 118, 151) . Importantly, atoxigenic A. 
flavus strains have been found in sub-Saharan Africa, which show promise for controlling 
aflatoxin in African maize (59, 62).  
Another intervention that reduces aflatoxin risk is NovaSil: a dioctahedral smectite clay 
that, as a dietary additive, can reduce bioavailability of aflatoxins in humans and animals (70). 
This anti-caking agent adsorbs aflatoxin in the gastrointestinal tract between interlayer spaces 
and surfaces of clay molecules. In a human study in Ghana, NovaSil, at a 3-gram daily dose for 3 
months, significantly reduced two biomarkers of aflatoxin exposure, aflatoxin M1 and aflatoxin-
albumin adduct, compared with the control (104).  
Because the HBV vaccine reduces the risk of chronic HBV, it can reduce not just cancers 
caused by HBV alone, but also cancers caused by the synergism of aflatoxin and chronic HBV. 
Therefore, the HBV vaccine has been listed as an aflatoxin risk-reduction strategy (6, 150). Once 
infected by HBV, children are more likely to become chronic carriers than adults (152, 153); 
consequently, the infection could lead to premature deaths from cirrhosis and liver cancer. HBV 
vaccination in infants, therefore, is especially important for long-term protection against chronic 
HBV infection (154). Indeed, the HBV vaccine is believed to be one of the best preventive 
methods to control the spread of liver cancer. The HBV vaccine has been recommended for 
populations in areas with high liver cancer incidence (139, 149, 155).  
Nigeria, the most populous country in sub-Saharan Africa, has a long history of aflatoxin 
contamination in food crops and chronic HBV infection (69, 156-159). The age standardized 
death rates of liver cancer in Nigeria ranges from 10.1 t o 15.2 pe r 100,000 (160, 161). The 
purpose of our study is to quantitatively estimate burdens of aflatoxin-induced liver cancer and 
HBV-induced liver cancer in Nigeria; and to estimate the impacts of the HBV vaccine in 
comparison with other two aflatoxin control interventions, biocontrol and NovaSil clay, in 
reducing liver cancer burdens through three risk reduction estimates: absolute risk reduction 
(ARR), relative risk reduction (RRR), and number needed to treat (NNT).  
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3.3 METHODS 
3.3.1 Liver cancer risk in Nigeria 
3.3.1.1 HBV-induced liver cancer risk 
We estimated the number of liver cancer cases in Nigeria based on the Nigerian age standardized 
death rate obtained from a World Health Organization (WHO) database (160) and the 
International Agency for Research on Cancer (IARC) GLOBOCAN 2008 database (161). As 
these rates are not HBV-specific death rates, we adopted the attributable fraction approach to 
determine the number of liver cancer cases attributable to HBV. The attributable fraction is the 
proportion of diseases that may be eliminated by getting rid of an exposure or a particular risk 
factor (114).  It can be presented in a simple equation as follows:  
 
𝐴𝐹 = 𝑃𝑟 (𝐸,𝐶 ) 𝑋 ((𝑟𝑖𝑠𝑘 𝑟𝑎𝑡𝑖𝑜 − 1)/𝑟𝑖𝑠𝑘 𝑟𝑎𝑡𝑖𝑜)  
Equation 2. Attributable fraction (114) 
Where AF = Attributable Fraction and Pr (E,C) = Prevalence of exposure among cases 
The risk ratio for HBV infection resulting in liver cancer is often reported to be much 
greater than 10 (162-164). As the result, the attributable fraction is close to the prevalence of 
HBV infection among liver cancer cases (114); which, in Nigeria, ranges from 59% to 62% 
(165-168). These numbers are almost the same as the calculated attributable fraction (58.8%) of 
HBV on liver cancer in less developed countries reported by Parkin in 2006 (169), and 63%, the 
number of HBsAg+ (surface antigen biomarker of chronic HBV infection) in Gambian HCC 
patients (170).  
3.3.1.2 Aflatoxin-induced liver cancer risk 
We collected Nigerian data on aflatoxin levels in maize (69, 156, 157 )  and groundnuts (158, 
159, 171), maize and groundnuts consumption rates per head (172), and prevalence of hepatitis B 
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chronic infection in Nigeria (173-189). Five year (2003–2007) maize and groundnut 
consumption rates per capita per day, obtained from the FAOSTAT database, were used to 
project consumption rates in 2010.  The geometric mean levels of aflatoxin in maize and 
groundnuts based on available published literature were calculated. We divided detection limits 
by two for the samples in which aflatoxin was not detected to derive the lower range of aflatoxin 
levels. To obtain the upper range of aflatoxin levels, only positive samples were included.   
Next, we estimated burdens of liver cancer induced by aflatoxin in HBV+ and HBV– 
populations in Nigeria. These numbers were calculated by cancer risk assessment methodologies, 
based on the aflatoxin cancer potency factors proposed by The Joint Expert Committee on Food 
Additives (JECFA) of the World Health Organization and Food and Agriculture Organization 
(145), and multiplied by the aflatoxin exposure data found above, assuming average bodyweight 
of 60 k g. JECFA proposed two carcinogenic potencies of aflatoxin: 0.30 cases per 100,000 
individuals per year, per nanogram of AFB1 intake per kilogram body weight per day, in the 
presence of HBV infections; and 0.01 corresponding cases per 100,000 without HBV infections 
(145). The difference between the number of HBV-induced liver cancer cases and the number of 
liver cancer cases caused by the synergistic effect between aflatoxin and HBV represents the 
number liver cancer cases caused by the interaction between chronic HBV infection and non-
aflatoxin factors. Similarly, the difference between the numbers of non-HBV-induced liver 
cancer cases and aflatoxin-induced liver cancer cases in the HBV-negative population represents 
the number of liver cancer cases induced by non-aflatoxin and non-HBV factors. These other 
risk factors for liver cancer may include alcohol consumption, tobacco smoking, other dietary 
and environmental toxins, HCV infection, liver fluke, and metabolic syndrome (190).     
3.3.1.3 Proportions of liver cancer induced by aflatoxin and HBV in relative to total liver 
cancer and the estimated numbers of liver cancer in the 2010 birth cohort in Nigeria 
The proportions of liver cancer of these following groups, (I) aflatoxin/HBV+, (II) 
aflatoxin/HBV–, (III) non-aflatoxin factors/HBV+, and (IV) non-aflatoxin factors/HBV–, were 
calculated in relative terms to total liver cancer cases in Nigeria.  
The baseline lifetime liver cancer risk was generated based on the mortality rates by age 
groups obtained from WHO (191) for the 2010 birth cohort. This baseline risk was multiplied by 
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the proportions of liver cancer of the 4 groups described above.  We obtained the number of 
infants born in 2010 by multiplying the Nigerian population in 2010 by the Nigerian birth rate. 
From this, we subtracted the number of neonatal deaths, obtained by multiplying the number of 
infants by the Nigerian neonatal death rate, to estimate population size of the 2010 birth cohort.      
We then estimated the number of infants perinatally infected with HBV and determined 
the number of infant deaths from HBV infection. The HBV infection mortality rate in newborns 
obtained from Goldstein et al. 2005 (192) was applied to the number of infants born with 
HBsAg+ to estimate the number of infant deaths from fulminant hepatitis.  
We applied the 2008 Nigerian life table (193) to the 2010 birth cohort, from which the 
number of infant deaths from fulminant hepatitis was subtracted, to generate the expected 
numbers of deaths by HCC of the 2010 birth cohort at different ages: 0–14 years, 15–59 years, 
and >60 years, based on liver cancer death rates by age groups presented in the WHO Global 
Burden of Disease 2004 data (191). The numbers of liver cancer cases in different age groups 
were combined to obtain lifetime liver cancer cases in the 2010 birth cohort. The proportions of 
liver cancer induced by (I) aflatoxin/HBV+, (II) aflatoxin, (III) non-aflatoxin/HBV+, and (IV) 
non-aflatoxin/non HBV calculated earlier were applied to generate the numbers of liver cancer 
cases in different groups in the 2010 birth cohort, which were used as baseline risk 
3.3.2 Efficacy of HBV vaccine and aflatoxin control methods in reducing liver cancer risk 
The efficacies of biocontrol and NovaSil in reducing aflatoxin or aflatoxin-associated biomarkers 
were obtained from published literatures or personal communication, and applied to the baseline 
lifetime liver cancer risk induced by aflatoxin calculated earlier. It is widely accepted that the 
HBV vaccine is approximately 95% effective in reducing the prevalence of chronic hepatitis B 
carriage (HBsAg+) (115, 154). Therefore, 95% vaccine efficacy in reducing chronic HBV was 
used to determine number of liver cancer cases prevented by the vaccine in each age group. We 
applied 80% efficacy of biocontrol in reducing aflatoxin in maize in relative to total dietary 
aflatoxin exposure and 40% efficacy of NovaSil in reducing aflatoxin bioavailability to the 
numbers of liver cancer cases attributed to aflatoxin in the 2010 b irth cohort to determine 
numbers of cases which would be prevented by the interventions.          
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Three risk reduction estimates, absolute risk reduction (ARR), relative risk reduction 
(RRR), and number needed to treat (NNT) of the HBV vaccine are calculated to determine the 
efficacy of the vaccine:  
𝐴𝑅𝑅 =  𝑐𝑎𝑠𝑒 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 (𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛−)– 𝑐𝑎𝑠𝑒 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 (𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛+) 
Equation 3. Absolute risk reduction (194) 
           
𝑅𝑅𝑅 =  𝐴𝑅𝑅/𝑐𝑎𝑠𝑒 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 (𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒) 
Equation 4. Relative risk reduction (194) 
𝑁𝑁𝑇 = 1/𝐴𝑅𝑅 
Equation 5. Nuber needed to treat  (194) 
3.4 RESULTS 
3.4.1  Liver cancer risk in Nigeria 
3.4.1.1 HBV-induced liver cancer risk 
Age standardized mortality rates of liver cancer in Nigeria, 10.1–15.2 per 100,000 (161, 191), 
were multiplied by 152 million, the number of Nigerian population in 2010 (195), to obtain the 
number of total liver cancer cases in 2010: 15,352–23,104 cases.  Of these numbers, 9,058–
14,324 cases are estimated to be HBV-related and 6,294–8,780 cases are non-HBV-related.     
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3.4.1.2 Aflatoxin-induced liver cancer risk 
Table 3-1lists the studies surveying aflatoxin levels in maize and groundnuts or products made 
from these two commodities in Nigeria. In many cases, the maximum detected levels were 
higher than 20 ng/g, the maximum tolerable limit in Nigerian food, even when testing in 
preharvest grains. One recent study detected aflatoxin at levels up to 480 ng/g in maize tested 
within 23 days after being harvested (69). In dry-roasted groundnuts sold in markets in Nigeria, 
aflatoxin levels as high as 165 ng/g were detected. Percentages of aflatoxin positive maize 
samples ranged from 18.4% to 85%, which were relatively lower than those of groundnuts 
(64.2%–100%). Large variations of aflatoxin levels in food samples were detected in all but one 
study.  The mean levels of aflatoxin in Nigerian maize and groundnuts ranged from 13.3 to 36.2 
ng/g and 64.8 to 67.5 ng/g, respectively.       
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Table 3-1. Aflatoxin in maize and groundnuts in Nigeria 
Commodity Range 
(ng/g)a 
Median 
(ng/g)b 
% positive 
sample 
Detection 
limit 
Note 
 
First author, 
Year 
Maize 5–360 2.5 45% 5 Market Adebajo 1994 
(157) 
Corn cake 5–345 25 85% 5 Market Adebajo 1994 
(157) 
Corn roll 5–80 10 60% 5 Market Adebajo 1994 
(157) 
Maize 3–130 <2 18.40% 5 Pre-
harvest 
Bankole 2004 
(156) 
Maize 1.1–480 4.2 >50% 1 Within 23 
days after 
harvested, 
grains 
stored in 
paper bags 
Bandyopadhyay 
2007 (69)  
Groundnuts 
cake 
19–455 97.5 100% NA  Market 
goods 
Akano 1990 
(159)  
Groundnuts 5–165 NA 64.20% 5 Dry-
roasted 
Bankole 2004 
(158) 
Groundnuts 74.03–
82.12 
NA 100% NA Market 
goods 
Odoemelam 
2009 (171) 
Note: aonly aflatoxin levels of positive samples were included, baflatoxin levels of all samples were counted   
 
Maize and groundnut consumption rates in 2010 were about 73.6 g and 6.4 g per capita-
day, respectively (172). Hence, aflatoxin exposure from consuming maize and groundnuts 
ranged from 16.37–44.36 ng/kgBW-day and 6.91–7.22 ng/kgBW-day, respectively. The 
estimated mean aflatoxin exposure from consuming both maize and groundnuts is 23.28–51.58 
ng/kgBW-day.  
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While there are several studies to determine HBV prevalence rates in Nigeria, most of the 
studies focus on s pecific regions or specific groups of populations. In any case, a number of 
studies confirm high prevalence rates of the HBV infection in various populations in Nigeria 
(173-189); for example, HBV prevalence ranges from 13%–22% in blood donor groups (173-
176), 2%–12% in pregnant women (176, 178-181), 18.7% in female sex workers (183), 23% in 
male prisoners (184), and 26%–52% in HIV positive individuals (173, 186-189). In this study, 
the Nigerian HBV prevalence is assumed to be 15%. 
Aflatoxin exposure in Nigeria would result in 1.05–2.32 liver cancer cases per 100,000 
HBV carriers, and 0.20–0.44 per 100,000 HBV-negative individuals annually. In the 2010 
population of 152 million, 1,596–3,526 liver cancer cases per year in Nigeria are estimated to be 
due to the interaction between chronic HBV infection and dietary aflatoxin exposure, and 299–
668 liver cancer cases per year would be due to dietary aflatoxin exposure alone.  
3.4.1.3 Proportions of liver cancer induced by aflatoxin and HBV in relative to total liver 
cancer and the estimated numbers of liver cancer in the 2010 birth cohort in Nigeria 
The estimated numbers of liver cancer cases distributed in these following groups: (I) aflatoxin-
induced liver cancer in individuals with chronic HBV infections, (II) aflatoxin-induced liver 
cancer in individuals without HBV infections, (III) non-aflatoxin-induced liver cancer in HBV 
carrier population, and (IV) non-aflatoxin-induced liver cancer in HBV-negative population are 
presented in table 3-2.   
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Table 3-2. Age standardized attributable risk of aflatoxin and hepatitis B infection on liver cancer in Nigeria 
Liver cancer HBV + HBV - Total 
AF-related I 
1,596–3,526 
(7%–23%) 
II 
299–668 
(1%–4%) 
1,895–4,194 
(8%–27%) 
Non-AF-related III 
5,532–12,728 
(36–55%) 
IV 
5,626–8,481 
(35%–39%) 
11,158–21,209 
(73%–92%) 
Overall 
 9,058–14,324 
(59–62%) 
 6,294–8,780 
(38–41%) 
15,352–23,104 
(100%) 
Note: Population =152 million 
 
Aflatoxin exposure accounts for about 8% to 27% of total liver cancer cases in Nigeria. 
Aflatoxin exposure in the presence and absence of chronic HBV infection account for 7%−23% 
and 1%−4% total liver cancer cases in Nigeria, respectively.     
Given the population in 2010 in Nigeria of 152 million (196), Nigerian birth rate of 36.65 
per 1,000 (197), and neonatal death rate of 47 per 1,000 (198); the population of the 2010 
Nigerian birth cohort is approximately 5.3 million. Because 13–30%, of HBsAg-positive mothers 
contained HBeAg (176, 199), of the 5.3 million, about 20,800–48,000 infants of 5.3 m illion 
infants born in 2010 are expected to born with HBV seropositive caused by perinatal 
contamination. In any case, the likelihood of children to develop fulminant hepatitis is less than 
10 in a million (192). None of the 2010 N igerian neonates would be expected to die from 
perinatal acute HBV infection (data not shown). 
Table 3-3 shows the estimated lifetime risk to develop liver cancer in the 2010 bi rth 
chort. About 43,000 (806 per 100,000) liver cancer cases would be developed during the lifetime 
of the 2010 birth cohort. The estimated numbers of lifetime HBV-related liver cancer cases in the 
2010 birth cohort would range from 25,372 to 26,662. The lifetime numbers of non-HBV related 
liver cancer cases would range from 19,081 to 20,587 cases.      
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Table 3-3. Estimated lifetime risk to develop liver cancer and health impacts of the HBV vaccination in the 
2010 Nigerian birth cohort 
 HBV+ HBV- Total 
cases 
reduction 
 Baseline Hepatitis 
B vaccine 
# cases 
prevented 
Baseline Hepatitis 
B vaccine 
# cases 
increase 
AF-
induced 
2,951–
9,902 
148–495 2,804–
9,407 
557–
1,870 
651–
2,184 
(94–314) 2,710–
9,093 
Other 
factors 
(X)–
induced 
15,470–
23,711 
774–
1,185 
14,696–
22,525 
15,761–
15,784 
18,403–
18,430 
(2,642–
2,646) 
12,054–
19,879 
Overall 25,372–
26,662 
1,269–
1,333 
24,103–
25,329 
16,341–
17,631 
19,081–
20,587 
(2,740–
2,956) 
21,147–
22,589 
Note: numbers in brackets indicate that numbers in groups after vaccination program higher than baseline (negative 
values). 2010 birth cohort population =5,336.8 thousand 
 
3.4.2 Efficacy of HBV vaccine and aflatoxin control methods in reducing liver cancer risk 
In the 2010 birth cohort, the vaccine is expected to prevent liver cancer in HBV positive group 
by 24,103–25,329 cases (see table 3-3). Of these numbers, the vaccine would prevent aflatoxin-
induced liver cancer in the HBV population by 2,804–9,407 cases. The increased number in 
HBV-negative population, as a result of the vaccine, would lead to the increased number of liver 
cancer in non-HBV carriers by 2,704–2,956 cases. Overall the vaccine would prevent 2,710–
9,093 cases from aflatoxin-related liver cancer, 24,103–25,329 cases from HBV-induced liver 
cancer by, and 21,147–22,589 total liver cancer cases.      
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Table 3-4. Expected health impacts of select aflatoxin control interventions on liver cancer in the 2010 
Nigerian birth cohort 
 
No. of cases 
without 
interventions 
Biocontrol NovaSil 
No. of cases 
No. of cases 
prevented 
No. of cases 
No. of cases 
prevented 
HBV+ 2,951–9,902 1,282–3,102 1,669–6,800 1,771–5,941 1,180–3,961 
HBV– 557–1,870 242–586 315–1,284 334–1,122 223–748 
Total 3,508–11,772 1,524–3,688 1,984–8,084 2,105–7,063 1,403–4,709 
Table 3-4 lists the expected number of liver cancer cases prevented by the two aflatoxin 
control strategies biocontrol and NovaSil clay. Unlike the HBV vaccine, both biocontrol and 
NovaSil can reduce liver cancer risk in either HBV-positive or HBV-negative populations. 
Biocontrol and NovaSil prevent about 2,000–8,000 and 1,400–4,700 liver cancer incidents, 
respectively, over the lifetime courses of the 2010 birth cohort.  
Overall, the HBV vaccine reduces the greatest numbers of total liver cancer compared 
with biocontrol and NovaSil. Of 43,000 total liver cancer cases, the HBV vaccine, biocontrol, 
and NovaSil reduce liver cancer by 49%–53% (21,147–22,589 cases), 5%–19% (1,984–8,084 
cases), and 3%–10% (1,403–4,709 cases), respectively.   
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Table 3-5. Risk reduction estimates of selected control interventions in liver cancer by etiology 
Items Interventions 
Aflatoxin-related 
liver cancer 
HBV-induced 
liver cancer 
Overall liver 
cancer 
Baseline risk (per 
100,000) 
 65.73–220.58 475.42–499.59 805.78 
ARR (per 100,000) Vaccine 50.76–170.39 450.44–475.81 395.05–424.47 
 Biocontrol 37.17–151.47 31.27–127.41 36.98–151.82 
 NovaSil  26.29–88.23 22.12–74.22 26.30–88.23 
RRR Vaccine 0.77 0.95 0.49–0.53 
 Biocontrol 0.57–0.69 0.06–0.27 0.05–0.19 
 NovaSil  0.40 0.04–0.16 0.03–0.11 
NNT Vaccine 587–1,970 210–222 236–253 
 Biocontrol 660–2,690 785–3,198 659–2,704 
 NovaSil 1,133–3,803 1,347–4,521 1,133–3,803 
 
To summarize: per 100,000 populations, the HBV vaccine, if 100% adopted is estimated 
to prevent 51–170 (77%: 51/66, 170/221) and 450–476 (95%: 450/475, 476/500) cases from 
developing liver cancer induced by aflatoxin and HBV, respectively. About 395.05–424.47 (49–
53%) cases in 100,000 would be prevented from developing liver cancer, regardless of cause.  In 
order to prevent one liver cancer case, regardless of cause, 236 t o 253  infants need to be 
vaccinated. About 587 to 1,970 and 210 to 222 infants need to be vaccinated to prevent one liver 
cancer case caused by aflatoxin and HBV, respectively.   
About 6%–27% and 4%–16% of HBV-induced liver cancer incidents are expected to be 
reduced by biocontrol and NovaSil, respectively. NovaSil would reduce liver cancer by 3%–11% 
of total liver cancer. Approximately 5%–19% of total liver cancer would be avoided if biocontrol 
was adopted. The HBV vaccine reduces total liver cancer by about 50%. The ARRs of biocontrol 
and NovaSil indicate that they reduce fewer liver cancer cases, compared with the HBV vaccine, 
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as a result these two aflatoxin control interventions requires greater numbers of individuals to 
adopt these interventions than the HBV vaccine. 
3.5 DISCUSSION  
In general, the incidence of liver cancer increases after 20 years of age, then reaches a peak and 
stabilizes around the age of 50 (200). At present, the life span of a Nigerian is estimated to be 47 
years old (201). If overall Nigerian public health were improved, leading to longer life 
expectancy, the lifetime risk of liver cancer could become higher than the numbers presented in 
this study. 
Though liver cancer is a multi-factorial disease, we show that a significant portion of 
liver cancer cases in Nigeria is associated with HBV infection, aflatoxin, or both. HBV 
vaccination in infants would greatly reduce the numbers of liver cancer cases in Nigeria either 
induced by HBV alone, or a combination of aflatoxin and HBV. Though some regions have high 
vaccine uptake rates, overall national vaccination rates are still low (202, 203), at about 41% 
(198). Among Global Alliance for Vaccines and Immunisation (GAVI) eligible countries, 
Nigeria was ranked second after India in nations that have the highest proportion of children 
unvaccinated against HBV (204). One study estimated that only 1% of children whose mothers 
were market traders in Ibadan were immunized against HBV  (205). Our analyses reveal that the 
HBV vaccine reduces a greater number of liver cancer cases than two effective aflatoxin control 
strategies. Aside from liver cancer, one of the advantages of the HBV vaccine is the reduction in 
premature deaths caused by HBV-related conditions and diseases, such as acute HBV infection 
and HBV-induced cirrhosis.  
One of the limitations of the study is the estimation of aflatoxin exposure. Hall and Wild 
(1994) described this difficulty in 1994, a nd discussed how biomarkers could resolve some 
problems related to obtaining accurate aflatoxin exposure data (206).  In the intervening time, 
several serum- and urine-based biomarkers of aflatoxin exposure, internal dose, and biologically 
effective dose have been validated in experimental models and epidemiological studies (74).  
Use of these biomarkers has greatly assisted epidemiological studies.  However, these have not 
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been collected in the broad Nigerian population, so aflatoxin exposure was estimated from food 
samples and estimates of food intake. Limits of detection of aflatoxin analysis methods may 
affect the number of positive samples found in assays. Bandyopadhyay et al. (2007) identified 
aflatoxin in more than 50% of maize samples using the method that can detect aflatoxin levels as 
low as 1 ng /g, while only 18.4% and 45% of pre-harvested maize and maize sold in markets 
were found to be aflatoxin-contaminated in studies using less sensitive techniques.  
The results of this study should not be interpreted as recommending greater HBV vaccine 
uptake in lieu of aflatoxin control interventions. Aflatoxin causes adverse health and economic 
impacts beyond liver cancer.  Although the HBV vaccine can reduce hepatotoxicity caused by 
the HBV infections, or by the synergistic effects between aflatoxin and the HBV infection, it 
cannot reduce aflatoxin in food or feed staples. Therefore, the vaccine does not prevent other 
toxicities of aflatoxins, such as aflatoxicosis, growth impairment, or immunosuppression. 
Moreover, aflatoxin may compromise markets and trade due to unacceptable levels in food (38). 
One important characteristic of aflatoxin-specific interventions is that either HBsAg- or HBsAg+ 
individuals do benefit from them, unlike the HBV vaccine, which only provides benefits to those 
who are or were not already HBV-infected. An individual who is already chronically infected 
with HBV does not benefit from the HBV vaccine.  Therefore, both the vaccine and specific 
aflatoxin control strategies are needed to improve health outcomes in Nigeria. 
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4.0  AFLATOXIN CONTROL INTERVENTIONS:                                                               
COST-EFFECTIVENESS ANALYSIS 
4.1 ABSTRACT 
The costs and health-based efficacy of four aflatoxin control interventions: biocontrol, the 
postharvest intervention package, NovaSil clay, and hepatitis B vaccine in Nigeria are evaluated.  
The benefits of preventing liver cancer are presented as the numbers of disability life years 
(DALYs) averted. A 3% discount rate was applied to the benefits of preventing liver cancer to 
convert benefits of preventing liver cancer in the future to current values. The cost effectiveness 
ratios (CERs)–the costs to reduce one disability life year–range from $1,073 to $1,146 for the 
HBV vaccine to $26,467 to $69,110 for biocontrol. Regarding WHO criteria, the HBV vaccine is 
a worthy intervention to reduce liver cancer in Nigeria (CER<3GDP per capita). Biocontrol 
could be a worthy or non-worthy intervention depending on aflatoxin levels in staple crops. 
Either reductions in cost or improvements in efficacy are needed for the postharvest intervention 
package and NovaSil clay to be a worthy intervention to reduce liver cancer in Nigeria.      
  
4.2 INTRODUCTION 
In the previous chapter, we have shown that aflatoxin and the chronic hepatitis B virus (HBV) 
infection are responsible for 8–27% and 59–62% of liver cancer cases, respectively in Nigeria. 
We also determined the health impacts of the HBV vaccine and the other two aflatoxin control 
interventions on l ifetime liver cancer in the 2010 birth cohort. Though the efficacy of each 
intervention differs from 3–11% in NovaSil to 49–53% in the HBV vaccine, it can still be 
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difficult for an individual to determine whether any of these interventions is worthy to be 
adopted.  
Understanding the costs and efficacy of different aflatoxin control interventions can help 
decision makers–be they government policymakers or farmers or consumers–to optimally 
allocate resources, particularly in conditions of scarcity. At least three techniques can be used as 
a tool to compare benefits and costs of different types of public health interventions. These three 
techniques include cost-benefit analysis (CBA), cost-effectiveness analysis (CEA), and cost-
utility analysis (CUA).  
These three techniques measure outcomes differently. In CBA, both cost and benefits are 
often presented in monetary units; whereas in CUA, the benefits are often expressed in terms of 
quality of life or life year gained. In contrast, the outcomes in CEA  are generally clinical effects 
(207).  
Comparing interventions can be a  problem if the clinical outcomes differ. Therefore, 
many studies utilize the concept of disability adjusted life year (DALY). DALYs for a d isease 
are the sum of the present value years of life lost due to the premature deaths (YLL) and the 
years lost due to disability (YLD) for incidents  of disease or injury (208).  One DALY equals 
one healthy life year lost. 
Because DALY is a t ime-based measure, DALYs are affected by time discount rate for 
the future outcome and age. Fewer DALYs are assigned if an incident happens to children or the 
elderly than middle aged persons. Moreover, men and women are assigned different numbers for 
DALYs even when they have the same disease (209).  
The World Health Organization (WHO) recommended the gross domestic product (GDP) 
per capita as a readily available threshold value to classify an intervention into one of the 
following three cost-effectiveness categories: highly cost-effective, cost-effective, and not cost-
effective (130).  
We previously determined the cost-effectiveness of two aflatoxin control interventions; 
biocontrol in Nigeria and the postharvest intervention package in Guinea. If the benefits were 
projected to occur five years after the aflatoxin levels in staple crops were reduced by these two 
interventions, either biocontrol or the postharvest intervention package would be cost-effective 
(135). In this study, we extended the expected time that benefits occur to 10 years, included the 
HBV vaccine and NovaSil clay in the analysis and compared these four interventions if they 
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were adopted in the selected country, Nigeria. Our objective was to determine whether these 
aflatoxin control interventions were worthy to be implemented in Nigeria using the cost-
effectiveness assessment method. Intervention characteristics, costs, and efficacy of various 
types of aflatoxin control interventions   including biocontrol, the postharvest intervention  
package, NovaSil clay, and the HBV vaccine are intensively discussed in our previous work 
(150).  
Biocontrol is the name given to atoxigenic Aspergilli deliberately applied to crops to 
outcompete the toxigenic Aspergilli, so that the final crops may be infected with fungus, but 
there is little or no toxin.  These biocontrol methods have been tested in maize, groundnuts, and 
cottonseed worldwide. A number of non-toxin producing fungi have been identified and tested in 
various countries. Importantly, atoxigenic A. flavus strains have been found in sub-Saharan 
Africa, which show promise for controlling aflatoxin in African maize (59, 62). Afla-safeTM is a 
biocontrol developed by the International Institute for Tropical Agriculture (IITA) based in 
Nigeria. Sorghum is used as the substrate of Afla-safeTM.  Currently, Afla-safeTM offers about 
80% response in reducing aflatoxin contamination in Nigerian maize field trials (Dr. Ranajit 
Bandyopadhyay, IITA plant pathologist, personal communication).  
To improve drying and storage conditions of groundnuts in Guinea, Turner et al. 2005 
incorporated several components into their postharvest intervention package. These components 
included educating the public on how  to sort and dry nuts; using materials that enhance air 
ventilation, such as fibre mats to dry nuts, and fibre bags to store nuts; using a wooden pallet on 
which to store bags; and applying insecticide on storage floor to control pests in storage 
structures (67). Turner et al. (2005) tested this package in Guinea and found a reduction of 69% 
in the mean aflatoxin level in groundnuts (67).  
NovaSil clay is an anti-caking agent in animal feed. It reduces bioavailability of aflatoxin 
by adsorption of aflatoxin in the gastrointestinal tract between interlayer spaces and surfaces of 
the clay molecules. Based on a study done in Ghana, NovaSil clay, at a three-gram daily dose, 
can reduce aflatoxin bioavailability by 40% (104). 
The hepatitis B vaccine is believed to be one of the best preventive methods to control the 
spread of liver viruses, which together with aflatoxin, greatly increase the liver cancer risk above 
the risk of either risk factor alone. At present, the third generation recombinant hepatitis B 
vaccines are cheaper than prior generations. The monovalent hepatitis B vaccine costs $0.21 per 
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dose (210)–less than one dollar per three-dose course.  However, in Africa where percentages of 
primary vaccination coverage are low, the Global Alliance for Vaccines and Immunisation 
(GAVI)–a global partnership between the public and private sectors, e.g. WHO, UNICEF, the 
World Bank Group, Bill & Melinda Gates Foundations, etc–provides supports for pentavalent 
vaccines over the monovalent vaccines.  
The pentavalent vaccine requires three dose vaccinations, similar to the monovalent 
hepatitis B vaccine, but aside from HBV infections, the pentavalent vaccine provides protective 
effects to other four diseases: diphtheria, tetanus, pertussis, and hemophilus influenza type b 
(Hib). However, the cost of the pentavalent vaccine is much higher than monovalent vaccines, 
but in 2009, it was projected to be reduced to $2.94 per dose in 2010 (129). 
4.3 METHOD 
We determined efficacy of aflatoxin control interventions in reducing liver cancer of an 
implementation of a particular intervention if it were 100% adopted.  
4.3.1 Cost-effectiveness analysis 
We performed the CEA by introducing the approach of cost-effectiveness ratio (CER), which is 
the ratio between the costs of interventions and expected outcomes. The numbers of bad 
incidents prevented are multiplied by average burdens per case, obtained from the 2004 global 
burdens of diseases (208). Regarding the JECFA’s aflatoxin carcinogenic potencies, the effects 
of aflatoxin were calculated as annual liver cancer cases per 100,000. We assumed that the 
effects would happen at the tenth-year after the interventions were introduced. But for the HBV 
vaccine, the protective effects are life-long. The numbers of prevented DALYs were discounted 
by 3% per year to account for future benefits from current investment.       
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4.3.1.1 Costs of interventions 
The costs of interventions are the annual cost of each intervention if they are 100% adopted in 
Nigeria. The aflatoxin control interventions, including biocontrol, the postharvest intervention 
package, and NovaSil, must be repeated annually or infants must be given three dosages for the 
HBV vaccine.    
4.3.1.2 Efficacy of interventions 
Aflatoxin-induced liver cancer: The Nigerian aflatoxin exposures per kilogram bodyweight 
were calculated based on aflatoxin levels in maize and groundnuts, and the Nigerian 
consumption rates of these two major staples. Quantitative liver cancer risk assessments in 
Nigeria in the presence and absence of a particular intervention were performed regarding the 
number of Nigerian population in 2010 and carcinogenic potencies of aflatoxin proposed by 
JECFA. These were 0.3 per 100,000 per year for a nanogram of aflatoxin intake per kilogram 
body weight for an individual chronically infected by the HBV and 0.01 in a corresponding case 
for a HBV-free individual (132).   
HBV-induced liver cancer (HBV vaccination): The 2010 cohort population structure was 
generated using the calculated number of survival infants born in 2010 and applied to the 2008 
Nigerian life table (193). Then the mortality rates by age groups were applied to the 2010 cohort 
to generate estimated liver cancer throughout the 2010 cohort lifetime, which is the base line 
liver cancer risk in this population. Later, we calculated the expected number of liver cancer 
cases prevented based on 95% efficacy of the HBV vaccine to prevent chronic HBV infection 
and the attributable fraction of chronic HBV infection on Nigerian liver cancer which is about 
59-62%.  
4.3.1.3 Cost-effectiveness ratio (CER) 
The CER– the ratio between the cost and the benefit of a particular intervention to determine the 
cost to prevent one healthy life year lost–of each intervention was compared with the Nigerian 
GDP per capita, which was about $2,360 in 2010 (211). Based on this ratio, each intervention 
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was assigned to one of three following categories proposed by WHO (130): highly cost-effective 
(CER< one GDP per capita), cost-effective (one GDP<CER<three GDP), and not cost-effective 
(CER> three GDP per capita). 
4.4 RESULTS 
4.4.1 Costs of interventions 
4.4.1.1 Biocontrol  
The cost of Afla-safeTM –biocontrol developed by IITA and tested in Nigeria–is about $18 per 
hectare (2010 Personal communication Dr. Ranajit Bandyopadhyay, IITA plant pathologist). 
This cost includes material and distribution costs. The 2010 Nigerian maize planting area 
projected from the FAO 2004–2008 databases (212) is approximately 4.19 million hectares.  
Therefore, the total cost of biocontrol if this intervention were applied into all maize fields in 
Nigeria would be about $75.40 million.  
4.4.1.2 The postharvest intervention package  
The cost of the postharvest intervention package proposed by Turner et al. 2005 is $50 to store 
500–1,250 kg of groundnuts (67). In 2010, this package would cost about $65.03. The 
purchasing power parity (PPP) approach was employed to convert the cost of the package in 
Guinea to the cost of this package in Nigeria. Purchasing power parity (PPP) is the exchange rate 
that equates the price of a basket of identical traded goods and services in two countries. PPP is 
an extension of the law of one price (LoOP) –one of the most basic laws in economics– which 
states that identical goods should be sold at the same price in two different markets if there is no 
transportation cost and no difference in tax rate between these two markets. The simplest way to 
think of the PPP is to compare the cost of “a standard good” that identical across countries. 
Hamburger index, which is the price of Mcburger around the world is one of the most typical 
samples of the PPP approach (213). PPPs are often very different from the current market 
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exchange rates. While market exchange rates reflect short-term relative value of different 
currencies, PPPs provide information of long-term value.  
Table 4-1. 2005 Purchasing power parity (PPP) and market exchange rate of Nigeria and Guinea 
Country PPP (1 $US) (214) 
 in local currency unit 
Exchange rate 
(1 $US) (215) 
Guinea 1,219.35 GNF 3,644.33 GNF 
Nigeria 60.23 Naira 131.27 Naira 
               Note: (PPP= purchasing power parity) GNF = Guinean Franc,  
$50 USD = 50 x 3,644.33 (GNF) = 182,216.50 GNF 
Using PPP to normalize to standardize USD 182,216.50/ 1,219.35 GNF per 1 USD 
       = 149.44 USD 
The PPP of $149.44 is similar to = 149.44 x 60.23  
     = 9,000.77  Nigerian naira 
9,000.77 PPP of Nigerian naira converted to USD based on exchange rate 
     = 9,000.77/131.27 
     = 68.57 USD in 2005 
The cost of the postharvest intervention in 2005 converted to 2010 currency value 
     = $ 89.19 
The 2010 gr oundnuts production in Nigeria was about 4.32 million tons. This number 
was projected based on the FAO 2004–2008 databases (212). The estimated costs of the package 
per year to store this amount of groundnuts range from $103.68 m illion to $259.20 million; 
assuming the package lasts for three years.  
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4.4.1.3 NovaSil clay as a dietary preventive agent  
Currently, the most effective dose of NovaSil clay to reduce aflatoxin bioavailability tested in 
humans is three grams per meal. The cost of NovaSil clay was $0.67 per kilogram in 2009 (2009 
Personal communication: Dr.Timothy Phillips) which was about $0.71 per kilogram in 2010. 
With three meal daily basis and the number of Nigerian population in 2010 of 152 million, about 
166.44 million kilograms or 166,440 tons of NovaSil clay were required to serve the Nigerian 
population in 2010 leading to a $117.54 million cost of the clay. Unlike other previous 
interventions, at present, there is no known source of NovaSil clay in Nigeria. The costs to 
export NovaSil clay from the USA, transport, and import to Nigeria are included in our analysis, 
assuming the clay is exported from USA to Lagos, Nigeria.  
Table 4-2 lists the parameters used for calculating the cost of NovaSil clay. The loose 
bulk density of NovaSil clay is 40 lb per ft.3 (216). The dimensions of standard 20-ft. container 
are 19' 4"x 7' 8"x 7' 9"(217). After a 10% deduction of capacity of standard containers for 
packaging and internal capacity, about 8,800 of 20-ft. containers are required. The costs of 
export from the US and import to Nigeria per 20-ft. container measured the fees levied on a 20-
ft. container are $1,050 (218), and $1,440 (219)1, respectively.  The freight transport cost to 
transport 8,800 of 20-ft containers from the USA to Lagos Nigeria is $39.53 million (Online 
freight calculator for a full load container 2010 May 11). Johns et al., 2003 estimated that, in 
general, the cost of domestic transport would be about 1-3% of original product cost (220).  In 
this study, the domestic transport cost is assumed to be 2% of original cost. Therefore, NovaSil 
would cost $181.33 million per year, assuming NovaSil clay is shipped in 20-ft. containers.     
 
  
                                                 
1 All the fees associated with completing the procedures to export or import the goods are included. These 
include costs for documents, administrative fees for customs clearance and technical control, customs broker fees, 
terminal handling charges and inland transport. The cost measure does not include tariffs or trade taxes. 
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Table 4-2. Cost of NovaSil clay per year in Nigeria 
Items Results References 
Direct cost of intervention   
Cost of NovaSil clay($)  $0.71/kilogram (3 grams 
per meal dose) ($0.73 per 
person per year) 
Dr. Timothy Phillips 
Personal communication, 
author calculation 
2010 Nigerian population  152 million (201) 
Total cost per year ($) 117.54 million Author calculation 
Transport cost   
Loose bulk density of the clay (per ft.3) 40 lbs. (216) 
Percent reduction of capacity due to packaging 
and internal capacity 
10 Author assumption 
Number of 20-ft. container required 8,800 Author calculation 
Export cost from USA per a 20-ft. container ($) 1,050 (218) 
Import cost to Nigeria per a 20-ft. container ($) 1,440 (219) 
Freight transport cost from USA to Lagos 
Nigeria for 8,800 of 20-ft. containers ($) 
39.53 million Online freight quote for 
full load container 2010 
May 11 
Domestic margin ($) 2.35 million Author calculation 
Total shipping cost ($) 63.51 million Author calculation 
Total cost (clay+shipping) ($) 181.33 million Author calculation 
4.4.1.4 Hepatitis B vaccine 
Table 4-3 listed all required parameters used for calculating the cost to immunize the 2010 birth 
cohort against the HBV infections. Given reserve stock of the vaccine to be zero, the cost of 
pentavalent vaccine was expected to be  $2.94  per dose in 2010 (129).  The average costs per 
children without vaccines range from $5.9 to $8.8 (221). These non vaccine cost, based on the 
data from eight countries, in which vaccine coverage rates were either low (< 50%) or high 
(>90%), were converted to 2010 values–$8.99 to $13.40.  
In 2009, the estimated Nigerian birth rate was 36.65 per 100,000; whereas, the population 
of Nigeria in 2009 was 149.23 million (201). Therefore, the estimated number of children born in 
2010 was about 5.47 million. The costs of the pentavalent vaccine and non vaccine were divided 
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by three to reflect the cost of the HBV vaccine. The overall costs in 2010 to HBV vaccinate all 
new born children in Nigeria ranged from $37.83 million to $ 45.88 million.    
Table 4-3. Cost of HBV vaccination per year in Nigeria 
Items Results 
Cost of intervention ($)  
Vaccine cost ($)  2.94 per dose (129) 
Numbers of dose required 3 
Wastage rate 25%  (222) for liquid vaccines in a 10 or 20 
dose vials 
Total  ($) 21.44 million 
Non vaccine cost ($) 8.99–13.40 per dose (221) 
2009 Nigerian population 149.23 million (201) 
Birth rate (per 1,000) 36.65 (201) 
Number of infants born in 2010 5.47 million 
Total ($ millions) 16.38 to 24.44  
Total cost of HBV vaccination program ($ millions) 37.82 to 45.88 
4.4.2 Efficacy of Interventions 
4.4.2.1 Aflatoxin control interventions  
In our previous chapter, we collected the data of aflatoxin levels in Nigerian maize and 
groundnut goods from various sources (69, 156, 157, 159, 171)  and showed that per kilogram 
bodyweight per day, a Nigerian is exposed to 16.37–44.34 and 6.91–7.22 nanogram of aflatoxin 
from consuming maize and groundnuts contaminated with aflatoxin. Together with the high 
prevalent of chronic HBV infections (173-189)–Assuming the HBV prevalence rate of 15%– 
without any interventions, aflatoxin exposure in Nigeria would induce liver cancer developments 
by 1.25–2.76 per 100,000 per year. Of these numbers 0.88–2.37 cases per 100,000 per year are 
the results of consuming maize contaminated with aflatoxin and 0.37–0.39 case per 100,000 are 
due to aflatoxin exposure in groundnuts.    
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Table 4-4 presents estimated numbers of liver cancer cases and disability life years lost 
which could be prevented if each of the three aflatoxin control interventions were adopted. A 
standard 3% discount rate was applied for ten years to obtain current DALYs values. On 
average, a Nigerian consumes maize in a larger amount compared with groundnuts (76.53 
grams/day versus 6.46 grams/day) (172). Biocontrol, the postharvest intervention package, and 
NovaSil clay would reduce aflatoxin-related liver cancer cases by 1,065–2,886, 388–405, and 
758–1,677, respectively. All of these interventions can provide thousands DALYs averted 
depending on levels of aflatoxin in food crops. 
Table 4-4. Estimated numbers of preventable liver cancer cases and DALYs averted from reducing aflatoxin 
exposure by select aflatoxin control interventions 
Items Biocontrol The postharvest 
intervention 
package 
NovaSil clay 
Target staple crops Maize Groundnuts Not specific 
Efficacy of intervention 80% (M) 69% (G) 40% (NS) 
AF exposure per kgBW-day (ng) due to 
maize consumption (Intervention +) 
3.27–8.87 16.37–44.34 9.82–26.60 
AF exposure per kgBW-day (ng) due to 
groundnuts consumption (Intervention +) 
6.91–7.22 2.14–2.24 4.15–4.33 
Total aflatoxin exposure (Intervention+) 10.18–16.09 18.51–46.58 13.97–30.93 
HCC cases predicted per 100,000 
(intervention+) 
0.54–0.86 0.99–2.49 0.75–1.65 
HCC cases prevented per 100,000 0.70–1.90 0.26–0.27 0.50–1.10 
Total HCC cases prevented 1,065–2,886 388–405 758–1,677 
Total DALYs saved 13,842–37,514 5,047–5,261 9,849–21,799 
Total DALYs saved (adjusted)a 10,300–27,914 3,755–3,915 7,328–16,220 
Note:  aDALYs were adjusted by discounting 3% for the effects assumed to begin at the 10th year. Total 
population of Nigeria in 2010 = 152 million (196). 
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4.4.2.2 Hepatitis B vaccine  
Liver cancer in 2010 birth cohort  
In the previous chapter, we estimated the numbers of liver cancer cases in the 2010 birth cohort 
in Nigeria and the reduced liver cancer burdens when the HBV vaccine was 100% adopted in 
this population. Given the Nigerian liver cancer death rates by age groups (191) and the 
attributable fractions of HBV infections, 59–62%, on l iver cancer, the HBV infections would 
induce liver cancer by 0.10, 3.11–3.27, and 47.92–50.36 per 100,000, in populations aged 
between 0–14, 15–59, and older than 60 years old age, respectively. The DALYs given to a liver 
cancer case developing at the age 0–14, 15–59, and older than 60 years old are: 30, 20, a nd 7, 
respectively.   
Table 4-5. Estimated lifetime health impacts of the HBV vaccination in 2010 Nigerian birth cohort   
Age Baseline HBV vaccine # reduced 
cases 
DALYs Adjusted 
DALYs 
HBV+ HBV- HBV+ HBV- 
0–14 63–66 40–44 3 47–51 53–56 1,587–
1,680 
1,290–
1,378 
15–59 5,085–
5,344 
3,275–
3,534 
254–267 3,824–
4,126 
4,238–
4,528 
84,760–
90,555 
28,393–
30,329 
>60 20,224–
21,252 
13,025–
14,054 
1,011–
1,063 
15,209–
16,410 
16,856–
18,006 
110,214–
117,730 
10,358–
11,064 
Overall 25,372–
26,662 
16,340–
17,632 
1,269–
1,333 
19,079–
20,588 
21,147–
22,591 
196,561–
209,965 
40,041–
42,771 
Note: Population = 5.07 million 
Table 4-5 shows the estimated lifetime health impacts of the HBV vaccination in the 
2010 birth cohort. Overall the vaccine would reduce liver cancer in 21,147 to 22,591 cases. The 
estimated DALYs averted from liver cancer by adopting the HBV vaccine range from 196,561 to 
69 
209,965. With the 3% discounted rate, the vaccine would prevent about 40,041 t o 42,771 
disability adjusted life years lost.  
Table 4-6. Potential DALYs prevented and cost effectiveness ratios (CERs) 
Items Biocontrol The postharvest 
intervention 
package 
NovaSil clay HBV vaccination 
 Lower 
bound 
Upper 
bound 
Lower 
bound 
Upper 
bounds 
Lower 
bound 
Upper 
bound 
Lower 
bound 
Upper 
bound 
Cases prevented 1,065 2,886 388 405 758 1,677 21,147 22,591 
DALYs prevented 13,842 37,514 5,047 5,261 9,849 21,799 196,561 209,965 
Adjusted DALYs 
preventeda 
10,300 27,914 3,755 3,915 7,328 16,220 40,041 42,764 
Worthy if the 
costs lesser than  
(US$ million) 
72.92 197.63 26.59 27.72 51.88 114.84 283.49 302.77 
Upfront Cost ($ 
million) 
75.40 103.68–259.20 187.85 37.82–45.88 
According to WHO, an intervention will be cost effective if its CER is less than three 
times GDP; therefore, the product of its total outcome (adjusted DALYs prevented) and 8,070 
(three times the Nigerian GDP) must be higher than its upfront cost for a particular intervention  
to be considered cost-effective.  
The HBV vaccine, but not the postharvest intervention package and NovaSil, is cost-
effective at either 59% or 62% HBV attributable fraction on liver cancer. Depending on aflatoxin 
exposure levels, biocontrol can be either cost-effective or not cost-effective. At the upper bound 
aflatoxin level, biocontrol is a cost-effective intervention to prevent liver cancer in Nigeria. 
However, at the lower bound level of aflatoxin, biocontrol is not cost-effective.    
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4.4.3 Sensitivity Analysis 
The sensitivity analyses of these four methods were performed to determine the CERs of these 
four interventions if their costs and efficacy were changed. We varied the costs by 30–500% of 
the current costs; and the efficacy from 40% of the original efficacy to their full capacity to 
completely reduce aflatoxin, aflatoxin bioavailability, or chronic HBV infections.   
Table 4-7 through table 4-14 present the CERs of four different types of aflatoxin control 
interventions at various costs and efficacy. At the lower bound aflatoxin level, either a reduction 
in cost or an improvement in efficacy is needed for biocontrol to become a worthy intervention. 
In contrast, even when the cost of the postharvest intervention package was reduced to only 30% 
of its original cost and its efficacy was improved to completely reduce aflatoxin in groundnuts; 
this intervention was still not cost-effective. NovaSil needs both cost reductions and efficacy 
improvements to become a cost-effective intervention. It is worthwhile to note that in this case it 
does not allow much opportunity for anyone to spend more money to promote or to perform 
extra activities since it would increase the cost of NovaSil. On the other hand, the HBV vaccine 
is much more tolerant to cost and efficacy changes compared with the other three interventions 
in this study.   
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4.4.3.1 Biocontrol 
          Table 4-7. Cost effectiveness ratios of biocontrol at the lower bound level of aflatoxin 
 
Table 4-8. Cost effectiveness ratios of biocontrol at the upper bound level of aflatoxin 
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4.4.3.2 The postharvest intervention package 
Table 4-9. Cost effectiveness ratios of the postharvest intervention package at the lower bound level of 
aflatoxin 
 
Table 4-10. Cost effectiveness ratios of the postharvest intervention package at the upper bound level of 
aflatoxin 
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4.4.3.3 NovaSil clay 
Table 4-11. Cost effectiveness ratios of NovaSil clay at the lower bound level of aflatoxin 
 
Table 4-12. Cost effectiveness ratios of NovaSil clay at the upper bound level of aflatoxin 
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4.4.3.4 Hepatitis B vaccine 
Table 4-13. Cost effectiveness ratios of HBV vaccine at 59% attributable fraction of HBV on liver cancer 
 
Table 4-14. Cost effectiveness ratios of HBV vaccine at 62% attributable fraction of HBV on liver cancer 
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4.5 DISCUSSION 
In our previous chapter, we have shown that the HBV vaccine is an effective intervention to 
control liver cancer in Nigeria. In this study, we show that the HBV vaccine is a cost-effective 
intervention based on WHO  criteria. Aside from preventing liver cancer developments, an 
immunization against the HBV also reduces the chance of acute infections by the HBV and 
reduces other consequences of chronic HBV infections, including cirrhosis. Therefore, total 
benefits of the HBV vaccine could be much more than the numbers presented in this study. 
None of the aflatoxin control interventions selected in our studies show superior efficacy 
to prevent liver cancer in Nigeria over the HBV vaccine. Though at the upper bound level of 
aflatoxin, biocontrol can be a cost-effective intervention; the other two interventions are less 
likely to be cost-effective. At the lower bound aflatoxin level, reducing the costs or improving 
the efficacy will increase the chance of biocontrol to be a cost-effective intervention. In order to 
be worthy, huge cost reductions (<30% of the original cost) together with efficacy improvements 
are needed for the postharvest intervention package. Because the cost of wooden pallets–used for 
uplifting stored groundnuts bags– was the main cost of this package, using readily available 
materials in households would greatly reduce the cost of the intervention. Since a Nigerian 
consumes a much larger amount of maize than groundnuts; therefore, one of the strategies to 
improve the efficacy of the postharvest intervention package is to apply this package to maize.  
To become a cost-effective intervention, NovaSil requires both cost reductions and 
efficacy improvements in most of cases. One possible way to reduce the cost and improve its 
efficacy is by targeting this intervention to high risk populations, such as individuals who are 
HBV-positive.               
Though some aflatoxin control interventions are not worthy to prevent liver cancer in 
Nigeria if preventing liver cancer development is the only outcome of interest, it can be 
misguided for anyone to inscribe these interventions to be non-worthy without taking into 
account of their other benefits, such as preventing growth impairment induced by aflatoxin. In 
the next two chapters, we reviewed the associations between aflatoxin and growth performances 
in animals and humans and performed the cost-effective assessment to determine whether the 
cost-effectiveness results change if benefits from preventing growth impairment are included.    
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5.1 ABSTRACT  
Aflatoxins, fungal toxins produced by Aspergillus flavus and A. parasiticus in a variety of food 
crops, are well-known as potent human hepatocarcinogens. Relatively less highlighted in the 
literature is the association between aflatoxin and growth impairment in children.  F oodborne 
aflatoxin exposure, especially through maize and groundnuts, is common in much of Africa and 
Asia: areas where childhood stunting and underweight are also common, due to a variety of 
possibly interacting factors such as enteric diseases, socioeconomic status, and sub-optimal 
nutrition. The effects of aflatoxin on g rowth impairment in animals and human children are 
reviewed, including studies that assess aflatoxin exposure in utero and through breastfeeding.  
Childhood weaning diets in various regions of the world are briefly discussed.  O ur review 
suggests that aflatoxin exposure and its association with growth impairment in children could 
contribute a significant public health burden in less developed countries.  
5.2 INTRODUCTION 
5.2.1 Aflatoxins 
Much of the policy attention surrounding aflatoxin, a common contaminant in the global food 
supply, has focused on its role in inducing liver cancer in humans (132, 223-225); with little or 
no attention devoted to the role of aflatoxin in growth impairment. Among other reasons, it is 
because the weight of evidence linking aflatoxin to human growth impairment has historically 
been much weaker than that linking aflatoxin to human liver cancer.  However, animal studies 
over the last several decades have demonstrated a significant association between aflatoxin and 
growth impairment; and, especially in the last decade, epidemiological studies have emerged 
suggesting similar effects in human children.  Validation of serum- and urine-based biomarkers 
of aflatoxin exposure and effect in the last two decades has greatly assisted these epidemiological 
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studies (Groopman et al. 2008).  In this paper, we review the literature associating aflatoxin with 
growth impairment in both animals and humans.  
Aflatoxins are secondary metabolites of the fungi Aspergillus flavus, A. parasiticus, and 
occasionally other Aspergillus species.   These fungal species are prevalent in food crops, 
particularly maize, groundnuts, oilseeds, and tree nuts, in tropical and subtropical regions 
worldwide.  Factors that influence whether these fungi produce aflatoxin include drought stress and 
rainfall, adaptation ability of crop genotype for its climate, insect damage, and agricultural 
practices (226).  These fungi can also produce aflatoxin in postharvest conditions: food storage, 
transportation, and processing.  Maize and groundnuts are the major sources of aflatoxin exposure 
in humans (the number of exposed persons exceeding several billion) because of the high 
consumption rates of these foods worldwide and their susceptibility to Aspergillus infection (6).  
Aflatoxin B1 (AFB1), the most toxic form of the aflatoxins, is the most potent naturally 
occurring chemical liver carcinogen known.  For people who are chronically infected with 
hepatitis B virus (HBV; common in China and Africa), aflatoxin consumption synergistically 
increases the risk of hepatocellular carcinoma (HCC; liver cancer) compared with either 
exposure alone (121).  Acute aflatoxicosis, characterized by hemorrhage, acute liver damage, 
edema, and death, can result from extremely high doses of aflatoxin in the diet (227).  In 2004 
and 2005, hundreds of acute aflatoxicosis cases in Kenya and 125 deaths were associated with 
the consumption of contaminated home-grown maize (6).  Aflatoxin exposure has also been 
associated with immunotoxicity in humans (10, 20, 22, 23); and, as this review highlights, with 
stunted growth and other indicators of growth impairment in children. 
5.2.2 Growth impairment and global burden of disease 
Childhood growth performance is usually measured by one or more of three indicators: height 
for age, weight for age, and weight for height. Based on W HO definitions, children whose 
heights for ages, weights for ages, and weights for heights are two standard errors or more below 
WHO growth standards (z score ≤ –2) are considered to be stunted, underweight, and wasted, 
respectively (228). Wasting is an indicator of deficits in tissue and fat mass, which may be 
caused by acute malnutrition; while stunting is regarded as  the indicator of chronic malnutrition. 
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The prevalence of severe wasting decreases by 24 months of age, while stunting prevalence 
increases by age and reaches a plateau at 24–36 months (229, 230). 
Stunting is a widely used indicator of chronic malnutrition in early childhood, including 
malnutrition during fetal development due to poor maternal nutrition.  Children are considered 
stunting if their height-for-age z-score (HAZ) is -2 or lower. Once established, stunting and its 
effects usually last for years.  Children who are stunted often develop long-term developmental 
and cognitive problems, and are more vulnerable to infectious diseases (231).  In one study, 
Filipino children aged between 8 and 11 years old who were stunted as two-year-olds had 
significantly lower test scores than non-stunted children later in life; as well as delays in school 
enrollment, increased school absences, and repetition of school years (232).  
An average disability weight, a weight factor that reflects severity of a disease, of 0.002 
for each stunting case, based on a 0–1 scale assigned by the World Health Organization (208), is 
relatively low compared with other conditions, diseases, or injuries. This is because the 
associated risk factors of stunting (increased susceptibility to infectious disease, cognitive 
impairment) are not included in the estimation of the disability weight of stunting.  However, 
stunting may still cause a high global burden of disease because of its prevalence, as well as its 
associated risk factors, and hence deserves public health attention. In 2004, an estimated 182.7 
million children in developing countries were considered to be stunted. 70% of these stunted 
children live in South and Southeast Asia and sub-Saharan Africa (208).  Globally, 21% of 
deaths and disability adjusted life years (DALYs)  in children aged five years and under are 
estimated to be attributed to stunting, severe wasting and intra-uterine growth restriction (229).  
Table 5-1 lists socioeconomic characteristics of selected nations worldwide, and 
estimated dietary aflatoxin exposure and proportion of stunted children.  Though the relationship 
is not consistent, it appears that in general, the proportion of childhood stunting is directly 
correlated with proportion of population living below the national poverty line, and inversely 
correlated with GDP per capita. As is the case with HCC, childhood stunting is prominent in 
world regions where foodborne aflatoxin exposure is high: South and East Asia, and sub-Saharan 
Africa.   
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Table 5-1. Economic, aflatoxin exposure, and health characteristics of selected nations. 
Country 
% population living 
below national poverty 
line (233) 
GDP per capita, 2010 
USD (PPP) (211) 
Aflatoxin 
exposure, 
ng/kgBW/day 
(142) 
% stunted 
children (233) 
Argentina NA 15,030 0–4 8 
China 5 7,240 17–37 22 
France NA 34,250 0.3–1.3 NA 
The Gambia 58 1,479 4–115 28 
India 29 3,176 4–100 48 
Kenya 52 1,783 3.5–133 36 
Nigeria 34 2,357 139–227 43 
Philippines 37 3,604 44–54 34 
Spain NA 29,649 0.3–1.3 NA 
Tanzania 36 1,484 0.02–50 44 
Thailand 13 8,479 53–73 16 
USA NA 47,702 0.26 4 
Note: . GDP = gross domestic product per capita, NA = not available, PPP = purchasing power parity 
 
Underweight children are significantly more at risk of death from diseases including 
diarrhea, pneumonia, malaria, and measles. It has been estimated that children with a weight-for-
age z-score (WAZ) of –1 to –2 are twice as likely to die from diarrheal diseases compared with 
children of normal weight, while children with WAZ from –2 to –3 are five times as likely to die.  
Additionally, 52% of pneumonia deaths in children age 5 and under are associated with low body 
weight (234). Although the prevalence of underweight is expected to decrease from 26.5% in 
1990 to 17.6% in 2015, this decrease would not be uniform across the world. In Asia and Latin 
America, childhood underweight is expected to decrease by about 50%, while in Africa, 
underweight prevalence may even increase by 2–3% compared with 1990 (235). WHO does not 
assign a s pecific disability weight to childhood underweight; however, low birth weight is 
assigned a disability weight of 0.106 per case (208). 
Wasting in children (weight-for-height z-score, or WHZ, is -2 or lower) is believed to be 
a condition related to acute malnutrition (236, 237), either from insufficient food intake or 
infectious diseases. Immune system impairment in wasted children makes them more susceptible 
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to infections (238).  As a result, wasting increases the risk of death in children with this condition 
(239).  W HO assigns a disability weight of 0.053 per wasting case.  In 2004, the global 
prevalence of wasting in children aged 5 years and under was about 56.2 million (208). 
This manuscript reviews the evidence linking aflatoxin exposure to growth impairment in 
animals and in human children. We first review the literature on animal studies over the past 50 
years in which associations were found between aflatoxin exposure and reduced feed intake, 
reduced weight gain, and other measures of growth impairment in animals.  Then we describe 
the studies that show evidence of aflatoxin exposure in children in various parts of the world, 
review a previously examined association between aflatoxin exposure and kwashiorkor (a 
disease of protein energy malnutrition), and discuss the studies that link aflatoxin exposure with 
stunting, underweight, and wasting in children. We describe weaning foods in various cultures 
worldwide, and end with a discussion of possible mechanisms by which aflatoxin may result in 
growth impairment in animals and humans. 
5.3 AFLATOXIN AND GROWTH IMPAIRMENT IN ANIMALS 
The adverse effects of aflatoxin on various indicators of growth performance have been 
demonstrated in multiple animal species over the last five decades.  Reduced feed intake and 
subsequent weight gain reduction in animals exposed to aflatoxin have been reported in mule 
ducklings (240), mice (241), Japanese quail (242), Cherry Valley commercial ducks (243), 
chickens (71, 244-252), turkeys (246), pigs (21, 253-262), Nile tilapia (263), and channel catfish 
(264).  
In addition, increases in feed conversion ratio (FCR)–defined here as the mass of food 
intake per unit weight gain by the animal−were prominent in the animals dosed with aflatoxin 
(244, 246, 253, 254, 258,  265, 266). Aflatoxin at relatively lower doses (100–300 μg/kg) did not 
affect six-month old steer; but their weight, feed intake, and feed efficiency were adversely 
affected at higher doses (700–1,000 μg/kg) (265).  While channel catfish and rainbow trout were 
not affected by 2,154 μg/kg of purified aflatoxin in feed diet in terms of growth rate, FCR, or 
liver lesions (264), Nile tilapia showed significant reduction in weight and feed consumption 
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when exposed to 1.8 mg/kg diet (1,800 μg/kg) or higher doses of aflatoxin for 25 days (263).  
Taken together, these studies suggest that aside from reducing feed intake and weight gain, feed 
conversion efficiencies across multiple animal species were also reduced by aflatoxin exposure 
in the diet.   
Several studies observed effects of aflatoxin on growth in baby animals as a result of in 
utero exposure through maternal feed.  The effect of aflatoxin on of fspring was reported by 
Butler and Wigglesworth in 1966, who observed growth retardation in rat pups whose mothers 
were fed high doses of aflatoxin during late pregnancy (267). The fetuses of hamsters 
administered aflatoxin intra-peritoneally at doses of 4 mg/kgBW or 6 mg/kgBW on days 8 and 9 
of pregnancy experienced growth retardation, compared with controls, but there were no 
significant differences in malformations between the two groups (268).   Kihara et al. (2000) 
reported lower mean body weight, delayed physical and behavioral development in the pre-
weaning phase, and disability of locomotor coordination and impaired avoidance performance in 
the post-weaning periods, in rat pups whose mothers were exposed to 0.3 mg/kg/day of aflatoxin 
subcutaneously during pregnancy. Moreover, they found that numbers of live births were 
affected by aflatoxin exposure during prenatal periods (269). Maternal exposure to AFB1, not 
AFG1, decreased body weights of piglets significantly (270). While aflatoxin did not affect 
average egg production, feed conversion, and body weight, it affected feed consumption and egg 
weight of laying Japanese quail (271).  
 Table 5-2 and table 5-3 contain summaries of animal studies showing an association 
between aflatoxin exposure and growth reduction, in animals that directly consume aflatoxin 
(table 5-2) and in utero: in baby animals whose mothers were exposed to aflatoxin during 
pregnancy (table 5-3).  
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Table 5-2. Animal studies of the effects of aflatoxin exposure on animal growth. 
Animal Aflatoxin dose and 
duration of experiment 
Results Study 
Pigs  
(n=50) 
0 (A), 0.2 (B), 0.7 (C),1.1 
(D) mg/kg feed 
(16 weeks)  
No significant difference in body weight 
between groups. Increase in FCR [4.53 (A), 
4.55 (B), 4.67 (C), 4.76 (D)] (p<0.05) 
Armbrecht et al. 
(1971) 
 
Pigs  
(n=60) 
0 (A), 1.0 (B), 2.0 (C), 4.0 
(D) mg/kg feed (13 wks) 
Increase in FCR [3.14 (A), 3.82 (B), 4.13 
(C), NA (D)a] (p<0.001) 
 
Armbrecht et al. 
(1971) 
Weanling pigs 
(n=110)  
<2 (A), <8 (B), 51 (C), 105 
(D), 233 (E) μg/kg feed  
(120 days) 
No significant effect on weight gain or feed 
conversion 
Keyl and Booth 
(1971) 
 
Weanling pigs 
(n=110)  
<6 (A), 450 (B), 615 (C), 
810 (D) μg/kg feed  (120 
days) 
Decrease in ADG at the dose of 615 and 
810 μg/kg feed [0.71 kg (A), 0.60 kg (C), 
0.47 kg (D)] (p<0.05) 
Keyl and Booth 
(1971) 
Young cross-bred 
steers (n=50) 
0(A), 100 (B), 300 (C), 700 
(D), 1 000 (E) μg/kg (133 
days) 
Decrease in ADG at 700, and 1 000 μg/kg 
(p<0.01) [1.14 kg (A), 0.86 kg (D), and 
0.79 kg (E)]  
Increase in FCR at 700, and 1 0 00 μg/kg 
(p<0.01)  [5.7 (A), 6.4 (D), 6.6 (E)]  
Keyl and Booth 
(1971) 
30-day-old 
Sprague-Dawley 
rats 
(n=24)  
0 (A), DMSO (B), 5 
mg/kgBW of AFB1 in 
DMSO, 7 mg/kgBW of 
AFB1 in DMSO 
(IP single dose in 76 hrs) 
Weight gain in 0, and DMSO groups 
[13g/rat (A), 15 g/rat (B)] 
Weight lost in 5 and 7 mg/kgBW of AFB1 
in DMSO groups [1 g/rat (C), 8g/rat (D)]  
Doyle et al. 
(1977)  
30-day-old 
Sprague-Dawley 
rats 
DMSO, 10 mg/kgBW of 
AFB1 in DMSO (IP single 
dose in 54 hours) 
Weight gain in DMSO group [8g/rat] 
Weight lost in 10 mg/kgBW of AFB1 in 
DMSO group [20 g/rat (C)] 
Doyle et al. 
(1977) 
Chickens 
(n>900) 
0 (A), 0.3 (B),1.25(C), 2.0 
(D)  mg/kg (28 days) 
Decrease in body weight and food intake 
Increase in FCR  (p<0.001) 
Bryden et al. 
(1979) 
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Table 5-2 (continued) 
Animal Aflatoxin dose and 
duration of experiment 
Results Study 
Broiler chicks 
(n=40 –48) 
0 (A), 5 mg/kg feed 
aflatoxin (B), exercise (C), 
5 mg/kg feed aflatoxin 
+exercise (D) 
(24 days)  
Decrease in body weight in aflatoxin 
treated group which can be partially 
improved by exercise [557.6±9.3 g (A), 
542.7±9.0 g (B), 366.8±7.4 g ( C), 
412.5±7.4 g (D)]. Increase in FCR in 
aflatoxin treated group [1.54 (A), 1.89 
(C)] 
Randall and Bird  
(1979) 
 
Layer type chicks 
(n=40 –48) 
0 (A), 5 mg/kg feed 
aflatoxin (B), exercise (C), 
5 mg/kg feed aflatoxin 
+exercise (D) 
(39 days)  
Decrease in body weight in aflatoxin 
treated group which can be partially 
improved by exercise. 
[469.5±9.9 g (A), 469.5±9.9 g ( B), 
370.8±20.2 g (C), 384.1±14.4 g (D)]. 
Increase in FCR in aflatoxin treated 
group [1.59 (A), 1.75 (C)]. 
Randall and Bird  
(1979) 
Broiler chicks 
(n=40 –48) 
0 (A), 5 mg/kg feed 
aflatoxin (B), exercise (C), 
5 mg/kg feed aflatoxin 
+exercise (D) 
Decrease in body weight in aflatoxin 
treated group which can be partially 
improved by exercise. 
[510.5±12.5 g (A), 502.0±12.0 g (B), 
414.9±19.8 g (C), 434.0±8.1 g (D)]. No 
difference in FCR. 
Randall and Bird  
(1979) 
Pigs 
(n=32: 8 for each 
of 4 g roups of 
pigs) 
20(A), 385 (B), 750 (C), 
and 1 480 (D) μg/kg 
(control: 20 μg/kg group)  
Decrease in ADG (dose-related) [0.77 kg 
(A), 0.67 kg (B), 0.57 kg (C), 0.41 kg 
(D)]; and ADFI  [2.87 kg (A), 2.53 kg 
(B), 2.15 kg (C), 1.61 kg (D)] (p<0.05). 
Increase in FCR  in the 1 480 μg/kg 
treated group [3.74 (A), 3.97 (D) ] 
(p<0.05) 
Southern and 
Clawson (1979) 
Broiler chickens 
(n=75)  
0 (A), 0.075 (B), 0.225 (C), 
and 0.675(D) mg /kg feed 
(7 weeks) 
Decrease in body weight in all aflatoxin-
treated groups [2 256±21 g ( A), 2  
098±26 g (B), 1 989±20 g (C), 2 047±24 
g (D)] (p<0.05) 
Doerr et al. (1983) 
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Table 5-2 (continued) 
Animal Aflatoxin dose and 
duration of experiment 
Results Study 
Broiler chickens 
(n=75)  
0 (A), 0.3(B), 0.9 (C), and 
2.7 (D) mg /kg feed  
(7 weeks) 
Decrease in body weight in only 2.7 mg 
of aflatoxin  per kg feed-group 
[2 024±30 g (A), 1  671±36 g (D)] 
(p<0.05) 
Doerr et al. (1983) 
 
1-day-old broilers  
(n=70) 
0 (A), .625 (B), 1.25 (C), 
2.5 (D), 5.0 (E), and 10.0 
(F) mg/kg feed 
(3 weeks) 
Aflatoxin dose-related decrease in body 
weight at the dose 1.25 μg /g and higher  
[511±32 g (A), 463±16 g (D), 386±25 g 
(E), 286±13 g (F)] and feed consumption 
[851±52 g (A), 773±50 g (D), 703±55 g 
(E) 734±14 g (F)] (p<0.05)  
Huff (1980) 
14-day-old 
turkeys (n=200) 
0 (A), 100 (B), 200 (C), 400 
(D), or 800 (E)  μg/kg  
(AFB1)  
(35 days) 
Decrease in percent weight gain at the 
dose of 400 μg/kg  and higher [averaged 
5- week percent weight gain :48.2% (A), 
33.2% (D), 19.7%(E)]. Increase in FCR 
at the two highest doses [FCR averaged 
in 5-week: 1.81 (A), 1.89 (D), 2.28 (E)] 
(p<0.05)  
Giambrone et al. 
(1985) 
14 days old broiler 
chickens (n=200) 
0 (A), 100 (B), 200 (C), 400 
(D), or 800 (E)  μg/kg  
(AFB1) (35 days) 
No significant difference in weight gain 
(p>0.05) 
Increase in FCR at the dose of 800 μg/kg   
[FCR: 2.02 (A), 2.11 (E)] 
Giambrone et al. 
(1985) 
105 days old 
chicks 
(n=120) 
0 (A) , 2.5 (B), 5.0 (C), and 
10.0 (D) mg/kg feed  
(4 weeks) 
Aflatoxin dose related decrease in body 
weight (p<0.05) [1.85±0.03 kg (A), 
1.57±0.05 g ( B), 1.51±0.04 kg ( C), 
1.47±0.03 g (D)] 
Shukla and 
Pachauri (1985) 
Male broiler 
chicks (n=180) 
0 (A) , 2.5 mg/kg of 
aflatoxin (B) , and 2.5 
mg/kg of aflatoxin + 16 
mg/kg of deoxynivalinol 
(C) (3 weeks) 
Decrease in body weight [626±11 g (A), 
521±12 g (B), 488±9 g (C) ], weight gain 
[490±10 g (A), 397±10 g (B), 365±8 g 
(C)], protein serum levels 
[2.9±0.1g/100ml (A), 2.0±0.1 g/100ml 
(B), and 2.1±0.1 g/100 ml (C)] (p<0.05)  
Huff et al. (1986) 
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Table 5-2 (continued) 
Animal Aflatoxin dose and 
duration of experiment 
Results Study 
5–6 weeks old 
pigs (n= 30: 10 
each in control, 
300 and 500 μg/kg 
groups) 
0, 300 and 500 μg /kg of 
feed  
(10 weeks) 
Decrease in weight gain in both aflatoxin 
treated groups up to 2 kg in 10-week 
period and feed consumption in high 
dose group compared with controls 
(p<0.01) 
Panangala et al. 
(1986)  
1-day-old broilers 
and layer chicks 
(n= 40 each) 
0 (A), 1 (B), 4 (C) mg/kg 
feed  
(4 weeks) 
Aflatoxin dose dependent decrease in 
body weights (p<0.05). Broilers: 
[332±17.81 g (A), 254±14.35 g (B), 
239±13.50 g (C)], Layer chicks : 
[158±3.6 g (A), 139±4.41 g ( B), 
126±5.82 g (C)]  
Ram et al. (1988) 
7- week- old Pigs 
(n=15) 
0 (A), 2.0 mg of aflatoxin 
(B), , 2.0 mg of ochratoxin 
(C), and 2.0 mg of aflatoxin 
+ 2.0 mg ochratoxin (D) /kg 
of feed (28 days) 
Decrease in body weight gain in all 
aflatoxin –treated groups 
[18.2±0.9 kg ( A), 13.5±0.8 kg ( B), 
13.8±1.0 kg ( C), 8.8±0.9 kg (D)] 
(p<0.05)  
Harvey et al. 
(1989) 
Channel catfish 
(n=450) 
0, 100, 404, 2154, or 10 000 
μg/kg (10 weeks) 
Decrease in weight gain in the 10 000 
μg/kg group by 24% compared with the 
control (p<0.05)[weight gain per fish in 
the highest dosed group = 60 g compared 
with 80 g/fish in the control group]  
Jantrarotai and 
Lovell (1990) 
Weanling swine 
(n=90).  
0 (A), 420 ( B) , 840 (C) 
μg/kg feed (49 days) 
Decrease in ADG [0.52 kg (A), 0.46 kg 
(B), 0.28 kg C)]; ADFI [1.13 kg (A), 
0.95 kg (B), 0.67 kg (C)]  
Increase in FCR [1.72 (A), 1.92 (B), 2.70 
(C)] (linear p<0.01, and quadratic, p< 
0.05) 
Lindemann et al. 
(1993) 
Weanling swine 
(n=63) 
0 (A), 800 (B) μg/kg feed  
(42 days) 
Decrease in ADG  [0.64 kg  (A), 0.41 kg 
(B)], ADFI [1.32 (A), 0.82 kg (B)]  
Lindemann et al. 
(1993) 
Weanling pigs  
(n=96) 
0 (A), 922 (B) μg/kg feed (6 
weeks) 
Decrease in ADG [0.505 kg (A), 0.392 
kg (B)] and ADFI [1.10 kg (A), 0.88 
kg(B)] (p<0.01) 
Schell et al., 
(1993a) 
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Table 5-2 (continued) 
Animal Aflatoxin dose and 
duration of experiment 
Results Study 
Weaned Pigs  
(n=54)  
0 (A), 800 (B) μg/kg feed  
(4 weeks)  
Decrease in ADG [0.64 kg (A),  0.48 kg 
(B)] (p<0.05), ADFI  [1.32 kg (A), 1.0 kg 
(B)] (p>0.05) 
Increase in FCR [2.08 (A), 2.43 (B)] 
(p<0.05)   
Schell et al., 
(1993b) 
Weaned Pigs  
(n=81)  
0 (A), 500 (B) μg/kg feed  
(5 weeks)  
Decrease in ADG [0.66 kg (A), 0.46 kg 
(B)], ADFI [1.41 kg (A), 0.97 kg (B)] 
(p<0.05)   
Schell et al. 
(1993b) 
Weaned Pigs  
(n=63)  
0 (A), 800 (B) μg/kg feed  
(4 weeks)  
Decrease in ADG [0.63 kg (A), 0.52 kg 
(B)] (p<0.05), ADFI [1.29 kg (A), 1.02 
kg (B)] (p<0.01)    
Schell et al. 
(1993b) 
Nile tilapia 
(n= 160) 
0 (A), 0.94 (B), 1.88 (C), 
0.375(D), 0.752 (E), 1.50 
(F), 3.0 (G) mg/kg diet  
(25 days following with 
basal diet for 50 days) 
Decrease in ADG, and ADFI, but not 
FCR in 1.88 mg/kg group and higher  
ADG: [10.87–11.30 g (A),  7.28 g (C), 
7.10g (D), 4.78 g (E), 3.25 g (F), 3.66 g  
(G)]  (p<0.01 ) 
ADFI: : [0.143-0.160 g (A),  0.115 g (C), 
0.116 g (D), 0.711 g (E), 0.052 g (F), 
0.048 g  (G)]  (p<0.01 ) 
Chávez-Sánchez et 
al. (1994) 
Lambs 
(n=44) 
0 mg aflatoxin in soybean 
meal (A), 0 mg aflatoxin in 
fish meal (B), 2.5 mg/kg 
diet soybean meal (C) or 
2.5 mg/kg diet fish meal 
(D) 
(35 days, followed by 32 
days wash out period)  
Decrease in feed intake, daily gain, in 
aflatoxin-fed lambs (p<0.05) during 
treatment period and wash out period.  
ADG: 0.53 kg (A), 0.24 kg  (C), 0.50 kg 
(B), 0.05 kg (D). ADFI: 4.19 kg (A), 2.74 
kg (C), 4.05 kg (B), 1.70 kg (D) 
Increase in FCR in aflatoxin-fed lambs 
(p<0.05) 
FCR:  7 .6 (A), 11.2 (C), 7.6 (B), –45.5 
(D)   
Edrington et al. 
(1994) 
Growing barrows 
(n=40) 
0 (A), 3 (B) mg/kg feedb  
(28 days) 
Decrease in weight gain [19.1±0.73 kg 
(A), 10.7±1.06 kg (B)] (p<0.05)  
Harvey et al. 
(1994) 
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Table 5-2 (continued) 
Animal Aflatoxin dose and 
duration of experiment 
Results Study 
Pigs (n=27) 0 (A), 2.5 mg AF /kg feed 
(B), 2.5 mg of AF/kg feed + 
2400 IU tocopherol (C) (32 
days) 
Decrease in body weight [38.4±3.9 kg 
(A), 22.0±2.0 kg (B), and 23.5±3.0 kg 
(C)], and feed consumption  [138±20.0 
kg (A), 41±4.5 kg (B), and 45±2.0 kg 
(C)] (p<0.05) 
Harvey et al. 
(1995a) 
Pigs 
(n=18) 
0 (A), 2.5 (B), 2.5 mg of 
aflatoxin plus 100 mg of 
fumonisin  B1/kg of feed 
(C)  (35 days) 
Decrease in body weight [49.2 kg (A), 
33.2 kg ( B) , 23.9 kg ( C)], weight gain 
[31.6 kg ( A), 15.8 kg ( B) , 6.3 kg ( C)] 
and feed consumption per pen   [153.7 kg 
(A), 89.0 kg (B) , and 42.7 kg (C)] 
Harvey et al. 
(1995b) 
1- day-old broiler 
chicks 
(n=40) 
0 (A), 0.5(B) mg/kg feed 
(32 days)  
Decrease in body weight [246.32±2.14g 
(A), 140.79±1.31 g (B) ], percentage 
weight gain [100% (A), 57% (B)], and 
total feed consumption [691.0 g (A), 
590.0 g (B)](p<0.01)   
Prabaharan et al. 
(1999) 
Mule ducklings 
(n=320) 
0 (A),200 (B) μg/kg feed  
(3- week) 
Decrease in daily feed intake 
[37.74±2.57g (A), 31.99±0.33 g (B)], and 
average daily weight gain [25.29±1.23 g 
(A), 21.24±1.25 g (B)] (p<0.05). 
Cheng et al. (2001) 
4-week-old 
weanling piglets 
(n=36) 
0 (A), 240 , 480 μg/kg feed  
(30 days) 
Decrease in ADG [489±18g (A), 
453±12g (B), 326±17g (C) ] (p<0.05) 
Marin et al. (2002) 
7-week-old 
Japanese quail 
(n =256) 
 
0(A), 25 (B), 50 (C), or 
100(D) μg /kg feed (AFB1) 
(168 days) 
Decrease in ADFI groups exposed to 50 
and 100 μg AFB1/kg.  [28.69±2.17g (A), 
27.57±1.81g (C), 27.76±1.85g (D) 
](p<0.05) 
No effect: Average egg production, feed 
use, and body weights (p> 0.05) 
Oliveira et al. 
(2002) 
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Table 5-2 (continued) 
Animal Aflatoxin dose and 
duration of experiment 
Results Study 
6-week-old male 
Swiss albino mice  
(n=70) 
0 μg AFB1 + 5% protein 
diet (A), 0 μg AFB1 + 20% 
protein diet (B), 0.5 μg 
AFB1/day + 5% protein diet 
(C), 0.5 μg AFB1/day + 
20% protein diet (D) (7 
weeks).  
Decrease in percent weight gain 
(p<0.001) in aflatoxin/normal 
protein- fed mice (D) compared with 
nonaflatoxin/normal  protein treated (B),  
but contrast to the low diet groups  [4% 
(A), 18.2% 
(B), 7.2%(C) and 12.2% (D)].  
No significant difference of total protein 
and albumin levels between aflatoxin 
treated and non-aflatoxin treated mice (p 
> 0.05) 
Kocabas et al.  
(2003) 
1-day-old broiler 
chicks (n=48) 
0 (A), 5 (B) mg/kg of AFB1 
in feed (3 weeks) 
Decrease in weight gain [866±12.7 g (A), 
699±38.5 g (B)] (p<0.05) and feed intake 
[1369±45.7 g (A), 957±183.5 g ( B)] 
(p<0.05)]. No change in FCR.  
Pimpukdee et al. 
(2004) 
Cherry Valley 
commercial ducks 
(n=90) 
0 (A), 20 (B) or 40 (C) 
μg/kg AFB1-contaminated 
rice  
(6 weeks) 
Decrease in ADG in 20 a nd 40 μg/kg 
AF-treated groups [48.21±2.5 g ( A), 
42.52±2.5 g (B), and 37.44±2.7 g (C)]; 
and feed intake in the high dose group 
[142.20±4.6 g (A), 130.28±3.5 g]. 
Increase in FCR in both aflatoxin-treated 
groups [2.95±0.02 (A), 3.31±0.04 (B), 
3.48±0.04 (C)] (p<0.05) 
Han et al. (2008) 
Note: Letters (e.g., A, B, C, D) represent different dose groups.  a Eight of 15 pigs in 4.0 mg/kg feed had severe 
morbid, hemorrhaged or died. bAflatoxin content consists of 79% AFB1,16% AFG1, 4% AFB2, and 1% AFG2,    
ADG =average daily gain, ADFI = average daily feed intake, DMSO = dimethylsulfoxide, FCR= feed conversion 
ratio, IP= intraperitoneal,  NA = not available, , only animals referred in “aflatoxin dose and duration” were counted 
for sample size  
 
In summary, 30 animal studies are documented here (table 2). Twenty-nine of 30 studies 
indicated that animals treated with aflatoxin showed reduced weight gain or some deviant signs 
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such as reduced feed intake or increased feed conversion ratio. Only one study reported non-
significant effect in either body weight or feed conversion. 
 
Table 5-3. Studies showing an association between aflatoxin exposure in utero and reduced growth in baby 
animals. 
Animal Aflatoxin dose and 
duration of 
experiment 
Results Study 
Rats: (n= 25) 0 (n=NA), 1 mg 
crystalline aflatoxin in 
0.1–0.2 ml of 
dimethylformamide 
(dosed orally as single 
dose at d 6  (n=6), d6–
d12 (n=10), and d16 of 
gestation (n=9)) 
Decrease in fetal weight (p < 0.01) in 
offspring rats born from mothers given 
aflatoxin in late pregnancy [4.75± 0.059 g 
(untreated), 3.81±0.066 g (d-16 group)]  
Butler and 
Wigglesworth 
(1966) 
Hamster   
(n= 40: 16 control, 24 
tested) 
4 or 6 mg/kg of 
crystalline AFB1 by i.p. 
injection on days 8 and 
9 of pregnancy 
Decrease in fetal growth in offspring 
hamster by 0.5–0.7 centimeter differences 
in length (p<0.01) 
Schmidt and 
Panciera  (1980) 
2 –3 years old sows 
and their piglets 
(n=24) 
0 (A), 800 μg/kg 
AFG1(B),  800 μg/kg 
AFB1(C), 800 μg/kg 
AFG1+800μg/kg AFB1 
(D) 
(d60 of pregnancy to 
d28 of lactation) 
Decrease in piglets’ body weight in AFB1 –
treated groups, but not in AFG1–treated 
group[: [6.51±0.42 g (A), 5.66±0.39 g (B), 
5.32±0.63 g (C), 5.25±0.44 g (C)]  
(p<0.05, and < 0.005 for C and D groups, 
respectively 
Mocchegiani et al. 
(1998) 
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Table 5-3 (continued) 
Animal Aflatoxin dose and 
duration of 
experiment 
Results Study 
Rat, pregnant and 
offspring 
(n=30, 10 of each 
three groups) 
0 (A), 0.3 mg/kg/day 
AFB1 dissolved in 
dimethylsulfoxide 
subcutaneously on days 
11–14 (B) or 15–18  (C) 
of gestation 
Decrease in mean birth weights in both male 
and female offspring treated with AFB1 
[Male: 5.7±0.1 (A), 5.1±0.1 (B), 4.7±0.3 
(C); Female: 5.4±0.1 (A), 4.9±0.1 (B), 
4.7±0.3 (C) ] (p<0.05), decrease in number 
of live births in the group exposed to AFB1 
on d15 –18 [15.2±0.5 (A), 12.9±0.9] , 
delayed physical development, and delayed 
behavioral developments during pre-
weaning period, impaired locomotor 
coordination and deficits in avoidance 
performance in postweaning period 
Kihara et al., 2000 
7 weeks old Japanese 
quail 
(n =256) 
 
0(A), 25 (B), 50 (C), or 
100(D) μg /kg feed 
(AFB1) 
(168 days) 
Decrease in egg weight (p < 0.05)  in 
groups exposed to 50 and 100 μg AFB1/kg 
[10.67±0.24 (A), 10.53±0.21 (C), 
10.51±0.21 (D)].   
Increase : Percent shell of total egg weight 
(p< 0.05) in 100 μg AFB1/kg fed group 
Oliveira et al. 
(2002) 
Note: Only animals referred in “aflatoxin dose and duration” were counted for sample size 
 
Table 5-3 lists five animal studies which show the association between in utero aflatoxin 
exposure and growth parameters in baby animals. All five studies reported either the reduced 
fetal weights/ egg weights or fetal lengths of the offspring animals.    
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5.4 AFLATOXIN AND GROWTH IMPAIRMENT IN HUMANS 
5.4.1 Aflatoxin exposure in utero and in early childhood 
Exposure to aflatoxin begins early in the lives of many children worldwide.  Children may be 
exposed to aflatoxin through maternal food intake in utero, through breastfeeding, and through 
weaning and post-weaning foods; particularly where maize and groundnuts are dietary staples. 
Aflatoxin exposure increases most dramatically after children are weaned from breastfeeding 
(272). However, even in utero exposures can have a s ignificant effect on faltering in infant 
growth (32). 
Detection of aflatoxins and aflatoxin-albumin adducts (AF-alb) in the cord blood of 
babies in various countries confirm that children are exposed to aflatoxin and/or its metabolites 
in utero.  In a Taiwanese study, 11 of 120 placentas were found to contain aflatoxin DNA adduct 
levels ranging from 0.6 to 6.3 μmol/mol DNA.  In the same study, aflatoxin DNA adducts were 
detected in 6 of 56 cord blood samples in the range of 1.4–2.7 μmol/mol DNA (273).  Aflatoxin 
M1 (AFM1), a metabolite of AFB1, was detected in 68% (113/166) and 67% (111/ 166) of 
maternal blood and cord blood samples of neonates studied in the United Arab Emirates, with 
mean levels of 1040 pg/ml and 1880 pg/ml, respectively (274). 
Of 282 cord blood samples from Ghana, 101 samples from Kenya, and 78 samples from 
Nigeria, aflatoxins were detected in 31%, 37%, and 12%, respectively (275, 276). Though the 
detection rate of AF-alb in maternal blood samples was not stated, the levels of AF-alb found in 
755 Ghanaian mothers in a cross-sectional study were reported to range from 0.44 to 268.73 
pg/mg (29). Detectable levels of aflatoxins were found in 22% to 82% of cord blood of Nigerian 
neonates (277, 278), and 58% of the cord blood samples from Sierra Leone (279). AF-alb was 
detected in 29 of 30 (97%) maternal blood samples, and 22 of 30 (70%) matched umbilical cord 
blood sera from Gambian neonates (280). Turner et al. (2007) found AF-alb ranging from 5 
pg/mg to 896 pg/mg in 48 out of 99 (48%) Gambian cord blood samples.   
The studies in Kenya (275) and Sierra Leone (279) showed higher detection rates of 
aflatoxins in maternal blood samples (53% and 75%) compared with cord blood (37% and 58%). 
By contrast, aflatoxins (AFB1, AFG1, AFQ1) were detected with much greater frequency in Thai 
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cord blood samples (17 of 35) compared with the maternal blood samples (2 of 35), indicating 
trans-placental transfer of aflatoxins from mothers to fetuses (281). However, low trans-placental 
transfer of AF-alb or low efficiency of fetal metabolism to change free aflatoxins to the AF-alb 
form has been suggested, because of the much greater levels (up to 10 t imes) of AF-alb in the 
venous blood of Gambian mothers compared with those in matched cord blood samples (280).   
One study conducted to determine the efficacy of fetal-specific CYP3A7 and adult specific 
CYP3A4 in hamster rat found similar level of enzyme expressions to activate AFB1 in both 
CYP3A lines (282). An in vitro study was conducted in guinea pigs to compare the formation rates 
of aflatoxin-DNA adduct and AF-alb between adult and second trimester prenatal livers. Whereas 
lower expression of two aflatoxin detoxification enzymes, microsomal epoxide hydrolase and 
polymorphic glutathione S-transferase, and higher expression of lipooxygenase – an enzyme which 
can activate AFB1 to form AFB1-DNA adduct (283) – were detected in prenatal livers compared 
with adult livers, the formation rates of DNA-adducts and protein adducts in prenatal livers and 
adult livers were not different (284).  Recently, a human in vitro study showed that AFB1 was 
metabolized by human placentas to aflatoxicol, a less mutagenic but equally carcinogenic 
metabolite of AFB1 (285). However, fetal metabolism can be greatly different from adult 
metabolism as a result of reduced hepatic blood flow and incomplete hepatic formation. Still, 
little is known about biotransformation of aflatoxins in fetuses, and further studies are needed. 
The presence of aflatoxins, particularly AFM1, in maternal breast milk in several regions 
indicates that children worldwide may be exposed to aflatoxins through breastfeeding. Though 
AFM1 was found in none of the breast milk samples from French (286) and German mothers 
(287), about 30% to 60% of breast milk samples from Sudanese (288), Kenyan (275), Ghanaian 
(275, 276), and Egyptian mothers (289, 290) contained detectable levels of aflatoxins.  In Sierra 
Leone, 99 of 113, or 88%, of breast milk samples from mothers contained detectable levels of 
aflatoxins (291). However, only 11% of the breast milk samples from Zimbabwean mothers 
(286) and 5% of breast milk samples from mothers in Cameroon (292) were AFM1 positive.  
In Asia and the Middle East, AFM1 was detected in 20 out of 91 breast milk samples of 
Iranian mothers with the mean concentration of 6.96±0.94 pg/ml (293). About 45% of Thai 
mothers had detectable AFM1 in breast milk with a median concentration of 664 pg /ml. The 
AFM1 levels in Thai mothers ranged from 39 pg/ml to 1736 pg/ml (294). Very high percentages 
of the UAE mothers– more than 90%– had detectable levels of AFM1 in the breast milk (30, 
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295). Whereas two prior studies detected aflatoxins in only one of 231 (0.4%) and eight of 61 
(13%) breast milk samples from Turkish mothers (296, 297), aflatoxins were detected in all of 75 
breast milk samples from the lactating Turkish mothers in a more recent study (298). This 
discrepancy may have many causes, including differences in analytical methods, differences in 
study populations, or issues of seasonality. 
Gong et al. (2003, 2004) found that in Benin and Togo childhoods, AF-alb levels 
increased with age until three years old. This trend reflected the transitioning of children from 
breastfeeding to weaning and post-weaning foods. Children who were completely weaned had 
higher levels of AF-alb than breastfed or partially breastfed children.  
Because of multiple routes of exposure beginning from the fetal environment, high 
percentages of children in various countries have been exposed to aflatoxins, as detected in 
multiple studies. About 85% to 100% of children in African countries, such as Gambia, Guinea, 
Kenya, Benin, Togo and Senegal had either detectable levels of serum AF-alb or urinary 
aflatoxins (22, 36, 272, 299-302, 303, 1993). Levels of AF-alb in children from industrial nations 
are typically significantly lower than those living in less developed countries. Wild et al. (1990) 
found AF-alb levels as high as 350 pg/mg in almost all sera  o f children in various African 
countries. By contrast, none of the French or Polish sera contained AF-alb at levels higher than 5 
pg/mg albumin (303). 
The seasonality of sampling has been addressed in a number of studies (273, 275, 276, 
278, 290, 300, 303, 304). Many studies had detected aflatoxins in human body fluids more often 
in the wet season than the dry season. Some of them include the studies which determined 
aflatoxins in the cord blood samples from Kenya and Nigeria neonates (275, 278), AFM1 in the 
breast milk of Ghanaian mothers (276), and aflatoxins in the Taiwanese breast milk samples 
(273). Similarly, AFB1, AFB2, AFG1, and aflatoxicol were detected more often in the urine 
samples of Sierra Leone children collected during the rainy season, compared with the dry season 
(304). On the other hand, in two Gambian studies, AF-alb was detected more frequently in the 
serum of Gambian children collected during the dry season than the wet season (300, 305). 
Aflatoxin development in storage, after groundnuts had been harvested at the end of the wet 
season, was expected to be the cause of the elevated levels of AF-alb in the dry season (300, 306).  
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5.4.2 Past studies on aflatoxin and kwashiorkor 
An area of inquiry that had gained notice several decades ago concerned the possible link 
between aflatoxin exposure and childhood kwashiorkor, a disease of protein energy malnutrition.  
Both kwashiorkor and marasmus (another childhood condition common in less developed 
countries) are diseases of severe malnutrition. While protein deficiency is a major etiology of 
either kwashiorkor or marasmus, one key difference between these two conditions is that 
kwashiorkor can occur even when caloric intake of the children is sufficient, while marasmus 
can be caused by deficient caloric intake. Children with marasmus are less likely to suffer from 
fatty liver or edema: classical manifestations of kwashiorkor. Other symptoms of kwashiorkor 
include light-pigmented hair and skin and anorexia (307). An individual with edema from 
kwashiorkor and wasting from marasmus is considered to have marasmic kwashiorkor (308). 
While marasmus is sometimes perceived as an adaptive response to starvation, kwashiorkor is 
considered a maladaptive response to undernourishment (307, 309, 310).    
Since the 1980s, several studies have examined the possible association between 
aflatoxin exposure and kwashiorkor (292, 311-316). These studies found that aflatoxins or their 
metabolites were detected with greater frequency in the blood or urine of children with 
kwashiorkor than in healthy children or children with other protein malnutrition-related 
conditions, such as marasmus.  Moreover, aflatoxins were detected more frequently, but not 
statistically significant, in autopsies of lungs and livers, but not in kidneys, of children who died 
from kwashiorkor; compared with those who died from other diseases or other forms of 
malnutrition (312, 315, 317) . It is worthwhile to note that only seven liver specimens were 
included in Lamplugh and Hendrickse, 1982−three from kwashiorkors, three from marasmic-
kwashiorkors and one from  marasmic children. 
Other factors could explain these phenomena, however.  In a study conducted in a 
hospital in Durban, South Africa (318), children with kwashiorkor were matched with controls 
with no symptoms of protein energy malnutrition. Aflatoxins were detected in the serum and/or 
urine of all children. The serum/urine ratio was significantly higher in the kwashiorkor group; 
the controls, however, had a higher proportion of urine aflatoxins than the kwashiorkor group. 
These findings may reflect impaired liver function in kwashiorkor, which could in turn lead to 
differences in how aflatoxin is metabolized; rather than aflatoxin’s playing any direct role in 
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causing kwashiorkor.  Indeed, it has been proposed that children who suffer from kwashiorkor 
are at greater risk to the hazards of dietary aflatoxin (37). 
5.4.3 Aflatoxin and growth impairment in children 
Various studies have demonstrated that aflatoxin exposure, through a variety of sources as 
described above (in utero, through maternal breast milk, and in weaning diets), is linked with 
growth impairment. Table 5-4 summarizes the studies that have shown an association between 
aflatoxin exposure and various measures of growth impairment in human children. 
 
  
97 
Table 5-4. Human studies of the effects of aflatoxin on growth impairment. 
Country/ Study 
population 
Results Study 
Benin/ Children 
ages 16–37 months 
(n=200) 
a) Significant negative correlation (p < 0.0001) between AF-alb 
adduct and height increase over 8-month study period 
b) A mean 1.7 cm reduction difference in growth over 8 months in the 
AF-alb adduct highest quartile, compared with the lowest quartile 
c) No association between AF-alb and micronutrient levels 
Gong et al. (2004) 
Benin and Togo/ 
Children ages nine 
months to five 
years (n = 480) 
a) Negative correlation between individual AF-alb adduct and HAZ, 
WAZ, WHZ (p=0.001, 0.005, 0.047 respectively) 
b) Factors influence AF-alb adduct level: age (up to 3 years) and 
weaning status (p= 0.0001) 
c) Twofold higher mean AF-alb adduct levels in weaned children than 
those receiving a mixture of breast milk and solid foods after 
adjustment for age, sex, agro-ecological zone, and socioeconomic 
status 
Gong et al. (2002, 
2003) 
The Gambia/ 
Children ages six 
to nine years old 
(n= 472) 
a) 93%  AF-alb adduct detection rate  
b) Geometric mean level = 22.3 pg/mg; range 5–456 pg/mg) 
c) Significant association between AF-alb adduct and the weight for 
height score (p=0.034) 
d) Significant lower levels of sIgA in children with detectable AF-alb 
adduct compared with those with non-detectable levels [50.4 μg/mg 
protein (95% CI: 48.0, 52.8) and 70.2 μg/mg protein (95% CI:  
61.1, 79.2) respectively, p<0.0001] 
Turner et al. 
(2003) 
The Gambia/ 
Infants to one year 
old (n=138) 
a) The geometric mean AF-alb adduct levels = 40.4 pg/mg (4.8–
260.8), 10.1 pg/mg (5.0–189.6), and 8.7 pg/mg (5.0–30.2) in 
maternal, cord and infant blood, respectively  
b) Associations between the reduction of maternal AF-alb from 110 
pg/mg to 10 pg/mg & 0.8 kg increase in weight & 2 cm increase in 
height of children within first year of life 
c) AF-alb adduct in maternal blood as a strong predictor of both 
weight (p = 0.012) and height (p = 0.044) gain, with lower gain in 
those with higher exposure 
Turner et al., 
(2007) 
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Table 5-4 (continued) 
Country/ Study 
population 
Results Study 
Ghana/ Pregnant 
women and their 
infants  (n=785)   
a) Odds ratio of having low birth weight babies in the highest AF-alb 
adduct quartile mothers is 2.09 (p=0.007) 
Shuaib et al., 
(2010) 
Iran/  Lactating 
mothers (n= 160: 7 
preterm delivery 
mothers, and 153 
with full term 
infants) 
b) 98% (157 of 160 breast milk samples) AFM1 positive detection rate 
(average concentration: 8.2±5.1 ng/kg, range: 0.3–26.7 ng/kg) 
c) Significant association between aflatoxin and height at birth of 
infants (p<0.01)  
Sadeghi et al. 
(2009) 
Iran/ Lactating 
women (n=182: 91 
from urban areas in 
Tabriz and 91 from 
rural area)  
a) 22% and 0% detection rates of AFM1 in breast milk of mothers 
living in rural areas, and urban areas, respectively 
b) AFM1 : 6.96±0.94 pg/ml 
c) Significant association between the HAZ of infants and maternal 
AFM1 (p<0.015) 
d) Significant lower scores in HAZ and WAZ of infants born to 
AFM1–positive mothers (p<0.05) 
Mahdavi et al.  
(2010) 
Kenya/ Children 
ages 3–36 months 
(n =242) 
a) Significant association between numbers of children who were 
wasting and were being fed on flour contaminated with aflatoxin 
(p=0.002)  
Okoth and Ohingo 
(2004) 
United Arab 
Emirates/ 
Pair maternal -cord 
blood samples from 
women admitted 
1995–1998 (n=166 
pairs) 
a) 100% cord blood AFM1detection rate in low birth weight neonates  
VS 55% detection rate in normal weight neonates  
b) Strong negative correlation between aflatoxin levels and birth 
weights (r =–0.565, p <0.001)  
 Abdulrazzaq et al. 
(2004) 
Note: AF-alb: aflatoxin albumin adduct, HAZ, height for age z-score, WAZ, weight for age z-score, WHZ: weight 
for height z-score. 
The studies that examined these associations were conducted primarily in the Middle East 
and in Africa.  In a study in the United Arab Emirates, Abdulrazzaq et al. (2004) detected AFM1 
in 100% (43 of 43) of neonates born with low birth weights, but only in 55% (68 of 123) of 
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neonates with normal birth weight.  Aflatoxin levels in the cord blood and maternal blood 
samples were inversely associated with weight at birth (r =–0.565, p =  0.001 and  r  =–0.654, 
p=0.0001)  (274).   
Two recent Iranian studies have linked AFM1 levels in mothers’ breast milk with growth 
impairment in babies. AFM1 was found in 157 of 160 (98%) of breast milk samples collected 
from Iranian mothers living in Tehran, with concentrations ranging from 0.3–26.7 ng/kg.  The 
levels of AFM1 in breast milk were inversely correlated with length of infants at birth (p<0.01) 
(31).  Another study collected breast milk from mothers living in urban areas of Tabriz and its 
surrounding rural areas. Only 22% of breast milk samples from mothers in the rural surroundings 
of Tabriz contained detectable levels of AFM1, and none of the breast milk samples from 
mothers living in urban areas of Tabriz were found to have AFM1.  The levels of AFM1 in the 
breast milk of mothers from rural areas of Tabriz ranged from 5.1–8.1 pg/ml. There was a 
significant inverse relationship between AFM1 levels in maternal breast milk and the height-for-
age z-scores (HAZ) in infants 90–120 days old (β=–0.31, p<0.015). The children whose mothers 
were AFM1-positive had lower HAZ and weight-for-age z-scores (WAZ) than children born to 
mothers with no detectable AFM1 (293). 
In Africa, studies associating aflatoxin exposure with growth impairment in children were 
conducted in Kenya and several West African nations.  In an early study on 125 babies in rural 
Kenya (319), aflatoxins were detected in 53% of mothers’ blood, and the mean birth weight of 
females born to mothers whose blood tested positive for aflatoxin was significantly lower (255 g) 
than those born to mothers with no aflatoxin detected in the blood.  Additionally, the two 
recorded stillbirths were both to mothers who tested positive for aflatoxins. 
A series of studies conducted in Togo and Benin in the early 2000s provides insightful 
information into the cross-sectional, longitudinal, and dose-response aspects of the association 
between aflatoxin exposure and childhood growth impairment (35, 36, 272).  In a cohort of 480 
children aged 9 months to 5 years in these two countries, the prevalence of stunting and 
underweight were reported to be 33% and 29%, respectively (35, 272). AF-alb was detected in 
99% of the children, with a geometric mean level of 32.8 pg/mg (95% CI: 25.3, 42.5).  Clear 
dose-response relationships were found between mean AF-alb levels and lower HAZ and WAZ 
scores. Children who were stunted (HAZ ≤ –2) had 30–40% higher mean AF-alb levels 
compared with non-stunted children.  Household socioeconomic status and maternal education 
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were not significantly associated with AF-alb levels in children. There was no consistent pattern 
between the socioeconomic status of the mothers and the adduct levels in the children (35, 272). 
A subsequent eight-month longitudinal study in 200 children aged between 16 and 37 months in 
Benin showed a significant negative association between height velocity, but not weight, and 
mean AF-alb levels (36). A difference of 1.7 cm over the eight-month study period in adjusted 
height between the highest and lowest AF-alb quartile was observed.  
Unlike Gong et al. (2002), a study in Gambia on a cohort of 472 children between 6–9 
years old did not find that AF-alb levels were associated with HAZ or WAZ (22). It is 
noteworthy that the participants in the Gambian study were born during the implementation of a 
five-year maternal supplementation program, in which pregnant mothers were given two 
groundnut biscuits daily which provided 4,250 kJ, 22 g protein, 56 g fat, 47 mg calcium, and 1.8 
mg iron per day to the mothers (320).  However, a subsequent study did find an association 
between in utero aflatoxin exposure and growth impairment. Following 138 Gambian neonates 
for one year, Turner et al. (2007) found a significant association between aflatoxin exposure in 
mothers during pregnancy and height and weight gain of their infants in the first year of life. 
They concluded that if the maternal AF-alb levels dropped from 110 p g/mg to 10 pg/mg, the 
weights and heights of one-year old infants would increase by 0.8 kg  and 2 cm on average, 
respectively (32).  
In a study in the Kisumu District of Kenya (321), weaning flours from 242 households 
with children aged 3–36 months old were analyzed for aflatoxins. The weights and heights of the 
children were measured to determine prevalence of stunting, underweight, and wasting. While 
only 28% of non-wasted children were from households with aflatoxin contaminated flour, about 
54% of the wasted babies were from households with detectable aflatoxin in the flour. There was 
a significant association between aflatoxin exposure and wasting (p=0.002). Aflatoxins were also 
more frequently detected in the flour of stunted and underweight children compared with normal 
children. However, these differences were not statistically significant (321).  
In a recent cross-sectional study, Shuaib et al. (2010) found levels of AF-alb ranging 
from 0.44 to 268.73 p g/mg in maternal blood samples from 755 G hanaian mothers. After 
adjusting for sociodemographic variables, it was found that the mothers in the highest quartile of 
AF-alb levels were at significantly higher risk of having babies with low birth weight, defined as 
being below 2.5 kg (OR=2.09). There were also increased odds of having preterm deliveries and 
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stillbirths with for mothers who had AF-alb in the highest quartile, though the associations 
between AF-alb and these risk factors were not statistically significant (29). 
5.4.4 Childhood weaning foods  
A focus of interventions to reduce aflatoxin exposure in childhood could be on improving the 
quality and composition of weaning foods.  In Africa and Latin America, childhood weaning 
foods are usually prepared from maize (322), which can lead to high aflatoxin exposures early in 
life. Several maize-based foods such as gruel, ogi (fermented maize gruel), pap (maize porridge), 
and eko – boiled and gelatinized ogi (323) – are used as weaning foods in Africa.  Groundnuts 
can also be commonly used as a weaning food in various African regions. 
The weaning process in the West African countries starts in many cases at early ages, 
when the children are about 3–6 months old (324). Up to 50% of children in Makurdi, Nigeria, 
consume pap as their main weaning food, followed by Cerelac, a commercial infant formula 
(26.5%) and pap mixed with other food (11%) (325). Weaning foods in West Africa are usually 
made of maize, groundnuts, sorghum, millet, and guinea corn (28). Likewise, maize is a major 
weaning food in some countries in East Africa. In Uganda, 89% of children are fed maize 
porridge regularly. About 24.5% of children aged three to 28 months have maize porridge seven 
days a w eek (326). Gruels prepared from maize are used as weaning foods in Kenya (327), 
Tanzania (324), and Ethiopia (328). Other staple crops are also used to prepare weaning foods in 
these East African countries. Some of them include sorghum in Tanzania, sorghum and millet in 
Kenya, barley and wheat in Ethiopia. Sorghum porridge (nasha) is a traditional weaning food in 
Sudan (329).  
Many children in Latin America also consume large amounts of maize in their weaning 
diets, which can increase aflatoxin exposure. Maize-based gruels are among several kinds of 
Brazilian weaning foods, which also include rice flour or cassava flour-based gruels, cassava, 
sugar, and diluted milk (330).  M aize tortillas consumed with milk, beans, bread, pasta, fruit, 
chicken soup, flavored gelatin, or soft drinks are commonly used as weaning foods in Mexico 
(331).        
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Children’s weaning foods in Asia vary substantially from region to region. Weaning 
foods in China are whole eggs, vegetables and fruits, porridge (rice, maize, or wheat), and infant 
formula (332-335). Maize and even rice are contaminated with aflatoxin in many parts of China 
(336-340).  In 1992, maize consumption among residents of Guangxi, where HCC prevalence is 
among the highest in the world, was as high as 350–500 g/day (337). In India, children may be 
weaned on  various kinds of food: formula, porridges (maize, rice, millet, etc), commercial 
cereals, pulses, fruit, rice with milk and/or ghee, roti, and potatoes (341-343). Nepalese children 
are weaned on porridge and animal milk at ages of 2.5–6.5 months old. Thai weaning foods 
include rice-based food, fruit juice, fruit, meat, fish and vegetable soup (318, 344).   
Because aflatoxin exposure in children increases markedly following weaning (272) and 
is associated with multiple adverse health outcomes, reducing aflatoxin levels in weaning foods 
is crucial in high-risk regions of the world.  Interventions could include dedicating cleaner maize 
and groundnuts to weaning foods, or provision of weaning foods that contain wide varieties of 
food crops instead of few food crops. 
5.5 DISCUSSION  
Growth impairment in children is a pervasive public health probl in low- and middle-income 
countries worldwide, and is associated with a wide variety of factors such as poor nutrition, poor 
hygiene, socioeconomic status, local political instability, repeated infectious diseases, and 
environmental toxins (229).  Aside from adverse health effects associated with childhood growth 
impairment, such as cognitive impairment and increased risk of infectious diseases and death, 
there are also economic consequences: childhood undernutrition as indicated by stunting has 
been associated with lower human capital in low- and middle-income countries (345). Stunting, 
wasting or underweight is associated with increased mortality risks in childhood (229) Reducing 
risk factors for growth impairment in children age under five could be a way: One of the eight 
goals to improve socioeconomic and human health, endorsed by the leading international 
organizations and world leaders in 2000, is to reduce mortality rate among children age under 
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five,  by two-thirds in 2015  (346). Reducing risk factors for growth impairment in children age 
under five can be another way, along with other interventions, to achieve this goal.  
Among the risk factors associated with growth impairment, aflatoxin emerges as playing 
a potentially important contributory role.  The weight of evidence linking aflatoxin with growth 
impairment has been increasing over the last five decades of research: first primarily in animal 
studies, and in the last decade increasingly in epidemiological studies. When considering the 
Bradford Hill criteria for causality (347), the recent epidemiological studies have provided useful 
supporting evidence.  When controlling for other socioeconomic and environmental factors, the 
strength of association between aflatoxin and stunting and underweight is strong. Moreover, the 
dose-response relationship between aflatoxin exposure and growth impairment is monotonically 
increasing (35), which is consistent with a causal effect, although other confounding factors 
cannot be excluded (148).  Animal and epidemiological studies are concordant in their findings.  
One critical piece of information that is currently unavailable is a mechanism by which 
aflatoxin causes growth impairment in humans and animals. If such a mechanism could be 
elucidated, then the weight of evidence linking aflatoxin with growth impairment would become 
even stronger. Though this exact mechanism has yet to be identified, several have been 
proposed.  One is that immunomodulation associated with aflatoxin exposure (22, 348) can cause 
recurrent infections in children, which can lead to growth impairment (27).  Another is that 
changes in intestinal integrity (possibly in part resulting from immunomodulation) could make 
hosts more vulnerable to intestinal foreign microbes (27).  Other possible mechanisms include 
down-regulation of genes associated with energy production and fatty acid metabolism (349), 
impairment of protein synthesis and the inability to mobilize fat (241), and changes in hepatic 
metabolism of vitamins and micronutrients (350).  
Given the increasingly strong evidence that aflatoxin contributes to growth impairment in 
children, and the knowledge that it is a common contaminant of weaning foods in many parts of 
the world where childhood stunting is prevalent (e.g., sub-Saharan Africa and Asia), it is  
important to attempt to reduce aflatoxin exposure in foods consumed by children. Multiple 
aflatoxin control strategies have been developed to lessen aflatoxin exposure by reducing 
aflatoxin development in fields, during storage or reducing aflatoxin bioavailability. We 
previously reviewed the cost and efficacy of various types of aflatoxin control methods (150), 
and reported that at least two aflatoxin control interventions were cost-effective to reduce 
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aflatoxin in maize in Nigeria and groundnuts in Guinea, respectively (135). However, 
implementing aflatoxin control interventions needs extensive involvement from multiple 
stakeholders, from the levels of individuals to national and international institutions. Moreover, 
in the parts of the world where they are most needed, aflatoxin risk-reduction interventions must 
be evaluated for feasibility: safety, standardizability, characteristics of delivery, requirements on 
government capacity, and usage characteristics, among other factors (351).  
In summary, aflatoxin appears to play a contributory role in growth impairment in both 
children and animals. In children, aflatoxin exposure is especially problematic in parts of the 
world where maize and groundnuts are dietary staples. Childhood exposure to aflatoxin can 
occur in utero, in mothers’ breastmilk, and particularly in weaning foods.  Aflatoxin-associated 
growth impairment can, in turn, contribute to increased risk of mortality and morbidity in 
children worldwide.  Strategies should focus on reducing aflatoxin exposure in children and 
mothers’ diets, in ways that are cost-effective and technically feasible in parts of the world where 
aflatoxin risks are especially high. 
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6.0  AFLATOXIN AND GROWTH IMPAIRMENT IN NIGERIA 
6.1 ABSTRACT 
Aflatoxin not only induces hepatic cancer, but may also impair child growth development. A 
growing body of evidence from animal and human studies indicated the negative impacts of 
aflatoxin exposure on growth performance. Stunting, a condition defined as a child’s height-for-
age score below minus two standard deviations from the mean standard height, is highly 
prevalent in Nigeria. We performed this study to supplement our prior investigation on t he 
analysis of the costs of a particular aflatoxin control intervention to prevent one healthy life year 
lost due to liver cancer. We previously found that the HBV vaccine provided a significant lower 
cost to avert one disability life year compared with the aflatoxin control interventions. In this 
study, we included the benefits from preventing stunting to the outcome of three interventions: 
bicontrol, the postharvest intervention package, and NovaSil. Our results showed that dietary 
aflatoxin exposure would cause about 0–18% of stunting in children aged five years and below, 
depending on aflatoxin levels in food crops. At the upper bound level of aflatoxin, biocontrol and 
NovaSil clay would reduce aflatoxin exposure to levels that cannot cause stunting; the 
postharvest intervention package would prevent 5% of children from becoming stunted. Each 
single intervention is cost-effective to prevent stunting in Nigeria.     
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6.2 INTRODUCTION 
In the previous chapter, we have reviewed a number of studies showing the associations between 
aflatoxin and growth impairment. In several animal species, including chickens, pigs, rats, mice, 
and fish, aflatoxin has shown to reduce average daily feed intake (ADFI) , reduce weight gain 
and increase feed conversion ratios (FCR)−the ratios between amounts of feed intake and weight 
gain. Furthermore, reduced birth weights following in utero exposure to aflatoxin were presented 
in both animal and human studies. The epidemiological studies from several countries, such as 
Benin, Togo, Gambia, Ghana, Iran, Kenya, and UAE, focusing on t he associations between 
aflatoxin and growth faltering have been released during the past decade. These studies showed 
significant negative associations between aflatoxin exposures and growth performances in 
children.       
Though there are a number of growth performance parameters, such as weight-for-age, 
height-for-age, and weight-for-height, the parameters usually used to indicate chronic 
malnutrition is the impairment in height-for-age. Children whose height-for-age scores (HAZ) 
are below two standard deviation (SD) of the mean height-for-age standard is classified as 
stunted.   
Recently, there was a study showing that children who were stunted were more likely to 
die from various diseases. This study, following children from birth to the age of three years in 
36 countries, found that children, whose height for age scores (HAZ) were between two and 
three standard deviation (SD) below the means HAZ, were 1.6 times more likely to die from 
diarrhea, malaria, and respiratory tract infections compared with children whose HAZ were 
higher than –1SD HAZ score. The mortality rate from diarrhea, pneumonia, malaria, and measles 
in children who were severely stunted (HAZ< –3SD) were increased to four times higher than 
children whose HAZ >–1SD (229).        
To the best of our knowledge there is no study conducted in Nigeria to determine burdens 
of growth impairment related to aflatoxin. Based on the WHO database about 43% of Nigerian 
children age five years old and below were estimated to be stunted (233).  Currently, the number 
of children age 0–5 years old in Nigeria is about 23.6 millions (196), which means about 10.1 
million Nigerian children are being stunted.     
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6.2.1 Odds ratio between aflatoxin and growth impairment in humans 
A number of human studies have determined the relationships between aflatoxin and growth 
performances. But they differ in either methodologies or study populations. For example,  a  
study conducted in Kenya determined the associations between the presence of aflatoxin in 
family flour and growth performances in children aged 3-36 months; whereas, a UAE study 
exhibited the relationships between in utero aflatoxin exposure and birth weights. A number of 
studies conducted in Benin, Togo, and Gambia used AF-alb adduct as an dietary aflatoxin 
biomarker and determined the associations between AF-alb adducts levels and various growth 
performance parameters, such as height-for-age, weight-for-age, and height-for-weight. Some of 
these studies provided enough data to determine odds ratios, a measure of the strength of an 
association.           
Table 6-1 lists three studies and the odds ratios between aflatoxin exposure and growth 
performance parameters. Between October 2000 and March 2002, Okoth and Ohingo collected 
weaning flour samples from 242 households from Kisumu District, Kenya, and assessed growth 
performances of children aged between 3-36 months in these households (321). Prevalence rates 
of being stunted, underweight, and wasted in the studied populations were: 34%, 30%, and 6%, 
respectively. Compared with the normal children, a significant higher percentage (p=0.002) of 
the wasted children was fed on aflatoxin-contaminated flour (53.8% and 27.7%). About 28.9% 
of the normal children and 32.4% of the stunted children were fed aflatoxin contaminated flour 
(p=0.67). There was a non-significant difference between the percentages of normal children and 
underweight children who were fed the contaminated flour (27.3% and 41.4%, p= 0.13). Based 
on the Wellcome Classification of Severe Protein Energy Malnutrition, 66% of malnourished 
children had aflatoxin contaminated flour, while only 27.4% of nourished children were fed 
aflatoxin contaminated flour (p=0.004).   
The associations between AFM1, an aflatoxin metabolite, in newborns and their mothers 
and low birth weight were studied by Abdulrazzaq et al. 2004 (274). They collected 250 cord 
blood and maternal blood samples from 1,500 women admitted to the labor wards in two UAE 
hospitals between 1995 and 1998. A ll of the low birth weight neonates (n=43) were AFM1 
positive (> 10 mg/ml); whereas, only 68 of 123 normal weight neonates had AFM1 higher than 
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10 mg/ml in their cord blood. The correlation coefficient between AFM1 levels in cord blood and 
birthweight was –0.565 (p=0.001).   
In order to determine the odds ratio when none in the low birth weight groups was AFM1-
free, we added 0.5 to all four cells in 2x2 table to treat the problem of having a zero value in the 
table (352, 353). The odds of being low birth weight in a baby, whose cord blood contains AFM1, 
was 70 times higher than a baby, whose cord blood was free from AFM1.       
Instead of measuring aflatoxin in food, Gong et al. 2002 determined peripheral blood AF-
alb adducts levels of 480 B enin and Togo children aged between nine months to five years. 
About 99% of children contained detectable levels of AF-alb adducts with a geometric mean of 
32.8 pg/mg albumin. Among 475 children who had detectable levels of AF-alb adducts, 148 
children and 129 children were stunted and underweight, respectively (35).  
Regarding WHO definition of stunting, as long as the HAZ are more than the negative 
two standard deviation of WHO growth standard, the children are not classified to be stunted, 
even if aflatoxin deteriorates growth performance in children. In order to obtain the odds ratio 
between AF-alb adducts and growth performances from Gong et al, 2002, we classified children 
into quartiles based on their AF-alb adduct levels and compared the odds of being stunted and 
underweight between the children in the lowest quartile and the children in the upper three 
quartiles. Each quartile contained 113–114 children. Of total 479 children, 307 children, whose 
serum AF-alb adducts levels were less than 32 pg/mg albumin, were not stunted, and 148 
children, who contained higher AF-alb adducts levels, were stunted. The AF-alb adducts levels 
and HAZ of 24 children were not mentioned. We assumed that their HAZ and AF-alb adduct 
levels did not follow the dose-response relationship. We divided these 24 children equally into 
quartiles and put six and 18 i nto the lowest quartile and three upper quartiles, respectively to 
obtain the highest possibility that these 24 children did not follow the dose-response relationship.  
Therefore, the three upper quartiles consisted of 114 non-stunted and 148 s tunted children and 
the lowest quartile contained 211 non -stunted children and six stunted children. The odds of 
children whose AF-alb adduct levels were in the three upper quartiles having been stunted was 
about 13 times higher than the lowest quartile children.  
Similarly, the odds ratio of underweight children to having had high AF-alb levels is 
about 9.05. Of 480 children, 113 and 230 normal weight children had AF-alb adducts in the first 
quartile and the three upper quartiles, respectively. Only seven underweight children contained 
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low levels of AF-alb adduct (first quartile) compared with 129 underweight children, whose AF-
alb adduct levels were in the three upper quartiles. The odds ratio suggests that children, whose 
AF-alb adducts levels were in the upper three quartiles to be stunted, and underweighted, were 
13 times, and 9 times higher than children whose AF-alb adducts levels were low. 
Table 6-1. Odds ratio between aflatoxin and growth performance 
Countries Subject Aflatoxin  Growth parameter Odds ratio 
Benin and Togo 
(35) 
Children aged <5 
years old 
AF-alb adduct (the 
three upper quartiles 
versus the  lowest 
quartile) 
Stunting 13.32 
Underweight 9.05 
UAE (274) New born babies Cord blood AFM1 Low birth weight 70 
Kenya (321) Children 3−36 
months 
Aflatoxin in family 
flour 
Malnourished* 3.95 
Wasted 3.16 
Stunted growth 1.20 
Underweight 1.86 
Note: aSignificant association between the HAZ of infants and maternal AFM1 (p<0.015), Significant lower scores 
in HAZ and WAZ of infants born from AFM1 –positive mothers (p<0.05). 
Though the odds ratio can identify the strength of the association between aflatoxin and 
growth parameters, it does not provide much information on the burdens of growth impairment 
in a particular area. In this study, we employed data from Gong et al. 2002 t o develop dose 
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response functions between AF-alb adducts levels and proportions of stunting and adopted these 
functions to determine the burdens of stunting in Nigeria.   
6.3 METHODS 
6.3.1 Dose-response relationships development 
The dose-response relationships between AF-alb levels and HAZ scores, along with the numbers 
of children in each HAZ score group in Gong et al. 2000 (35), were transformed to the dose-
response functions between AF-alb and proportions of stunting. The children whose HAZ were 
below -2SD of HAZ were considered to be stunted.  Then we identified the cumulative numbers 
of stunted and non-stunted children in each adduct level for HAZ groups. Twenty-four children, 
whose HAZ were not mentioned in Gong et al. 2002, were classified to be either stunted or non-
stunted. We generated two linear regression functions based on the transformed data. The lower 
and upper bound functions were obtained when the 24 c hildren were considered to be non-
stunted and stunted, respectively.     
6.3.2 Burdens of aflatoxin-related stunting in Nigeria estimation  
We estimated AF-alb adduct levels in Nigeria based on the Nigerian aflatoxin dietary exposure 
levels calculated in the previous chapter, using the conversion factor from Shephard 2008 (37). 
Later, we determined the estimated numbers of aflatoxin-related stunting cases, and the numbers 
of stunting cases prevented if biocontrol, the postharvest intervention, and NovaSil clay were 
adopted in Nigeria using the two aforementioned dose-response functions. 
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6.3.3 Cost-effectiveness assessment 
Though in general childhood growth performances refer to the growth performances in children 
age 0-5 years old, some studies found that stunting prevalence peaked and reached the plateau 
when the children were aged about three years old. The numbers of prevented DALYs were 
discounted by 3% per year by three years to account for future benefits from current investment.  
The efficacy of the interventions consisted of two parts, efficacy in preventing liver cancer and 
efficacy in preventing aflatoxin-induced stunting. The methods to calculate the costs of aflatoxin 
control interventions and the efficacy in preventing liver cancer were already presented in 
chapter 5. The numbers of stunted cases were multiplied by stunting DALY per case, assuming 
5% of cases would die because of stunting-related conditions. The numbers of DALY per 
survival case (0.23 DALY per case), and dead case (33.2 per case) obtained from Bhutta et al. 
2008 (354).          
6.3.3.1 Cost-effectiveness ratio (CER) 
The CER– the ratio between the cost and the benefit of a particular intervention to determine the 
cost to prevent one healthy life year lost–of each intervention was compared with the Nigerian 
GDP per capita, which was about $2,360 in 2010 (211). Based on this ratio, each intervention 
was assigned to one of three following categories proposed by WHO (130): highly cost-effective 
(CER< one GDP per capita), cost-effective (one GDP<CER<three GDP), and not cost-effective 
(CER> three GDP per capita). 
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6.4 RESULTS 
6.4.1 Dose –response relationship  
Table 6-2 shows the numbers of children with the average AF-alb adduct levels of 17.0, 26.4,  
27.9 and 29.1 pg/mg albumin based on Gong et al. 2002 (35). In that study, they determined the 
adduct levels in 480 Benin and Togo children aged between nine months and five years. One 
sample was lost, and 4 s amples were free of AF-alb adducts, leaving 475 s amples in their 
analysis. But, only 455 samples were presented in dose-response relationship between AF-alb 
adduct levels and the HAZ. We included 24 children (four AF-alb free and 20 non-mentioned 
children) in either the non-stunting group (the lowest possible stunting proportion) or the 
stunting group (the highest possible stunting proportion).  
Table 6-2. Prevalence of stunting and aflatoxin albumin adducts  
Mean adduct 
levels 
Numbers of 
children 
Lowest possible stunting 
proportion 
Highest possible stunting 
proportion 
17.0 25 0% 7.25% 
26.4 282 0% 7.25% 
27.9 108 24.6% 30.07% 
29.1 40 30.9% 35.91% 
Note: (adapted from Gong et al., (2002)) 
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The linear regression functions between the levels of AF-alb adduct and proportions of 
stunting were: 
𝑌 =  0.0196𝑋 − 0.2918 
Equation 6: Levels of AF-alb and proportions of stunting (lower bound) 
and       
𝑌 =  0.0212𝑋 − 0.3928 
Equation 7: Levels of AF-alb and proportions of stunting (upper bound) 
Where X= AF-alb adduct levels, and Y = proportions of stunting 
To the best of our knowledge, aside from Gong et al. 2002,   t here was only one study 
providing data of AF-alb adduct levels and proportions of stunting, Turner et al. (2003). Turner 
et al. (2003) determined the geometric means of AF-alb adduct levels of 472 Gambian children 
aged six years to nine years old to be 22.3 pg/mg albumin. The calculated stunting prevalence 
rates in Gambia based on our dose-response functions were 8.0% and 14.5%. The average from 
the upper and lower calculated stunting prevalence was 11.3%. (actual prevalence = 11.5%) 
6.4.2 Potential aflatoxin-related stunting in Nigeria  
In general, children consume three to four times much more food per kilogram body weight than 
adults (355). Moreover, several food taboos arose in Africa can hinder children from having 
varieties of food. Therefore, children are more likely to be exposed to aflatoxin compared with 
adults. To convert adult dietary aflatoxin exposure to aflatoxin exposure in children, we 
multiplied maize and groundnuts consumption rates adopted from FAOSTAT by five.  Table 6-3 
shows the estimated stunting prevalence as the results of maize, groundnut, and both maize and 
groundnut consumptions.   
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The results presented in table 6-3 accentuate the need of employing total aflatoxin 
exposure levels in the analysis of aflatoxin-induced stunting. Aflatoxin levels in groundnuts, 
without any aflatoxins from other sources, cannot produce stunting. However, when combined 
with aflatoxin exposure in maize, aflatoxin in groundnuts adds 7.4% more stunting proportions 
than that produced by aflatoxin in maize alone. Consuming groundnuts increases levels of total 
aflatoxin exposure children receiving per day. Our results are in good agreement with the data 
from Gong and colleagues in 2003 that groundnuts consumptions do not correlate with AF-alb 
adduct levels in Benin and Togo children aged less than five years; however, they expressed their 
awareness of an importance of aflatoxin in groundnuts on the levels of total aflatoxin exposure 
(272).  
 
Table 6-3. Potential stunting burden in Nigeria from consuming maize and groundnuts contaminated with 
aflatoxins 
Items Staple crops 
Staple crops Maize Groundnuts Total 
Average aflatoxin levels (ng/g) 13.4−36.2 64.8−67.5 − 
Children consumption rate (g/kgBW-day) 6.14 0.54 − 
Aflatoxin exposure  
(ng/kgBW-day) 
82.0−222.15 35.0−36.46 117.0−258.61 
Estimated AF-alb adducts from chronic 
ingestion (pg/mg albumin)a 
8.2−22.22 3.5−3.65 11.7−25.87 
Percent of stunted childrenb 0−11.1 0 0−18.5 
Expected no. of stunted children 0 to  2,619,600  0 0 to  4,377,800  
Note:aa 100 pg AF-alb adduct/mg albumin is expected to be a result of chronic ingestion of 1000 ng/kgBW-day(37), 
baverages of two dose-response relationship between aflatoxin-albumin adduct and portions of stunting,  number of 
children aged under 5 y.o. in 2010 is 23,600,000 (196)  
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6.4.2.1 Impacts of aflatoxin control interventions on stunted growth prevalence 
Table 6-4. Potential impacts of aflatoxin control interventions on aflatoxin-related stunting burden in Nigeria 
(Upper bound level of aflatoxin) 
 Biocontrol 
The postharvest 
intervention package 
NovaSil clay 
 Maize 
Groun
dnuts 
Total Maize 
Groun
dnuts 
Total Maize 
Groun
dnuts 
Total 
AF exposure per 
kgBW-day (ng) 
225.1 36.5 258.6 225.1 36.5 258.6 225.1 36.5 258.6 
% aflatoxin-related 
stunting a 
15.6%-21.6% 15.6%-21.6% 15.6%-21.6% 
Efficacy of 
intervention 
80% NA NA NA 69% NA 40% 40% 40% 
Total exposure/ kg-d 
in ng (treated ) 
45.0 36.5 80.5 225.1 11.3 236.4 135.1 21.9 157.0 
Predicted %  
stunting  (int+) 
 
0% 
 
10.2%-16.6% 
 
0%-1.2% 
No. of cases 
preventedb 
 736,320 to  1,014,800   231,280 to  254,880   
 
 736,320 to  958,160   
 
DALYs averted  1,269,172  to  1,749,180   398,650  to  439,329         
 
 1,269,172 to  1,651,551    
 
Note: abased on two dose response relationships between AF-alb adduct and proportions of stunting. bthe number of 
population age five years and under was divided by five to account for an annual cost.  One stunting survivor = 0.23 
DALYs, one dead case = 33.2 DALYs (354).  
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Table 6-4 presents the impacts of our selected aflatoxin control interventions on stunting 
burdens in Nigeria. If the stunting burdens prevented were included in the analysis, all 
interventions would become very cost-effective. This result suggests that aflatoxin would be 
responsible for a substantial number of public health burdens related to stunting in Nigeria.   
At the upper bound level of aflatoxin, when the benefits of preventing stunting burdens 
were included, all interventions were very cost-effective (CERs <1 GDP). The costs to prevent 
one healthy life year lost were dramatically decreased when the benefits of preventing stunting 
were included compared with the CERs of these three interventions, when liver cancer 
prevention was the only outcome of interest.  However, at the lower bound level of aflatoxin, 
there was no di fference in the CERs of these three interventions, because at this low level, 
aflatoxin did not induce stunting. Hence, the burdens of aflatoxin do not increase linearly with 
exposure levels. At high doses, aflatoxin may induce other serious adverse effects, especially in 
sensitive populations. Though it can be impossible to completely get rid of aflatoxin, it is crucial 
to control aflatoxin exposure to the yet to be identified safe level.               
Table 6-5. Cost-effectiveness ratio of aflatoxin control interventions by outcomes of interest 
Outcome of 
interest 
Cost to prevent one healthy life year lost ($) 
Lower bound aflatoxin exposure Upper bound aflatoxin exposure 
BC PH NS BC PH NS 
Liver cancer  7,319 69,110 24,755 2,702 66,142 11,177 
Liver cancer 
+ Stunting 
7,319 69,110 24,755 49 614 130 
Note: BC= biocontrol, PH = the postharvest intervention package, NS = NovaSil clay    
The question is, if more than one highly cost-effective intervention is implemented, 
whether the combinations are worth doing. To determine the cost to prevent one extra DALY of 
aflatoxin control intervention combinations, we performed an incremental cost-effectiveness 
analysis. This type of analysis is a tool to determine cost per one unit outcome gained compared 
to the next best available method.   
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6.4.3 Incremental Cost-Effectiveness 
In our prior analysis, we determined the cost-effectiveness of three aflatoxin control strategies 
and treated them as independent of each other. This kind of analysis works in the situation for 
which only one intervention is adopted. But if there are no budget constraints, more than one 
intervention can be implemented to maximize benefits, as long as the combinations are worth the 
cost. The problem is that whether adding one more intervention makes the combination to be 
worthy to be implemented.  We performed an incremental cost-effectiveness analysis to answer 
this question. The incremental cost-effective ration (ICER) in incremental cost-effectiveness 
analysis provides information on how much the cost is to provide one additional unit of outcome 
to switch from current intervention or from doing nothing to alternative practices. The 
incremental cost-effective ratio can be presented as follows: 
 
))()(())()(( BEfficacyAEfficacyBCostACostICER −÷−≡  
Equation 8: Incremental cost effectiveness ratio 
We compared ICER of biocontrol, the most cost-effective intervention, and the 
combinations of biocontrol and the other two interventions as double intervention and triple 
intervention as follows:   
1) Biocontrol  
2) Biocontrol+ the postharvest intervention package  
3) Biocontrol+ NovaSil clay 
4) Biocontrol+ the postharvest intervention package+ NovaSil clay  
6.4.3.1 Baseline aflatoxin exposure  
Based on the Nigerian maize and groundnuts consumption rates (73.6 and 6.4 grams per person 
per day), the estimated daily aflatoxin exposures for a Nigerian from consuming aflatoxin 
contaminated maize and groundnuts are 44.34 and 7.22 ng/kgBW-day, respectively. In children, 
aflatoxin exposures from consuming aflatoxin-contaminated maize and groundnuts  range from 
82.0 to 222.15 ng/kgBW-day and from  35.0 to 36.46 ng/kgBW-day, respectively. Without any 
intervention, aflatoxin in maize and groundnuts combined would cause about 18.6% –an average 
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of upper and lower bound predicted values: 15.6% to 21.5% –stunting in Nigerian children age 
five years old and under (see table 6-3).      
6.4.3.2 Impacts of combinations of aflatoxin control interventions on preventing stunting 
(Children age 0-5 years old) 
With the application of biocontrol in maize fields, aflatoxin levels will be reduced to levels that 
cannot induce stunting in children, either in the presence or absence of other interventions. 
Numbers of stunting cases prevented and DALYs saved from the combinations of biocontrol and 
the other interventions (the postharvest intervention package and NovaSil clay) are similar to 
those of biocontrol alone,  875,560   fewer cases and  1,509,176  DALYs averted, respectively.  
6.4.3.3 Impacts of combinations of aflatoxin control interventions on preventing liver 
cancer 
Biocontrol (Scenario I): Please see table 6-5 
Biocontrol +   the postharvest intervention package (Scenario II):   Biocontrol reduces 
aflatoxin in maize by 80%; whereas, the postharvest intervention package reduces aflatoxin in 
groundnuts by 69%, leaving 20% aflatoxin in treated maize and 31% aflatoxin in treated 
groundnuts. Overall, the combination of biocontrol and the postharvest intervention package 
would reduce aflatoxin exposure by 40.5 ng/kgBW-day. As a result, 3,290 a flatoxin-induced 
liver cancer cases, and 31,822 DALYs can be prevented.   
Biocontrol + NovaSil clay (Scenario III): NovaSil will reduce aflatoxin bioavailability by 
40% of aflatoxin contamination in foods. Some of them include biocontrol-treated maize and 
untreated groundnuts. Therefore, the combination of biocontrol and NovaSil clay can reduce 
total aflatoxin bioavailability in maize by 88% and bioavailability of aflatoxin in groundnuts by 
40%.  On the whole, biocontrol, along with NovaSil clay, would reduce aflatoxin exposure by 
41.9 ng a flatoxin per kgBW per day.  Thus,  3,408  aflatoxin-induced liver cancer cases and  
32,965 DALYs will be averted. 
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Biocontrol + the postharvest intervention package + NovaSil clay (Scenario IV): 
Aflatoxin in contaminated maize would be reduced mainly through biocontrol and NovaSil clay. 
The overall aflatoxin reduction was 88% (80% from biocontrol and 40% of the remaining from 
NovaSil clay). Similarly, aflatoxin in groundnuts would be reduced by 81% (69% from the 
postharvest intervention and 40% of the remaining from NovaSil clay). The total aflatoxin 
prevented from consuming maize and groundnuts contaminated with aflatoxin would be 44.8 ng 
per kgBW-day. With this level of aflatoxin reduction, 3,649 liver cancer cases and  35,294 
disability life years lost will be prevented.  
Table 6-6. Marginal cost-effectiveness of some selected single or combinations of aflatoxin control strategies 
Strategy Cost (million $) DALYs saved 
Marginal cost 
(million $) 
Marginal 
effectiveness 
Ratio 
$/DALYs 
saved 
BC 75.4 1,537,079 75.4 1,537,079 49 
BC+PH 179.1 to 334.6 1,540,998 103.7 to 259.2 3,919 
26,457 to 
66,142 
BC+NSa 263.3 1,542,141 187.9 5,062 37,109 
BC+PH+NS 366.9 to 552.5 1,544,470 187.9 3,472 54,107 
Note:  BC: biocontrol, NS: NovaSil clay, PH: the postharvest intervention package, aThe combination of BC and 
NS was compared with BC, not BC+PH, numbers of prevented stunting cases were divided by five to obtain the 
annual effect of intervention. One stunting survivor = 0.23 DALYs, one dead case = 33.2 DALYs  (354)  
 
As a stand-alone intervention, each intervention could be a worthy intervention, but if we 
want to get higher benefits by implementing more than one intervention, the combinations would 
not be worth  since the new CERs are more than 3 Nigerian GDP. 
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To summarize, biocontrol, the postharvest intervention package, and NovaSil clay, as 
stand-alone interventions, are cost-effective; but our analyses indicate that if these interventions 
were combined, none of the combinations would be cost-effective.  In other words, any extra 
health benefits associated with an additional intervention would be significantly smaller than the 
corresponding costs, in WHO cost-effectiveness terms.  Combinations of biocontrol with either 
the postharvest intervention package or NovaSil clay provide extra benefits than biocontrol 
alone. However, the benefits gained are much fewer than the sum of the benefits from biocontrol 
and the other intervention. The reasons for the  i ncreased cost per DALYs prevented of the 
combinations are two-fold as follows: 
1) Interventions act directly or indirectly to the same food commodities. 
(Biocontrol/NovaSil clay and the postharvest intervention package/ NovaSil clay) 
2) Interventions act on food commodities taken in small amounts. For example, the 
postharvest intervention package, if applied to groundnuts only, would not be cost-
effective, because Nigerian consume a much smaller amount of groundnuts compared 
with maize. 
In the case of the combination of biocontrol and the postharvest intervention package, 
even if these two interventions were applied to different food commodities, biocontrol alone can 
reduce aflatoxin in maize to the levels that cannot produce stunting; therefore, implementing the 
postharvest intervention package to biocontrol-adopted areas does not produce extra benefits as 
far as reducing stunting risk. As a result, the extra benefits of this combination are due solely to 
the additional reduction of aflatoxin-induced liver cancer burdens from the reductions of 
aflatoxin in groundnuts. Similarly, no extra stunting prevention benefits from adopting NovaSil 
clay would be expected in a region, in which biocontrol is already 100% adopted. Furthermore, 
the efficacy of NovaSil clay is affected by the presence of biocontrol, as previously mentioned. 
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6.4.4 Sensitivity analysis 
We determined sensitivity of the cost-effectiveness ratio by varying either costs or 
efficacy of the interventions. For each intervention, we varied its efficacy from 0.4 to 1.6 times 
the original efficacy or until maximum efficacy (100%) was achieved. We varied the costs of 
intervention upward to determine the maximum cost in the terms of times the original costs that 
brings the CER beyond three times GDP per capita, the threshold for cost-effectiveness analysis.  
Table 6-7. Cost effectiveness ratios of biocontrol 
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Table 6-8. Cost effectiveness ratios of the postharvest intervention package 
 
 
Table 6-9. Cost-effectiveness ratios of NovaSil clay 
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6.5 DISCUSSION 
A threshold level of aflatoxin on growth development is one of the most important features of the 
dose-response relationship between aflatoxin exposure or its biomarkers and growth 
performance. Aflatoxin exposure must be high enough to deteriorate growth to the extent that a 
particular growth impairment defined (HAZ, WAZ, or WHZ <-2SD). The threshold of AF-alb 
derived from the Benin and Togo study is about 16.7 pg/mg albumin.  Based on the same study, 
once the threshold level of aflatoxin exposure  to  induce stunting was reached, the prevalence of 
stunting will increase by 1.96 to 2.12 per 100 per picogram of the adduct/mg albumin. 
The stunting burdens caused by aflatoxin contamination would be much higher than 
burdens from aflatoxin-related liver cancer. Whereas, the prevalence of liver cancer is per 
100,000 basis, the prevalence rate of stunting is based on 100 c hildren age between 0-5 years 
old. For a country in which birth rate is usually high and the number of elder population is 
relative low, compared with those of adolescents and adults, such as Nigeria, public health 
burdens from stunting can be several times higher than that of liver cancer. Burdens of aflatoxin-
related stunting in Nigeria can be significant high more than previously expected that if 
preventing stunting was included in the analysis, it turned the postharvest intervention package 
from not cost-effective to be very cost-effective.  
When benefits from preventing stunting are included, all of these four interventions as a 
single intervention are very cost-effective. Choosing a particular intervention over the others 
depends on several factors. Biocontrol, in our analysis, is the most cost-effective intervention in 
reducing aflatoxin toxicities. But in some circumstances that biocontrol cannot be performed– 
for example, atoxigenic fungi have not been identified in that particular area–NovaSil clay or the 
postharvest intervention package could be an alternative intervention. These three aflatoxin 
specific control interventions and hepatitis B vaccine reduce different risk factors of liver cancer; 
therefore, they can be considered as add-on interventions of each other. 
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7.0  EVALUATING THE TECHNICAL FEASIBILITY OF AFLATOXIN RISK 
REDUCTION STRATEGIES IN AFRICA 
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7.1 ABSTRACT 
Public health interventions must be readily accepted by their target populations to have any 
meaningful impact, and must have financial and infrastructural support to be feasible in the parts 
of the world where they are most needed.  At the same time, these interventions must be assessed 
for potential unintended consequences, either to the environment or to human health.  I n this 
study, we evaluate the technical feasibility of interventions to control aflatoxin risk, to be 
potentially deployed in parts of Africa where aflatoxin exposure poses a significant public health 
concern.  We apply a conceptual framework for feasibility to four interventions, one associated 
with each of four different stages of aflatoxin risk: biocontrol (preharvest), a postharvest 
intervention package (postharvest), NovaSil clay (dietary), and hepatitis B vaccination (clinical).  
For each intervention, we assess the following four components of technical feasibility: 1) 
characteristics of the basic intervention, 2) characteristics of delivery, 3) requirements on 
government capacity, and 4) usage characteristics.  We describe ways in which feasibility of 
each intervention is currently high or low from the perspective of adoption in Africa, how public 
education is crucial for each of these interventions to succeed, and how to align economic 
incentives to make the interventions more suitable for less developed countries. 
7.2 INTRODUCTION 
Aflatoxin, produced by the fungi Aspergillus flavus and A. parasiticus on crops such as maize, 
peanuts, and tree nuts, is recognized to be an important food safety risk worldwide.  Aside from 
causing acute poisoning at high doses (acute aflatoxicosis), aflatoxin can also cause liver cancer 
(hepatocellular carcinoma, or HCC), immunomodulation (10, 23, 348, 356) , and stunted growth 
in children at chronic lower-level doses (22, 27, 35).  More recent evidence shows that aflatoxin 
may also play a role in global cirrhosis morbidity (357).  Most of these health problems 
associated with aflatoxin exposure occur in less developed countries (LDCs) in tropical and 
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subtropical areas of the world, where the Aspergilli thrive and where food safety measures are 
less stringent. 
An interesting aspect of the aflatoxin public health issue is that the risk can be mitigated 
at so many different levels, in multiple different ways.  This stands in contrast to other foodborne 
risks such as harmful bacteria (e.g., Escherichia coli): no enterosorbents could reduce their levels 
in the gastrointestinal system, and no vaccines could mitigate their impacts.   Aflatoxin 
accumulation could be reduced in crop fields, in food storage, or in food processing.  
Additionally, even if aflatoxin is present in consumers’ food, certain dietary additives or clinical 
practices can mitigate adverse effects of the toxin in the body.   Hence, many different 
interventions have been developed either to reduce aflatoxin directly in the field and in food 
(preharvest and postharvest interventions), or to reduce aflatoxin’s harmful effects in the body 
once it is  ingested (dietary and clinical interventions).  These categories of interventions are 
described in greater detail in Khlangwiset and Wu (2009) and Wu and Khlangwiset (2009).   
Regulations on m aximum allowable levels of aflatoxin in food could also reduce 
aflatoxin exposure. These regulations are generally effective in controlling aflatoxin in industrial 
nations; commodities that contain aflatoxin levels exceeding regulatory guidelines for human 
food or animal feed are discarded, or sold at a lower price for a different use (38, 39).  However, 
aflatoxin regulations in many LDCs do little to protect public health, as there is limited 
enforcement of food safety regulations, especially among rural communities where food quality 
is rarely formally inspected (37).  Subsistence farmers and local traders sometimes have the 
luxury of discarding obviously moldy maize and groundnuts.  But in drought seasons, people 
often have no choice but to eat moldy food or starve.  Thus, regulations do little to help reduce 
aflatoxin and its related health effects in LDCs (37, 358).  Rather, the focus should be on 
promoting adoption of strategies that can control aflatoxin and its associated risks, in the field, in 
postharvest conditions or in the diet (135).   
This dichotomy between the feasibility of aflatoxin regulations against the feasibility of 
other kinds of public health interventions highlights the need for mycotoxin researchers to 
consider whether the control strategies they develop could actually be implemented widely to 
improve public health.  It is crucial that an intervention be technically feasible in the places 
where it is most needed.  The purpose of this paper is to highlight key components of technical 
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feasibility, which are then applied to analyzing four specific interventions that control aflatoxin 
risk.   
7.3 FRAMEWORK TO CONSIDER FEASIBILITY OF AFLATOXIN CONTROL 
STRATEGIES 
The cost-effectiveness of selected public health interventions to control aflatoxin-induced liver 
cancer has been assessed (135).  Yet cost-effectiveness of a strategy is not enough to ensure its 
successful adoption.  More questions must be posited, such as: Are there countervailing health or 
ecological risks to the strategy?  What would the delivery mechanism be, and would locally-
available infrastructures support the mechanism?  Do governmental regulations inhibit or 
promote the intervention?  Is the intervention culturally appropriate and easy to adopt by the 
target population (135).  If an intervention to reduce aflatoxin fails in any or all of these points, 
then it is not likely to be adopted on a global scale, no matter how cost-effective it may be. 
A conceptual framework to evaluate the technical complexity – and hence the feasibility 
– of public health interventions for less developed countries has been developed (359).   There 
are four relevant dimensions (see figure 7-1):  
1. Characteristics of the basic intervention 
2. Characteristics of delivery 
3. Requirements on government capacity 
4. Usage characteristics 
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Figure 7-1 Framework to assess technical feasibility of public health interventions. 
7.3.1 Aflatoxin control strategies 
Multiple public health interventions exist by which to control aflatoxin or its burden in the body, 
to prevent HCC.  Several of these are listed in Table 1, adapted from Wu and Khlangwiset 
(2010).  We are beginning to understand more about the cost-effectiveness of these interventions; 
what remains to be found is how technically feasible they would be in many parts of the world.   
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Table 7-1. Sampling of interventions to reduce aflatoxin risk in field, dietary, and clinical settings 
Setting Intervention 
Agricultural Preharvest  Suitable hybrid choice 
 Transgenic or conventional breeding for plant host 
resistance 
 Biocontrol 
 Chemical control (insecticides, fungicides) 
 Good agricultural practices 
 Antioxidants (e.g., caffeic acid, gallic acid) 
Postharvest  Cleaning 
 Mechanical sorting and segregation 
 Improved storage / drying / transportation conditions 
 Ammoniation 
 Ozonation 
 Chemical control (insecticides, fungicides) 
Dietary  Enterosorbents (e.g., calcium aluminosilicates, 
glucomannan, chlorophyllin) 
 Chemopreventive agents (e.g., Oltipraz, isothiocyanates, 
triterpenoids) 
 COX-2 inhibitors 
 Green tea polyphenols 
Clinical  HBV vaccination 
Interventions to reduce aflatoxin risk can be roughly grouped into three categories: 1) 
agricultural (preharvest and postharvest), 2) dietary, and 3) clinical. Agricultural interventions 
are methods or technologies applied either in the field (preharvest) or in drying, storage and 
transportation (postharvest) to reduce aflatoxin levels in food.  Agricultural interventions can 
thus be considered “primary” interventions, because they can reduce actual aflatoxin levels in 
food.  Dietary and clinical interventions can be considered “secondary” interventions. They 
cannot reduce aflatoxin levels in food, but can ameliorate aflatoxin-related illness; by reducing 
bioavailability either of aflatoxin (e.g., through enterosorption) or of its reactive oxygen species 
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that binds to DNA to initiate cancer (e.g., through induction of Phase 2 enzymes that detoxify the 
aflatoxin-8,9-epoxide).   
We assess the technical feasibility of one intervention from each of these categories, 
specifically for human use: 
1. Biocontrol (preharvest) 
2. A postharvest intervention package (postharvest) 
3. Calcium aluminosilicate clay (NovaSil) as an enterosorbent (dietary) 
Hepatitis B vaccine is included in our analyses, even though it is not literally considered 
as an aflatoxin control intervention. The vaccine itself has no impact on actual aflatoxin levels in 
diets, but it prevents the synergistic impact of HBV and aflatoxin in inducing liver cancer. 
For each of these, we evaluate characteristics of each intervention according to the 
aforementioned dimensions of the intervention’s basic characteristics, delivery characteristics, 
government capacity requirements, and usage characteristics.  In addition, we describe economic 
issues associated with wide-scale adoption of each intervention.  We describe the areas in which 
the characteristics of each intervention lend themselves to being more or less feasible in LDCs, 
with a focus on sub-Saharan Africa, where these interventions have shown success in field and 
clinical trials. 
7.4 APPLICATION OF TECHNICAL FEASIBILITY FRAMEWORK TO 
AFLATOXIN RISK-REDUCTION INTERVENTIONS 
7.4.1 Biocontrol: Technical feasibility 
Agricultural biocontrol involves the use of biological agents to control pests or toxin production.  
Specifically, biocontrol of aflatoxin refers to using organisms to reduce the incidence of 
toxigenic Aspergilli in susceptible crops, and thereby to reduce aflatoxin contamination.  The 
most widely used biocontrol method for aflatoxin employs nontoxigenic strains of Aspergilli that 
can competitively exclude toxigenic strains from colonizing crops. Grain seeds (of wheat, barley, 
sorghum, or other small grains) are either briefly colonized by or coated with conidia of a 
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nontoxigenic strain, and these seeds are applied to agricultural fields during a period favorable 
for competitive exclusion of toxigenic strains.   
These biocontrol methods have been used in maize, groundnuts, and cottonseed in several 
regions of the world (57-62).Importantly, nontoxigenic A. flavus strains have been found in sub-
Saharan Africa, which show promise for controlling aflatoxin in African maize (59, 62).  
Biocontrol methods, though applied in the field, can result in reduced aflatoxin in crops for 
months postharvest (360).   
Table 7-2 summarizes the characteristics of biocontrol as an aflatoxin reduction 
intervention in African countries that determine its overall feasibility. 
Table 7-2. Technical feasibility characteristics of biocontrol for aflatoxin control in Africa 
Category Criteria Intervention 
Intervention Characteristics 
Basic product 
design 
Stability Shelf life ~ 6 m onths; dependent on t emperature and 
moisture control 
Standardization Needed to ensure that each application unit of biocontrol 
contains sufficient amounts of living nontoxigenic fungi 
to competitively exclude toxigenic fungi  
Safety profile Low risk of inhalation aspergillosis and skin and eye 
irritation; minimal risk of toxicity and infectivity 
Ease of storage and 
transportation 
Must be stored and transported at low relative humidity 
and avoiding either temperature extreme 
Supplies Need for regular 
supplies 
Nontoxigenic spores must be maintained in cultures, and 
grains must be provided regularly as a substrate  
Equipment High-technology 
equipment and 
infrastructure needed  
Equipment to manufacture and maintain fungal spores, 
sterilize substrate, and mix spores and substrate with a 
binder 
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Table 7-2 (continued) 
Category Criteria Intervention 
Delivery characteristics 
Facilities Retail sector Needed if biocontrol application is done by farmers 
Outreach services Monitoring proportion of nontoxigenic spores in the field 
to ensure continued effectiveness 
Educating growers on why aflatoxin is an important 
problem, and how to optimally apply biocontrol 
Laboratories See “Equipment” above 
Human resources Trained scientific 
professionals 
Professional staff to produce and maintain nontoxigenic 
spores, operate equipment to produce all parts of 
biocontrol, and to apply it (in situations where farmers 
cannot themselves) 
 Outreach staff Community volunteers, agricultural and health care 
providers to highlight the importance to control aflatoxin 
in food and feed stuffs. 
Laboratory workers to routinely monitor aflatoxin levels 
in agricultural goods. 
Agricultural extension service to provide advice, 
suggestion or recommendation on biocontrol. 
Communication 
and transport 
Dependence of delivery 
on communication and 
transport infrastructure 
Crucial for biocontrol to reach diverse parts of African 
countries where maize and other aflatoxin-vulnerable 
crops are planted 
Government capacity requirements 
Regulation/ 
legislation 
Need for regulation Need for biopesticide registration in African countries 
Need for monitoring 
and enforcement 
Need for aflatoxin monitoring in agricultural goods 
Need for monitoring potential health effects produced by 
biocontrol agents (e.g., skin irritation, aspergillosis) 
Need for monitoring potential changes in toxigenicity of 
nontoxigenic fungi 
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Table 7-2 (continued) 
Category Criteria Intervention 
Collaborative 
action 
Collaborative efforts 
within government 
sectors and between 
government and other 
groups 
Collaborations among ministries of agriculture and health 
could provide a stronger basis for biocontrol as a means 
of improving public health through farming technologies.   
International organizations (e.g., IITA, WHO, 
Foundations) have made, and should continue to make, 
important contributions toward aflatoxin reduction in 
Africa (funding, staff, etc.). 
Usage characteristics 
Ease of usage Need for information, 
education, supervision 
If biocontrol application in hands of farmers: instructions 
can be printed on packages, agricultural outreach staff 
can assist and supervise in some areas.  More broadly, 
education is needed to inform farmers why aflatoxin is an 
important problem and how biocontrol can reduce risk. 
Pre-existing 
demand 
Need for promotion Little if any pre-existing demand for biocontrol in most 
African nations; promotion essential among farmers 
Black-market risk Need to prevent 
counterfeiting 
Counterfeiting is possible but unlikely: toxigenic fungi 
could be packaged and sold as biocontrol to farmers   
7.4.1.1 Biocontrol: Basic characteristics.   
Three main elements are important to consider here: the basic product design (stability, 
standardization, safety profile, and ease of storage and transport), supply requirements, and 
equipment needed.  Biocontrol agents have a shelf life in the United States of up to six months 
(361), which may be lower in the tropics depending on quality of storage conditions, including 
susceptibility to insect damage.  Standardizing biocontrol is highly important, to ensure that each 
application unit contains sufficient amounts of nontoxigenic fungi to competitively exclude 
toxigenic strains in the field. 
Safety is an important consideration regarding biocontrol use in Africa.  Because of the 
potential risk of invasive aspergillosis from A. flavus exposure among immunocompromised 
individuals (as highlighted in Krishnan et al. 2009 and Hedayati et al. 2007), it is  important to 
ensure that the biocontrol material is manufactured and applied in such a way as to minimize 
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direct inhalation of spores.  T he biocontrol methods used commercially and in field trials in 
various parts of the world, in which the nontoxigenic Aspergilli are applied in an oil or molasses 
mixture to seeds (60, 61) that are then applied to fields, minimize potential inhalation risks.  At 
the present time, no aspergillosis cases have been reported as a result of biocontrol 
manufacturing or application.  In the United States, it is  recommended that applicators wear 
protective gear – a long-sleeved shirt, long pants, shoes, sock and gloves−when working with 
biocontrol (362), because of concerns regarding potential moderate eye or skin irritation, though 
no cases have thus far been reported (363).  These precautions should be followed in other parts 
of the world where biocontrol is used. 
Several conditions are necessary for optimal storage and transport.  Grains colonized by 
nontoxigenic Aspergilli, once dried, should be kept in moisture-protected, insect-proof bags, 
which should not be exposed to high relative humidity or extreme temperatures, such as over 
80% RH, over 50° C , or below freezing (363). In most parts of Africa, these temperature 
constraints would pose no problem; however, relative humidity could be higher than optimal for 
storage of biocontrol agents.    
High-technology equipment, basic supplies, and trained professional staff are necessary 
to produce and maintain biocontrol agents: to maintain the cultures used, to manufacture the 
large numbers of nontoxigenic fungal spores needed for application to the substrate (the grains 
used to convey the spores in the field), to sterilize the substrate on a large scale, and to mix the 
spores and substrate with a binder (such as oil or molasses) to allow the spores to adhere (60, 
135).  The ability of African countries to meet these high-technology requirements varies from 
nation to nation.  Nigeria would benefit from the support of the Ibadan-based International 
Institute of Tropical Agriculture (IITA), with an active research and outreach group for 
biocontrol adoption.  Biotechnology has also flourished in certain African countries such as 
Kenya, Zimbabwe, Egypt and South Africa (364). These countries may thus be more capable of 
producing biocontrol agents than others, although training needs for biocontrol specifically may 
be minimal  
There are potential supply constraints as well.  The substrate itself, such as wheat, rice, or 
sorghum grains (365), must be available; this may be problematic to obtain in situations of food 
insecurity, when the grains would be better used as a food source rather than as a substrate to 
convey biocontrol agents.  Maize cobs have been proposed as a potential substrate on which 
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nontoxigenic fungi can be applied and then dispersed in fields (59), which would alleviate grain 
supply concerns.    
7.4.1.2 Biocontrol: Delivery characteristics.   
Specifics of biocontrol delivery in Africa may vary by nation.   There may be centralized 
laboratories and facilities to provide the biocontrol materials; or the facilities may be more 
widely distributed within the target population, particularly if individual farmers will apply the 
biocontrol to their fields.  If farmers are already using agricultural chemicals such as pesticides 
and fertilizers, the biocontrol agents could be obtained through the same venues.   
There are benefits and costs associated with both centralization and dispersion of 
facilities to produce and maintain biocontrol, and individuals who apply biocontrol to fields.  For 
example, transportation costs to get biocontrol materials to the places they are needed are lower 
if the facilities are more dispersed within a community; but having a greater number of facilities 
necessitates having trained professionals at each location, which may cause a s train on human 
resources.  Likewise, hiring trained professionals to apply biocontrol to crop fields would ensure 
better quality control of application.  However, it leads to questions of who would pay for and 
train these professionals, and whether there would be a sufficient number of them to ensure that 
the biocontrol was applied at exactly the right time to allow competitive exclusion of aflatoxin-
producing fungi in the field.  Ultimately, it should be the individual farmers who apply 
biocontrol, with guidance either from a local agricultural extension worker or from the biocontrol 
packaging materials. 
7.4.1.3 Biocontrol: Government capacity requirements.   
Two items should be considered: governmental regulations on use and commercialization of the 
intervention, and regulatory support and enforcement to ensure optimal benefits and minimal 
risk.  Biocontrol for aflatoxin reduction was first registered in the United States, by the 
Environmental Protection Agency (366).  A lengthy review ensured no evidence or likelihood of 
risks to human health or to the environment.  The review included tests with laboratory mammals 
to assess oral or lung infectivity, toxicity, and allergenicity; soil and air monitoring studies for 
environmental quality; survival tests of the fungi after crop processing, and ecological risk 
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assessments of endangered species encountering the fungi.  In all cases, risks were shown to be 
minimal or nonexistent (61). 
With this precedent to guide further health and environmental risk assessments in 
different parts of the world, governmental regulatory barriers may be minimal.  The International 
Institute of Tropical Agriculture (IITA) has held workshops aiming to create harmonized 
biopesticide regulation for African countries. The biopesticide regulation system within the 
member countries of the Permanent Interstates Committee for Drought Control in the Sahel 
(CILSS) has been proposed as a protocol of harmonized regulation for biopesticide registration.  
Pesticides registered by CILSS can be used in any CILSS member nations (367). If this approach 
is developed and accepted by African countries, biocontrol application in Africa could be 
implemented on a  wide scale.  M oreover, stakeholder involvement in select nations has been 
mobilized.  Recently, a stakeholder consultative meeting on biological control was held in April 
2009 at Ibadan-based IITA, Nigeria; to discuss biocontrol application in maize to lower aflatoxin 
levels, as well as its potential usefulness in other staple crops (368).     
Monitoring should also be conducted regularly, to ensure that the nontoxigenic strains do 
indeed continue to produce no aflatoxin in field conditions.  Recently, an inexpensive aflatoxin 
test kit was developed by IITA and ICRISAT: a mere $1−$2 per analytical sample. This kit is 
purported to be effective even for analyses in the most remote rural areas of Africa (369). 
7.4.1.4 Biocontrol: Usage characteristics.   
The three aforementioned considerations regarding the end user - the ease of usage, pre-existing 
demand, and black-market risks – are legitimate concerns regarding widespread biocontrol 
adoption.  Eventually, individual farmers must be the ones to apply biocontrol in African crop 
fields to control aflatoxin.  The education and outreach process could be complicated – both in 
convincing the farmers of the need for this product, and in providing guidance on how much and 
when to optimally apply the biocontrol (61).  There is little if any pre-existing demand for this 
product specifically, as it is a new technology; although there is pre-existing demand more 
generally for aflatoxin control.  Finally, it is possible that black markets may arise that provide 
materials that are not truly nontoxigenic.  This is why monitoring processes and quality control 
for marketed products are extremely important. 
137 
7.4.1.5 Biocontrol: Economic issues.   
The low cost of biocontrol ($10-$20 per hectare) and its effectiveness at aflatoxin reduction (50-
90%) make biocontrol a very cost-effective intervention in reducing aflatoxin-induced disease 
(135).  However, individual farmers may not have incentive to pay even this relatively small 
amount if they do not  understand the risks of aflatoxin, and moreover, have very little 
discretionary monies. 
Therefore, initially, governments (in partnership with internal and external funding 
agencies) would most likely need to provide the resources for widespread biocontrol 
application.   Alternatively, governments and/or commodity industries could establish a 
marketing system that provides a premium to growers for low aflatoxin levels (or penalizes high 
aflatoxin levels, which may be less successful).  This system would provide economic incentives 
for the growers to pay for biocontrol, and is, most likely, the rational long-term approach. 
Meanwhile, public education on t he health effects caused by aflatoxins and the method to 
manage aflatoxins at the field level must be provided regularly in order to encourage people to 
adopt this new technology, and change their behavior to protect themselves from aflatoxins 
exposure.    
7.4.2 Postharvest intervention package: Technical feasibility 
In industrial nations, food storage and processing practices usually prevent postharvest 
development of mycotoxins, but postharvest mycotoxin accumulation remains a threat in many 
LDCs.  Hence, attention to key critical control points during harvesting, drying, and storage of 
food is essential, to reduce postharvest aflatoxin in LDCs (63, 64).  Reducing postharvest 
aflatoxin accumulation can begin with simple physical methods.  Mechanical sorting can 
separate aflatoxin-contaminated kernels from relatively cleaner ones, and proper drying can 
further reduce risks.  To prevent the growth of Aspergilli in food storage, it is necessary to 
control moisture, temperature, and pests (66).     
Combinations of these methods to reduce postharvest aflatoxin have been tested for 
efficacy in actual storage conditions.  Turner et al. (2005) describe a postharvest intervention 
package to reduce aflatoxin in groundnuts, tested in Guinea.  The package consisted of six 
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components: education for groundnut farmers on hand-sorting nuts, natural-fiber mats for drying 
the nuts, education on proper sun drying, natural-fiber bags for storage, wooden pallets on which 
to store bags, and insecticides applied on t he floor of the storage facility under the wooden 
pallets.   
After five months in the Guinea groundnut intervention study, individuals who had 
received and practiced the postharvest intervention package had on average 57.2% lower 
aflatoxin-albumin concentrations in the blood (8 pg/mg), compared with individuals in the 
control group (18.7 pg/mg; Turner et al. 2005).  Indeed, the adduct levels in the intervention 
group after five months was similar to the adduct levels in both groups immediately postharvest, 
while the average adduct level in the control group increased by over 100%.  Because this 
biomarker can be directly correlated with aflatoxin exposure in the diet (370), the results of the 
Guinea study imply that the postharvest intervention package could essentially prevent aflatoxin 
from accumulating beyond its immediate postharvest level, even after five months of storage.  
We evaluate the technical feasibility of the entire package in this study. 
Table 7-3  summarizes the characteristics of the postharvest intervention package as an 
aflatoxin reduction intervention in African countries that determine its overall feasibility. 
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Table 7-3. Technical feasibility characteristics of postharvest intervention package for aflatoxin control in 
Africa 
Category Criteria Intervention 
Intervention Characteristics 
Basic product 
design 
Stability Drying/storage materials could last for 3-4 years if kept 
properly 
Safety profile Extremely safe. Only potential health risk concerns 
insecticide use: not expected to be a problem if already 
locally available and a familiar product to farmers. 
Ease of storage and 
transport 
Most raw materials are locally available; fiber mats and 
bags and pallets may need to be stored away from 
moisture and pests to extend lifetime 
Supplies Need for regular 
supplies 
Drying/storage materials could last for 3-4 years if kept 
properly 
Equipment High-technology 
equipment needed  
None; entire intervention relies on c ommunity-based 
technology and materials  
 Maintenance needed Fiber bag, mat and wooden pallet can become 
contaminated with fungi; sun drying and proper storage 
after use may reduce risk 
Delivery characteristics 
Facilities Retail sector and 
outreach services 
If drying and storage materials are not made by each 
household, large scale production of these materials 
could be an option (e.g., for pallets). Local retail stores 
could provide the finished mats, bags, and pallets. 
Human resources Skill level required for 
service provision 
Community volunteers/ agricultural extension staff or 
local agricultural authorities, to educate growers on the 
risks of aflatoxin and the methods of using the complete 
intervention to reduce aflatoxin 
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Table 7-3 (continued) 
Category Criteria Intervention 
Government capacity requirements 
Regulation / 
legislation 
Need for regulation No special regulation required 
Collaborative 
action 
Collaborative efforts 
within government 
sectors and between 
government and other 
groups 
Collaboration between health and agricultural sectors, as 
well as between national and local level governments, is 
important.  O utreach staff are an important part in this 
community based intervention.  
Funding from external agencies may be desirable to 
offset the initial costs of the packages. 
Usage characteristics 
Ease of usage Need for 
information/education 
While the need for information and education is high 
(e.g., hand-sorting, drying, specific storage 
requirements), usage itself should be simple because of 
the cultural familiarity of the overall practices  
Pre-existing 
demand 
Need for promotion Though the practices of drying and storage are familiar, 
the specifics (e.g., wooden pallets, fiber mats and bags) 
may not be, and growers may not understand the need for 
them.  Hence, the need for promotion is crucial. 
Black-market risk Counterfeit prevention Low risk of counterfeiting  
 
7.4.2.1 Postharvest intervention package: Basic characteristics.   
A beneficial feature of the postharvest intervention package is that most aspects of it are simple 
modifications of already-existing, culturally appropriate practices.  Groundnut growers 
throughout Africa are already employing various methods to dry and store – and even apply 
insecticides to – groundnuts.  The intervention builds upon what is already being done, with a 
specific goal of reducing aflatoxin accumulation. 
Hence, the package’s basic characteristics are simple and not substantially different from 
those of current practices for postharvest groundnut treatment in Africa.  The recommended 
drying and storage materials (natural fiber mats and bags, wooden pallets) could last 3 to 4 years 
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if kept properly (Dr. Christopher Wild, personal communication).  The mats and bags are, 
however, susceptible to mold and toxin contamination if not dried and stored properly; and 
people may use the wooden pallets for firewood or other uses if wood is scarce.  The materials 
themselves are generally safe; the only potential health risk is through exposure to the 
insecticide.  There is not likely to be additional risk, as insecticide recommendations for this 
package are based on what is already being used by growers.  Most raw materials are locally 
available (67).   
7.4.2.2 Postharvest intervention package: Delivery characteristics.   
In order to deliver the postharvest intervention package to groundnut growers, provisions must 
be made for both facilities and human resources.  As described above, wooden pallets should be 
custom-made and sold or distributed at local markets.  Natural-fiber mats and bags can likely be 
purchased locally or made at home, with materials from cloth retailers. 
A critical issue in the success of the postharvest package is public education. Hence, the 
human resource requirement is possibly the most important aspect of this intervention, as well as 
potentially the most difficult.  Farmers must be shown how to identify groundnuts that are visibly 
moldy or damaged, and to discard them before storage.  They must be shown how to judge the 
completeness of sun drying (on fiber mats) by shaking the kernels to listen for the free movement 
of the dried nuts.  They must also be educated on the proper way to store the dried nuts: in 
natural fiber bags, on wooden pallets, with insecticide spread underneath (Turner et al. 2005).  A 
substantial network of agricultural extension workers is needed to provide this education in rural 
groundnut-growing villages of Africa, to ensure the broader adoption that can lead to population 
health benefits.  With proper training from extension staff, individuals in communities may be 
able to educate and train other farmers in their communities to apply the postharvest intervention 
package properly.  It is crucial to develop community interest and support for such an 
intervention to succeed. 
7.4.2.3 Postharvest intervention package: Government capacity requirements.   
Presuming that the insecticides used are already registered in the target countries, no special 
regulation is required for wide-scale adoption of the intervention package anywhere in Africa.  
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Collaborative efforts between health and agricultural sectors would likely be beneficial in the 
efforts to educate groundnut growers throughout the nation, and to provide the necessary 
materials where growers would not be able to afford them.  Funding from external agencies may 
be desirable to aid in the public education efforts, as well as to offset the initial costs of the 
packages. 
7.4.2.4 Postharvest intervention package: Usage characteristics.   
As described above, this intervention would rely heavily on user knowledge of and adherence to 
practices that reduce aflatoxin in postharvest conditions.  Fortunately, growers are already 
practicing many of these post-harvest activities (sorting, drying, storage) in some form; it is  a 
matter of optimizing the activities to reduce aflatoxin accumulation.  The activities included in 
this intervention are culturally appropriate for many rural groundnut growers in Africa.  There 
may be, however, difficulties in changing current practices.  A previous study on a different 
postharvest intervention showed that only 6.3% of farmers in the Southern Guinea Savannah 
adopted an improved “crib” storage structure for crops, recommended by the Food and 
Agriculture Organization (371), though it was promoted in those communities.  Behavioral 
change, even if beneficial, may be slow among communities. 
7.4.2.5 Postharvest intervention package: Economic issues.   
As with biocontrol, the main challenge to widescale adoption of the postharvest intervention 
package is providing the right economic incentives.  Individual groundnut growers need the 
motivation to undergo the education and all the actions and costs needed to implement this 
package, which can be difficult if aflatoxin is not recognized as a significant public health or 
market problem.  In this case, unlike biocontrol, the package cannot be applied by agricultural 
staff going from household to household; the growers themselves must implement the 
intervention.  Moreover, the total package was estimated in 2005 to cost $50 per household (67).  
The wooden pallet, the largest cost in the total intervention package, is the most difficult part for 
groundnut growers to be able to make on t heir own.  These must be purchased or otherwise 
distributed from retail outlets.   
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Economic issues of a different nature concern the incentives of poor growers who do not 
understand or seriously regard the extent of aflatoxin-induced illness.  First, one must consider 
the fate of groundnuts sorted out because of high aflatoxin levels.  Even if growers are trained to 
do this with a high degree of accuracy (as part of the postharvest intervention package), it is not 
known what would happen to those contaminated nuts.  If they are kept out of the marketplace, 
then indeed, consumers who can afford to buy nuts from markets will be better-protected.  But if 
they are consumed by poor households who cannot afford to discard the nuts, then the poorest 
people in Africa would still suffer the greatest burden of aflatoxin-induced risk.  Second, if wood 
is a scarce resource in poor households, the wooden pallets may be destroyed for alternative uses 
(such as firewood) rather than used for their intended purpose: to elevate the stored groundnut 
bags for postharvest protection against aflatoxin accumulation. 
Hence, as part of this intervention package, public education on health risks of aflatoxin 
is absolutely crucial, to ensure the right economic and health incentives for groundnut growers to 
adopt the intervention and to remove highly contaminated nuts from the human food chain. 
7.4.3 NovaSil: Technical feasibility 
A variety of dietary interventions can reduce aflatoxin-related health risks.  One simple dietary 
intervention, where feasible, is to consume relatively less maize and groundnuts, in favor of 
other food crops that usually have lower aflatoxin levels such as sorghum and pearl millet (69).  
Where it is not easy to make such a conversion, however (e.g., where maize and groundnuts have 
traditionally been staples in the diet), other dietary interventions may prove helpful.  D ietary 
additives to reduce aflatoxin-induced risk include enterosorbents that “trap” aflatoxin in the 
gastrointestinal (GI) tract, facilitating elimination (70, 78); agents that induce Phase 2 enzymes 
to conjugate aflatoxin’s reactive oxygen species in the liver (74, 85, 86) ; or anti-inflammatory 
agents (76, 105). 
We focus on NovaSil clay, an enterosorbent of aflatoxin.  Enterosorbents can be blended 
into food or feed, or taken separately (e.g., in capsule form) during mealtimes to bind aflatoxin in 
the GI tract, resulting in reduced aflatoxin bioavailability in the body.  Several materials have 
varying degrees of this ability to bind aflatoxin, including bentonites, zeolites, diatomaceous 
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earth, activated charcoal, yeast cell walls, and fibers from plant sources.  One material that has 
proven effective in animal feed and is showing promise in human trials is calcium 
montmorillonite, marketed as NovaSil clay (NS).  NS has been shown to prevent aflatoxicosis in 
many animal species when included in their diet, by binding aflatoxin with high affinity and high 
capacity in the GI tract (70).  Importantly, in humans, aflatoxin-albumin adducts in both low-
dose and high-dose NS intervention arms were significantly lower than those in the control arm 
after three  months, with a roughly 25% reduction: 0.89-0.90 pmol/mg adducts in albumin 
compared to 1.20 pmol/mg in the control arm. However, only the high- dose group shows the 
significant lower levels of AFM1 after three months (104).    
One advantage of including NS (or other effective enterosorbents) in a comprehensive 
plan to reduce aflatoxin risk is that it can mitigate adverse health effects even if preharvest and 
postharvest conditions were conducive to high aflatoxin levels in food.  NS could conceivably be 
used in “emergency” situations when aflatoxin levels are determined to be high in foodstuffs – 
by then, it is too late to change preharvest or postharvest practices to improve the food available 
to people at that moment, and few other options to reduce aflatoxin risk are possible.  While NS 
does not directly reduce aflatoxin levels in food, it can reduce aflatoxin bioavailability.  The 
feasibility of including NS as an aflatoxin risk-reduction intervention is summarized in table 7-4. 
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Table 7-4. Technical feasibility characteristics of NovaSil clay for aflatoxin risk reduction in Africa 
Category Criteria Intervention 
Intervention Characteristics 
Basic product 
design 
Stability Stable under normal conditions; loss of binding capacity 
(primary mechanism to reduce aflatoxin bioavailability) 
if heated ≥ 200° C over 30 minutes  (372) 
Standardization Needed for human consumption purposes, to ensure 
reliable dose whether in capsule form or blended in meal  
Safety profile No significant changes in hematology, liver, kidney 
function, vitamin A and E levels, and mineral levels. 
Mild gastrointestinal symptoms have been observed. 
Sterilization and standardization necessary. 
Ease of storage / 
transport 
No special requirements for storage.  Transportation is 
needed from other parts of world where clays have 
shown aflatoxin-binding properties and can be sterilized 
and standardized. 
Supplies Need for regular supplies A regular supply is needed in aflatoxin-vulnerable 
regions, because of daily consumption requirements 
Equipment High-technology 
equipment and 
infrastructure needed  
If imported, no local high-technology equipment is 
needed. If produced locally, sophisticated manufacturing 
and packaging equipment is needed. 
Delivery characteristics 
Facilities Retail sector and 
outreach services 
Depending on de livery method (capsules, blended into 
meal, etc.), can be purchased or distributed in food 
markets or local health centers 
Human resources Skill level required for 
service provision 
Staffs are needed to distribute NS in the appropriate 
manner to the general public (e.g., blending the product 
into meal, selling or providing caplets). If production is 
done locally, trained scientists are required for 
manufacture and maintenance of the product. 
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Table 7-4 (continued) 
Category Criteria Intervention 
Government capacity requirements 
Regulation/ 
legislation 
Need for regulation May be subject to food additive regulations in target 
nations 
 Need for monitoring and 
enforcement 
Monitoring needed to prevent potential counterfeiting / 
inappropriate health claims of untested clay    
Management 
systems 
Need for sophisticated 
management systems  
Need for government financing and management to 
subsidize NS if it is incorporated in major food products, 
or if distributed for free in capsule form. It is also 
necessary to manage potential risks of counterfeiting and 
compliance (Gilbert 2008). 
Collaborative 
action 
Collaborative efforts 
within government 
sectors and between 
government and other 
groups 
Depending on NS’s delivery mechanism, coordination is 
needed between agricultural, health, pharmaceutical, and 
food-related governmental sectors. 
Community volunteers can help government to monitor 
inappropriate use or the presence of counterfeiting. 
Because this intervention requires continuous action 
(monetary support), funding from international 
organizations may be crucial. 
Usage characteristics 
Ease of usage Need for 
information/education 
In aflatoxin-vulnerable areas, education is needed on 
when, why, and how often to consume NS.  May be 
difficult for individuals to remember or to desire to take 
NS capsules with each meal, so alternative delivery 
mechanisms should be considered (e.g., blending NS into 
maize or groundnut meal). 
Pre-existing 
demand 
Need for promotion Geophagy is common in certain parts of world; however, 
there is a need to promote NS specifically as 
distinguished from common clays, and why aflatoxin is 
an important risk to control. 
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Table 7-4 (continued) 
Category Criteria Intervention 
Black-market risk Need to prevent 
resale/counterfeiting 
Potential risk of counterfeiting with common clays that 
do not adsorb aflatoxin in the GI tract 
7.4.3.1 NovaSil: Basic characteristics.   
NS is one of only several types of clays that can properly adsorb aflatoxin in the GI tract; hence, 
it is important to distinguish NS in any public education effort, to prevent the belief that any clay 
would have the same property.  NS is stable under normal conditions of temperature and 
moisture; it loses aflatoxin-binding capacity if heated to over 200°C for over 30 minutes (372).  
Standardization is important, whether NS is administered in capsules or blended into maize or 
groundnut meals, to ensure effective and safe doses for humans.  Although mild GI symptoms 
were reported in an initial human trial, Phase I (72) and Phase II (73) clinical trials confirm the 
safety of NS for use in human food, and provide assurance that it does not bind and result in 
elimination of nutrients such as vitamins A and E.  Indeed, NS has a notable preference and 
capacity for aflatoxin (70). 
A regular supply of NS would be needed in aflatoxin-vulnerable regions, because of daily 
consumption requirements; i.e., NS should be consumed whenever aflatoxin is present at 
potentially risky doses in food.  Because not every African geographic region has types of clays 
necessary to bind aflatoxin (70), NS (or other adsorbent clays) must be imported.  Hence, it is not 
necessary to set up the extensive high-technology equipment and infrastructure needed to 
produce and maintain NS throughout Africa.  However, because NS must be supplied from 
elsewhere on a regular basis, transportation and delivery costs may be high. 
7.4.3.2 NovaSil: Delivery characteristics.   
Depending on the delivery method to consumers (capsules, blended into meal, or other options), 
NS can be purchased or distributed in food markets or local health centers.  If any part of the 
production chain is carried out locally (including blending the clay into the meal), trained 
personnel are required.   
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If NS must be imported, as described above, transportation and delivery issues to at-risk 
populations are among the top priorities that need to be planned in advance. To whom, and how, 
will the clay be delivered, and what is the anticipated cost?  Is this a u niversal coverage 
intervention?  If not, which populations are the target groups? Will this intervention be used 
every day for an extended period of time, or only occasionally, when high levels of aflatoxin are 
detected in food crops?  All these issues must be resolved to understand and budget for demands 
on delivery mechanisms.  
7.4.3.3 NovaSil: Government capacity requirements.   
NS may be subject to regulations governing food additives in target nations.  National and local 
governments, in collaboration with outside partners, need to make a financial investment for the 
initial subsidy of NS, as many of the most aflatoxin-vulnerable populations do not  have 
sufficient funds to purchase quantities necessary to reduce risk through NS consumption on a  
regular basis.  There is also a need for government-funded inspection and monitoring to prevent 
potential counterfeiting of NS products; i.e., producing and marketing clays that do not  bind 
aflatoxin and may indeed cause adverse health effects.  Depending on the delivery mechanism of 
NS, coordination is needed among agricultural, health, pharmaceutical, and food-related 
government sectors.  
7.4.3.4 NovaSil: Usage characteristics.   
When considering who would use NS, and under what conditions, it is important to consider 
likelihood of adherence to a demanding regimen.  For optimal effectiveness, consumers should 
take NS at every meal in which aflatoxin-contaminated foodstuffs (such as maize or groundnuts) 
were present.  However, it is impossible under most circumstances for consumers to know 
whether their foods have high aflatoxin levels, so taking NS with every meal, regardless of 
aflatoxin exposure, is a possible recommended regimen.   
If NS were administered in capsule form, many people would likely object to the idea of 
taking a capsule with every meal for extended periods of time, especially if they do not  
understand or appreciate aflatoxin-related health risks.  Blending NS into maize and/or 
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groundnut meal eliminates the problem on adherence issue and has the advantage of including 
the product only with foodstuffs (maize and groundnuts) that could have high aflatoxin levels.   
As to whether the product itself would be accepted culturally: Geophagy, the practice of 
consuming clay(s), is widely accepted in many parts of Africa, as well as in several other parts of 
the world, such as China (70).  Certain African populations consume clay for several purposes, 
such as detoxifying dietary toxins, treating GI symptoms, and neuropsychological comfort (373).  
Even though promotion of NS clay as a dietary prevention is unlikely to be difficult from a 
cultural standpoint, promoting the right clay is important.  Public educational efforts are 
necessary to explain the benefits of NS-enriched meal (or NS capsules; for example, in the case 
of emergencies), and to direct consumers toward using the right product. 
7.4.3.5 NovaSil: Economic issues.   
The cost of the product itself is less than one dollar per year per person for 3-gram estimated 
daily dose (Dr. Timothy Phillips, personal communication).  Even such a low cost, however, 
may be unaffordable on a daily basis in certain parts of the world, where poverty is rampant and 
aflatoxin is a significant problem.  In all likelihood, governments in collaboration with external 
funding agencies would need to provide the resources to deliver NS to populations in need.  
Indeed, this low product cost may be insignificant compared with the higher cost of transporting 
the material from another part of the world.  NS proves most cost-effective when other methods 
– preharvest and postharvest – fail to prevent dangerously high levels of aflatoxin from entering 
the food supply.  More economic research is needed on whether it is more cost-effective to only 
supply NS during “emergency” situations, or whether NS should become a semi-regular part of 
diets in certain regions of the world.  
7.4.4 Hepatitis B vaccination: Technical feasibility 
Hepatitis B is an infectious disease that affects the liver.  The hepatitis B virus (HBV) can cause 
acute illness, characterized by GI symptoms, tiredness, jaundice, and muscle and joint pain.  In 
about 10% of cases, HBV can also cause chronic infection, which can result in liver cancer, 
cirrhosis, and death.  HBV is spread through contact with body fluids of an infected person.  In 
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LDCs, individuals are most commonly infected with HBV through maternal-to-child 
transmission.  HBV is also transmitted through contact with body fluids through breaks in the 
skin, contact with objects that have body fluids on them, unprotected sex with infected 
individuals, and needle sharing (374).  
A regular practice now in the US and other developed nations, HBV vaccination in 
children is still rare in many parts of the world.  Vaccinating children against HBV has been 
shown, over the last three decades, to significantly decrease HBV infection in several regions 
including Europe (91, 92), Taiwan (93), and Thailand (94).  This vaccine has already had, and 
will continue to have, significant impacts on liver cancer incidence, particularly in Africa and 
East Asia.   
Though the HBV vaccine itself does not affect actual aflatoxin levels in diets, it reduces 
aflatoxin-induced HCC by lowering HBV risk, thereby preventing the synergistic impact of 
HBV and aflatoxin in inducing liver cancer.  For individuals who are chronically infected with 
HBV (common in China and Africa), aflatoxin consumption raises by up to thirty-fold the risk of 
liver cancer compared with either exposure alone (33).  Hence, lowering the risk of chronic HBV 
infection through HBV vaccination could reduce by 30 times the risk of aflatoxin-induced liver 
cancer, and may also play some role in reducing aflatoxin-induced cirrhosis (357).  However, the 
vaccine may not prevent other adverse effects caused by aflatoxin (e.g., immunomodulatory 
effects).  The feasibility of including the HBV vaccine as an aflatoxin risk-reduction intervention 
is summarized in table 7-5. 
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Table 7-5. Technical feasibility characteristics of Hepatitis B vaccination for aflatoxin risk reduction in Africa 
Category Criteria Intervention 
Intervention Characteristics 
Basic product 
design 
Stability Vaccine should be stored between  2°C to 8°C 
(refrigerated, not frozen) (Drugs.com 2009) 
Standardization Necessary to ensure that all vaccine doses are the same 
for a given target group, and safe for that group 
Safety profile This vaccine is very safe. The most common side effect 
is pain at the site of injection. There is no clear 
association to other serious side effects (NFID 2009).  
However, it is crucial that needles be kept sterilized and 
that vaccines be kept refrigerated.  
Ease of storage and 
transport 
Vaccines require cold storage (See above; applies to 
transportation conditions as well) 
Need for regular 
supplies 
To reduce HBV prevalence, multi-generation vaccination 
is needed.  Therefore regular supply of vaccine is 
required 
High-technology 
equipment and 
infrastructure needed  
Cold storage is necessary to preserve the vaccines, which 
can be a challenge in areas without electricity. Existing 
infrastructures in hospitals and other health centers can 
facilitate vaccination. 
Number of different 
types of equipments 
Temperature controlled chambers/containers 
Needle syringe 
Antigen-antibody titer check 
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Table 7-5 (continued) 
Category Criteria Intervention 
Delivery characteristics 
Facilities Retail sector Vaccines must be provided by a reliable source to ensure 
efficacy, cleanliness, and proper dosage  
Outreach services Mobile vaccination services (door-to-door) may be 
possible and desirable in certain communities 
First level care Community education on HBV’s health effects and how 
to prevent infection is desirable 
Hospital care Clinics can provide vaccination to infants and previously 
unvaccinated, uninfected people 
Human resources Skill level required for 
service provision 
Nurses, medical assistants or other trained personnel to 
administer vaccines 
Skill level required for 
staff supervision 
Medical staff required 
Intensity of professional 
services 
(frequency/duration)   
Regular service is required to supply vaccines to health 
care facilities 
 Management and 
planning requirements 
Because this vaccine is not locally manufactured in most 
of the high-HBV-prevalent countries, planning and 
management of vaccine inventories and funding are two 
requirements.  Planning should also cover how the 
vaccine reaches the target population, evaluation, and 
up-scaling of the program.     
Communication 
and transport 
Delivery dependence on 
communication and 
transport infrastructure 
Cold storage needed.  To reach large proportions of the 
target population, it is important to distribute this vaccine 
to every part of the country: all local clinics and health 
centers, if possible.   
Government capacity requirements 
Regulation/ 
legislation 
Need for regulation No special regulation is required, but government must 
see HBV vaccination as priority to mobilize resources 
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Table 7-5 (continued) 
Category Criteria Intervention 
Management 
systems 
Need for sophisticated 
management systems  
Clinics and other health care centers must be connected 
with vaccine supply outlets, and staff should be trained 
to administer vaccines. 
Collaborative 
action 
Collaborative efforts 
within government 
sectors and between 
government and other 
groups 
Health departments within each nation should coordinate 
with each other and international health organizations to 
provide vaccines regularly where needed. External 
funding is necessary, because in order to achieve 
widespread vaccination, continuity of the program is a 
vital part. Without external funding or support from 
external agencies, it can be difficult for poorer nations to 
maintain this program.    
Usage characteristics 
Ease of usage Need for information / 
education 
Individuals must understand need for vaccine as well as 
where and how often to obtain it, for themselves and 
their children. 
Pre-existing 
demand 
Need for promotion Vaccination has already been promoted in many African 
nations, but especially in rural areas, greater effort is 
needed to educate the public on benefits of vaccines. 
Black-market risk Need to prevent 
resale/counterfeiting 
Low risk of resale or counterfeiting 
 
7.4.4.1 HBV vaccine: Basic characteristics.   
The HBV vaccine is made from a part of the virus, and cannot cause infection.  I t is usually 
given as a series of 3 or 4 shots, each one conferring ever-greater protection against chronic 
HBV infection risk.  It is recommended that all children receive their first dose of HBV vaccine 
at birth, because of the maternal-to-child transmission risk (375, 376) and complete the vaccine 
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series by 6-18 months of age.  A dditionally, any child, adolescent, or adult who has not been 
previously vaccinated should receive the vaccine (374). 
To maintain product stability, the vaccine should be stored between 36-46 °F 
(refrigerated, but not frozen; Drugs.com 2009).  Generally, vaccines have been standardized 
during their manufacturing processes.  This is necessary to ensure that all vaccine doses are the 
same, and at safe and effective doses, for the target population.  The HBV vaccine has been used 
for decades safely, with low risk of significant side effects; the most common side effect is pain 
and swelling at the site of injection (377).  However, it is crucial that needles be kept sterilized 
and not shared, and that the vaccine remains refrigerated at all times before use. 
One main technological challenge for many parts of rural Africa lies in providing and 
maintaining cold storage for the vaccines (376).  Cold storage is difficult where electricity is not 
available.  Indeed, the rate of accessibility to electricity in sub-Saharan African populations was 
approximately 15% in 2005 (378).  It is also not optimal for individuals to have to travel too far 
in order to receive the vaccine (e.g., to the clinic of the nearest village that does have electricity), 
as incentive to receive the vaccine may decrease.  Other types of equipment/supplies needed 
include needle syringes and antigen-antibody titer checks.  A regular supply of the vaccine is 
needed throughout populations in Africa, to vaccinate children when they are born, and to others 
who have not previously received the vaccine. 
7.4.4.2 HBV vaccine: Delivery characteristics.   
Vaccines could be delivered in at least two different general methods in Africa, to reach as much 
of the population as possible.  One is to deliver the vaccine at existing hospitals, clinics, and 
other health care centers.  This would be the main means by which to reach urban populations 
and more technologically sophisticated villages.   
Another option is to deliver the vaccine through a mobile vaccination service, traveling 
door-to-door as necessary with cold storage in the medical vehicle: focusing at first on reaching 
everyone who had never been previously vaccinated, then focusing primarily on reaching 
newborn babies (if possible).  Even if it were impossible to perfectly target the households with 
newborn babies, simply vaccinating the mothers in a broad vaccination outreach could 
dramatically reduce the risk of HBV transmission to babies.  To this end, the vaccine must be 
kept cold but not frozen during transport.  It is recommended to use frozen packs for hot-weather 
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conditions or refrigerated packs for cold-weather conditions during transportation.  Proper 
insulation such as crumpled paper or buble wrap should be use to keep the vaccine from direct 
contact with frozen pack or shifting during transport. Moreoverm insulated container should be 
kept in a cool place in the vehicle if possible (379). Even with this mobile vaccination option, 
reaching a broad population in Africa may be difficult; as averaged transport access rate by road 
in sub-Saharan Africa in 2005 ranged from 60% −70% (378).   
Vaccines must be provided by a reliable source to ensure efficacy, cleanliness, and proper 
dosage.  Nurses, medical assistants, or other trained personnel can administer the vaccines.  
Aside from administration of the vaccine, outreach services should also be provided to educate 
the public on the importance of vaccination and completing the recommended regimen.   
7.4.4.3 HBV vaccine: Government capacity requirements.   
Initiating, preparing, and maintaining a vaccination program is an extremely complex task; and 
requires governmental coordination at the administrative, technical, medical, logistic, 
educational, financial, and political levels (376).  Clinics and other health care centers must be 
connected with vaccine supply outlets, and staff should be trained on how to properly administer 
the vaccines, especially to avoid cross-contamination through needles.   
External funding is almost certainly necessary in most sub-Saharan African countries, 
because in order to achieve widespread immunity to the disease among a population, continuity 
of the program is a vital part.  Fortunately, the Global Advisory Group of the Global Alliance for 
Vaccines and Immunization (GAVI), supported by UNICEF, WHO, and the Bill and Melinda 
Gates Foundation, has specifically recommended that HBV vaccination be integrated into 
national immunization programs in all countries of the world (380).  GAVI provides funds and 
other resources to implement HBV vaccination in nations whose gross national income is below 
1000 USD per capita per annum.  Hence, most sub-Saharan African nations qualify for GAVI 
assistance, and efforts have been made to spread HBV vaccination there since the early 1990s.  
Yet as of 2008, 20% of all unvaccinated children globally were in sub-Saharan Africa (376).  
(The only place in the world that has a greater number of HBV-unvaccinated children is India.)  
African nations that accepted GAVI aid now have between 50-96% coverage of infant HBV 
vaccination, while Nigeria, which qualifies but did not accept GAVI aid, has HBV vaccination 
coverage of only 27% (376). 
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7.4.4.4 HBV vaccine: Usage characteristics.   
The goal of any vaccination program is to immunize as many individuals as possible, so as to 
prevent spread of the disease.  It is important to promote and educate about the HBV vaccination 
program to encourage individuals to complete their vaccination regimen (3 boosters on average 
to provide near-lifetime immunity).  For example, for individual boosters, coverage rate of HBV 
immunization in a large cohort of infants in Venda, South Africa dropped rapidly from 99% to 
53% and 39% for the first dose, second dose, and third dose, respectively (381).   
7.4.4.5 HBV vaccine: Economic issues.   
Economic considerations for the HBV vaccine are not substantially different from those of other 
common vaccines in less developed countries.  The vaccine itself is extremely inexpensive, 
considering its lifetime benefit: less than $1 per dose (127), with three doses are recommended 
per individual to provide up to 95% efficacy in HBV protection (112).   
Even so, in order to impact as many people as possible, HBV vaccination programs in 
relatively poor African nations may require external funding to be initiated and/or sustained.  
Currently, as described above, HBV vaccination in several African countries is financially 
supported by GAVI.  As a result of GAVI funding and other resource support, HBV vaccination 
among infants has increased enormously in the last decade (376).  Still, there are many African 
nationsthat do qualify for GAVI funding but have not yet applied for it.   
Economic issues surrounding HBV vaccination in Africa are largely out of the hands of 
individuals.  Governments need to decide that HBV vaccination is a priority, and to contribute 
funds or apply for funds in order to reduce the burden of HBV-related disease.  As populations in 
many of these nations are also vulnerable to high aflatoxin levels in their food, reducing HBV 
risk becomes an even more important problem, regarding liver diseases such as cancer and 
cirrhosis.  This information on the synergistic risks of aflatoxin and HBV should be conveyed to 
governments to emphasize the importance of reducing either, or both, risk factors. 
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7.5 DISCUSSION 
No  one  intervention  to  reduce  aflatoxin risk in Africa  emerges  as being  “most feasible” in all 
categories.  Each  has its  unique  benefits and drawbacks   for wide-scale adoption in Africa.  For 
example, biocontrol is highly cost-effective and reduces  aflatoxin at its earliest stages.  However, 
professional  staff and  training requirements may be high.  The postharvest intervention package 
has the benefits of cultural appropriateness and adaptability to multiple different local settings, as 
well as  low  technology and  equipment requirements.  However, there is a high public education 
component  for  proper  sorting  and  drying  practices,  and  compliance  requirement  for  health 
benefits.     NovaSil   may   prove   a   life-saver in   emergency  situations  when  preharvest  and 
postharvest  means  have failed  in keeping high aflatoxin levels out of food, but long-term public 
adherence  may  be  problematic.  The HBV vaccine has high global-level support and needs only 
be  administered  three  times in a lifetime to ensure high protection against liver-related diseases, 
but clinical and facility requirements are high.   
As  different  as  these  interventions  are  from  each  other, certain general trends emerge 
from  a  technical  feasibility  study.   The  first  is  that  public  and  governmental  education  on 
aflatoxin risk is absolutely crucial to provide economic incentives to adopt interventions.  Even if 
an  intervention  to  reduce  aflatoxin  risk  is cost-effective, in terms of lives saved and quality of 
life improved  (Wu and Khlangwiset 2009), there may still be no incentive to implement it unless 
health  and  market  effects  of  aflatoxin  are  fully  understood.   It  is worth noting that aflatoxin 
exposure  in  Ghana  has  been  shown  to  be significantly correlated with farmers’ knowledge of 
aflatoxin risk  (Jolly et al. 2006),  while farmers’ knowledge  of  aflatoxin  risk in Benin has been 
correlated with the motivation to implement aflatoxin-reduction interventions (Jolly et al. 2009).   
Education  must  take  place  in  at least three different  levels.  Government  policymakers 
must  first  receive  information  about  the  burden of aflatoxin-induced  disease in their nations – 
both  in  terms of health and market effects – as  well as information about  possible interventions, 
their   cost-effectiveness   in   reducing  aflatoxin,  and  their   technical  feasibility  requirements.
Obtaining  the  appropriate  information  will  motivate  them  to  provide  the  finances  and other 
resources   necessary   to   initiate   the   interventions.      Also,  depending   on   the   intervention 
characteristics, either  the farmers, or the consumers,  or both these groups must receive education 
on  why  aflatoxin  is  a  concern  and  how  to  implement  the intervention  in  question.   Finally, 
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international  health  and  agricultural  organizations  must  e  informed about the extent to which 
aflatoxin   can  affect  both  food  markets  and  public  health.   This will provide incentive to aid 
nations in which aflatoxin is still a significant problem in food. 
The  second  trend  is  that  interventions  would  ideally  be  combined  in a suite to solve  
aflatoxin  problems  in LDCs.  The one s analyzed in this study represent preharvest, postharvest, 
dietary,  and  clinical solutions to the problem.  Each one, taken alone,  could reduce a significant 
burden of aflatoxin risk;  but potential  failures in the  overall system could result in gaps through 
which   high  contamination  events  could  occur.     Biocontrol   would  help   reduce  preharvest 
aflatoxin accumulation from the start, to ameliorate any potential problems further along the food 
chain.   The  postharvest  intervention  package  significantly  reduces  aflatoxin in storage so that 
even  food  stored  for longer periods of time would have greater safety.   NovaSil can serve as an 
enterosorbent  to  reduce  aflatoxin  risk  in cases where food is already highly contaminated.  The 
HBV vaccine lowers the overall risk of specific liver diseases for which aflatoxin is a risk factor. 
The  third trend is that, after appropriate funds are obtained, delivery of the intervention to 
people  and  places  in need may be the most significant challenge to implementing aflatoxin risk-
reduction  interventions.     In  three  of  the  four case studies described in this study, the delivery 
would  cost  more  than  the  intervention  itself – in  some  cases,  significantly  more.     The one 
exception  is  the  postharvest  intervention  package, whose materials can be obtained locally.   In 
the  other  cases,  either  the  intervention  must  be  imported,  or  significant  effort  is  needed  to 
establish  the  equipment  and  personnel  necessary  in  various  parts  of  the country to reach the 
target population.   
Understanding  constraints  to  feasibility of interventions aids scientists and policymakers 
to think beyond efficacy,  and  even  beyond  material costs.   For  interventions to succeed in less 
developed   countries,    governments,   scientists,    international   organizations,    farmers,    and 
consumers must work collaboratively to overcome challenges in implementing the intervention – 
challenges  in  terms  of  human  resource  needs,  equipment  and  technology  and transportation 
requirements,   financial aid,   and  user  adoption  constraints.     Feasibility analyses can indicate 
research  and  development priorities in order to improve likelihood of adopting interventions that 
can improve public health and market outcomes. 
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8.0  CONCLUSIONS, LIMITATIONS, AND PUBLIC HEALTH SIGNIFICANCE 
8.1 CONCLUSIONS 
We have estimated that out of total liver cancer cases in Nigeria, more than 50% are HBV-
related (59-62%). The liver cancer caused by aflatoxin accounts for about 8-27% of total liver 
cancer in Nigeria. However, there is an overlap between the liver cancers caused by the HBV 
infection and aflatoxin; about 7-23% of total liver cancer are the results of the synergistic effect 
of aflatoxin and chronic HBV infection.   
Since HBV plays a major role in Nigerian liver cancer risk, and because the HBV vaccine 
has such high efficacy, this vaccine delivers greater benefit to prevent liver cancer cases – even 
those induced by aflatoxin - compared with aflatoxin-specific interventions. Aside from 
providing greater efficacy to prevent liver cancer, the HBV vaccine also costs the least compared 
with the other three interventions: biocontrol, the postharvest intervention package, and NovaSil. 
According to WHO guidelines to evaluate the cost-effectiveness of public health interventions, 
HBV vaccination is highly cost-effective.  If liver cancer prevention were the only health 
endpoint of aflatoxin in which we are interested, the postharvest intervention package and 
NovaSil clay are not considered to be worthy of adoption. Biocontrol, depending on the levels of 
aflatoxin that would otherwise have existed, can be either cost-effective or non-cost-effective.  
The results from our review on the relationship between aflatoxin exposure and growth 
impairment led credence to the hypothesis that aflatoxin is associated with childhood stunting in 
high-risk areas of the world. Though it is  impossible to completely eliminate aflatoxin, it is  
crucial to keep levels “low.” High levels of aflatoxin can induce growth impairment, which 
results in a large public health burden.   
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       Table 8-1.  Summary of the cost and the numbers of prevented cases of aflatoxin control interventions        
Intervention Annual cost Millions 
USD) 
Case prevented 
Liver cancer Childhood stunting 
HBV vaccine 37.82–45.88 21,147–22,591 NA 
Biocontrol 75.40 1,065–2,886 736,000–1,015,000 
The postharvest 
intervention package 
103.68–259.20 388–405 231,000–255,000 
NovaSil 181.33 758–1,677 736,000–958,000 
Table 8-1 summarizes the annual cost of four aflatoxin control interventions and the 
numbers of liver cancer cases and cases of stunting that can be prevented by each intervention. 
The malnourished condition in children is not associated with chronic HBV infection (382-384). 
Therefore, HBV vaccine does not provide benefits on preventing stunting.  
Because of the complexity of the diet-disease interaction, the results should be interpreted 
cautiously. Aflatoxin could play a role in reducing growth performance in children who have 
preexisting risk factors such as borderline malnutrition, but not in children who are well 
nourished. However, in animal studies, aflatoxin caused growth impairment in animals fed diets 
similar to control animals (see chapter 5).  Our study shows that if other factors related to 
stunting in Benin and Nigeria are similar, dietary aflatoxin exposure can induce impairment in 
growth performance, including stunting, which is associated with an increased risk of dying from 
several diseases and/or conditions, such as diarrhea, pneumonia, malaria, and measles (229).  
Childhood stunting carries a greater overall burden than liver cancer for two main 
reasons. First the incidence of liver cancer is much lower than stunting. In general, liver cancer 
incidence is reported per 100,000; whereas, the incidence of stunting is per 100. S econd, 
compared with liver cancer, stunting occurs much earlier in life. Therefore, a life lost due to 
stunting-related conditions causes more than 30 DALYs.     
In our study, the benefit of preventing stunting is large. Including this benefit in 
evaluating aflatoxin risk-reduction interventions can make the difference between their being not 
cost-effective to being cost-effective in terms of DALYs saved. The cost of the postharvest 
intervention package to prevent one healthy life loss due to liver cancer is much higher than the 
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three-time Nigerian GDP per capita, even when the cost is reduced to 30% of its original cost or 
its efficacy was much improved to completely reduce aflatoxin in groundnuts. But once the 
benefit of preventing stunting is included, the postharvest intervention package becomes very 
cost-effective and still cost-effective even when the cost is 10 times higher than its current cost. 
This is similar to the other two aflatoxin-specific interventions: biocontrol and NovaSil clay.  
While any single intervention is very cost-effective if the benefit of preventing stunting is 
included and aflatoxin exposure is high enough to induce stunting, combinations of interventions 
are not cost-effective. Marginal cost-effectiveness assessment determines the ratio between extra 
benefit gained and extra cost from including an additional intervention. As a single intervention, 
biocontrol is able to reduce total aflatoxin exposure to be lower than the threshold of aflatoxin to 
induce stunting. Therefore, having an additional intervention does not increase the benefit of 
preventing stunting. Though the new intervention can prevent liver cancer, the benefit of 
preventing liver cancer in this case is very small compared to the extra cost of having one more 
intervention implemented. It is worthwhile to note that the results can be different if the exposure 
levels are extremely high, that biocontrol cannot reduce aflatoxin levels under the level “safe” 
for stunting. In this situation, having an additional intervention could cause a significant benefit.        
However, this does not mean that the intervention which provides the greatest efficacy 
and the cheapest cost to prevent one bad outcome is the ideal intervention. There are other 
aspects of the interventions that need to be considered: basic features such as safety and 
standardizability, delivery characteristics, usage characteristics, and governmental support. Our 
technical feasibility analysis revealed that each intervention has its own advantages and 
disadvantages. Limited infrastructure and resources in rural areas can be the reason that the best 
intervention cannot be practiced. For example, the HBV vaccine–the best intervention in our 
efficacy and cost-effectiveness studies–requires a cold chain to ensure that the HBV vaccines are 
kept between 2°C–8°C and a sufficient number of public health personnel are available to 
perform the vaccination. This may be infeasible in many rural communities worldwide. 
Moreover, some religious and personal beliefs may prevent babies from being vaccinated.      
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8.2 LIMITATIONS 
The first limitation in our studies is the absence of the data of aflatoxin levels in maize and 
groundnuts stored in Nigerian households. Since the products sold in markets are often stored for 
shorter periods compared with maize and groundnuts stored in growers’ household, aflatoxin 
levels in household goods would likely have higher levels of aflatoxin.   
Another limitation in our study is caused by the lack of information on the kinetics of 
aflatoxin in children. The conversion factor (37) used in this study to convert the levels of dietary 
aflatoxin exposure to the levels of AF-alb adducts was derived from adult subjects. However, the 
levels of albumin in children and adults are not much different, 34-42 mg/ml and 37-56 mg/ml 
for infants age 1-3 years old and adolescence age 7-19 years old, respectively (385).  Moreover, 
it was estimated that only 1-3% of aflatoxin is bound with albumin (386). Therefore, the effect 
from using an adult conversion factor to calculate children AF-alb adducts should not be 
significant.  
Currently, epidemiological studies on aflatoxin and growth impairment are limited to 
West Africa, East Africa, and the Middle East. The one study that showed a dose-response 
relationship between aflatoxin exposure and growth impairment was conducted in Benin and 
Togo.  Because of the complexity between diet and disease, our data on stunting may not be able 
to generalize to other populations whose diet or preexisting factors are much different than the 
studied populations in Benin and Togo.       
8.3 PUBLIC HEALTH SIGNIFICANCE 
Public health policy makers can use our data in this study to help them appropriately allocate 
limited resources, such as human and monetary resources, to reduce public health burdens of 
liver cancer and stunting caused by aflatoxin. The data from this study would highlight the 
importance and the knowledge gaps yet to be filled regarding aflatoxin toxicity in children.  We 
encourage researchers and grant providers to pay more attention to the toxicity of aflatoxin in 
this sensitive population. In general, the metabolic function, which is important for aflatoxin to 
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exert their carcinogenicity in children, is less effective compared with adults; but per kilogram 
bodyweight, children consume a much larger amount of food than adults. Therefore, children are 
considered to be a sensitive population. Importantly, if aflatoxin does not need to undergo 
metabolic pathways to cause impairment in growth performance, reduced metabolic function in 
children compared with adults put children in a dangerous situation. Finally, intervention 
developers can use our data to justify and improve their interventions. The postharvest 
intervention package can be modified to be more appropriate to apply to other food crops, such 
as maize, which is consumed in a much larger amount than groundnuts and plays a bigger role on 
aflatoxin exposure. 
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